
<html lang="en"     class="pb-page"  data-request-id="834a783c-7ab0-48b1-a5e7-a8bc81c3f2be"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2013.56.issue-14;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm4004076"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design" /></meta><meta name="dc.Creator" content="André  Richters" /></meta><meta name="dc.Creator" content="Julia  Ketzer" /></meta><meta name="dc.Creator" content="Matthäus  Getlik" /></meta><meta name="dc.Creator" content="Christian  Grütter" /></meta><meta name="dc.Creator" content="Ralf  Schneider" /></meta><meta name="dc.Creator" content="Johannes M.  Heuckmann" /></meta><meta name="dc.Creator" content="Stefanie  Heynck" /></meta><meta name="dc.Creator" content="Martin L.  Sos" /></meta><meta name="dc.Creator" content="Anu  Gupta" /></meta><meta name="dc.Creator" content="Anke  Unger" /></meta><meta name="dc.Creator" content="Carsten  Schultz-Fademrecht" /></meta><meta name="dc.Creator" content="Roman K.  Thomas" /></meta><meta name="dc.Creator" content="Sebastian  Bauer" /></meta><meta name="dc.Creator" content="Daniel  Rauh" /></meta><meta name="dc.Description" content="Mutations in the catalytic domain at the gatekeeper position represent the most prominent drug-resistant variants of kinases and significantly impair the efficacy of targeted cancer therapies. Unde..." /></meta><meta name="Description" content="Mutations in the catalytic domain at the gatekeeper position represent the most prominent drug-resistant variants of kinases and significantly impair the efficacy of targeted cancer therapies. Unde..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 10, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm4004076" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm4004076" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm4004076" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm4004076" /></link>
        
    
    

<title>Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm4004076" /></meta><meta property="og:title" content="Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0007.jpeg" /></meta><meta property="og:description" content="Mutations in the catalytic domain at the gatekeeper position represent the most prominent drug-resistant variants of kinases and significantly impair the efficacy of targeted cancer therapies. Understanding the mechanisms of drug resistance at the molecular and atomic levels will aid in the design and development of inhibitors that have the potential to overcome these resistance mutations. Herein, by introducing adaptive elements into the inhibitor core structure, we undertake the structure-based development of type II hybrid inhibitors to overcome gatekeeper drug-resistant mutations in cSrc-T338M, as well as clinically relevant tyrosine kinase KIT-T670I and Abl-T315I variants, as essential targets in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML). Using protein X-ray crystallography, we confirm the anticipated binding mode in cSrc, which proved to be essential for overcoming the respective resistances. More importantly, the novel compounds effectively inhibit clinically relevant gatekeeper mutants of KIT and Abl in biochemical and cellular studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm4004076"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm4004076">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm4004076&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm4004076&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm4004076&amp;href=/doi/10.1021/jm4004076" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 5757-5772</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm400383w" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm400418p" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andr%C3%A9++Richters">André Richters</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julia++Ketzer">Julia Ketzer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matth%C3%A4us++Getlik">Matthäus Getlik</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Gr%C3%BCtter">Christian Grütter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ralf++Schneider">Ralf Schneider</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Johannes+M.++Heuckmann">Johannes M. Heuckmann</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefanie++Heynck">Stefanie Heynck</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+L.++Sos">Martin L. Sos</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anu++Gupta">Anu Gupta</a></span><span class="author-xref-symbol author-aff-symbol"><sup>▽</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anke++Unger">Anke Unger</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carsten++Schultz-Fademrecht">Carsten Schultz-Fademrecht</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Roman+K.++Thomas">Roman K. Thomas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sebastian++Bauer">Sebastian Bauer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Rauh">Daniel Rauh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Strasse 6, D-44227 Dortmund, Germany</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Duisburg-Essen Medical School, Hufelandstrasse 55, D-45122 Essen, Germany</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Chemical Genomics Centre of the Max-Planck-Society, Otto-Hahn-Strasse 15, D-44227 Dortmund, Germany</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">⊥</span> <span class="aff-text">Department of Translational Genomics, University of Cologne, Weyertal 115b, D-50931 Cologne, Germany</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Pathology, University of Cologne, Joseph-Stelzmann Strasse 9, D-50931 Cologne, Germany</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">▽</span> <span class="aff-text">Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States</span></div><div class="aff-info" id="aff7"><span class="aff-symbol">#</span> <span class="aff-text">Lead Discovery Center GmbH, Otto-Hahn-Strasse 15, D-44227 Dortmund, Germany</span></div><div class="corresp-info"><strong>*</strong>PD Dr. Sebastian Bauer: phone +49 (0)201-723 85558, fax +49 (0)201-723 5547; e-mail <a href="/cdn-cgi/l/email-protection#6f1c0a0d0e1c1b060e01410d0e1a0a1d2f1a04420a1c1c0a01410b0a"><span class="__cf_email__" data-cfemail="7003151211030419111e5e121105150230051b5d150303151e5e1415">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>Prof. Dr. Daniel Rauh: phone +49 (0)231-755 7056, fax +49 (0)231-755 5159, e-mail <a href="/cdn-cgi/l/email-protection#096d6867606c65277b687c61497d7c246d667b7d647c676d276d6c"><span class="__cf_email__" data-cfemail="e78386898e828bc99586928fa79392ca838895938a928983c98382">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm4004076&amp;href=/doi/10.1021%2Fjm4004076" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 5757–5772</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 17, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 March 2013</li><li><span class="item_label"><b>Published</b> online</span>10 July 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 July 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm4004076" title="DOI URL">https://doi.org/10.1021/jm4004076</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5757%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndr%25C3%25A9%2BRichters%252C%2BJulia%2BKetzer%252C%2BMatth%25C3%25A4us%2BGetlik%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D14%26contentID%3Djm4004076%26title%3DTargeting%2BGain%2Bof%2BFunction%2Band%2BResistance%2BMutations%2Bin%2BAbl%2Band%2BKIT%2Bby%2BHybrid%2BCompound%2BDesign%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5772%26publicationDate%3DJuly%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm4004076"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2088</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm4004076" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;André&quot;,&quot;last_name&quot;:&quot;Richters&quot;},{&quot;first_name&quot;:&quot;Julia&quot;,&quot;last_name&quot;:&quot;Ketzer&quot;},{&quot;first_name&quot;:&quot;Matthäus&quot;,&quot;last_name&quot;:&quot;Getlik&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Grütter&quot;},{&quot;first_name&quot;:&quot;Ralf&quot;,&quot;last_name&quot;:&quot;Schneider&quot;},{&quot;first_name&quot;:&quot;Johannes&quot;,&quot;last_name&quot;:&quot;M. Heuckmann&quot;},{&quot;first_name&quot;:&quot;Stefanie&quot;,&quot;last_name&quot;:&quot;Heynck&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;L. Sos&quot;},{&quot;first_name&quot;:&quot;Anu&quot;,&quot;last_name&quot;:&quot;Gupta&quot;},{&quot;first_name&quot;:&quot;Anke&quot;,&quot;last_name&quot;:&quot;Unger&quot;},{&quot;first_name&quot;:&quot;Carsten&quot;,&quot;last_name&quot;:&quot;Schultz-Fademrecht&quot;},{&quot;first_name&quot;:&quot;Roman&quot;,&quot;last_name&quot;:&quot;K. Thomas&quot;},{&quot;first_name&quot;:&quot;Sebastian&quot;,&quot;last_name&quot;:&quot;Bauer&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Rauh&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;5757-5772&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm4004076&quot;},&quot;abstract&quot;:&quot;Mutations in the catalytic domain at the gatekeeper position represent the most prominent drug-resistant variants of kinases and significantly impair the efficacy of targeted cancer therapies. Understanding the mechanisms of drug resistance at the molecular and atomic levels will aid in the design and development of inhibitors that have the potential to overcome these resistance mutations. Herein, by introducing adaptive elements into the inhibitor core structure, we undertake the structure-based development of type II hybrid inhibitors to overcome gatekeeper drug-resistant mutations in cSrc-T338M, as well as clinically relevant tyrosine kinase KIT-T670I and Abl-T315I variants, as essential targets in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML). Using protein X-ray crystallography, we confirm the anticipated binding mode in cSrc, which proved to be essential for overcoming the respective resistances. More importantly, the novel compounds effectively inhibit clinically releva&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4004076&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4004076" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4004076&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4004076" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4004076&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4004076" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm4004076&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4004076&amp;href=/doi/10.1021/jm4004076" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm4004076" /></input><a href="/doi/pdf/10.1021/jm4004076" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm4004076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm4004076%26sid%3Dliteratum%253Aachs%26pmid%3D23773153%26genre%3Darticle%26aulast%3DRichters%26date%3D2013%26atitle%3DTargeting%2BGain%2Bof%2BFunction%2Band%2BResistance%2BMutations%2Bin%2BAbl%2Band%2BKIT%2Bby%2BHybrid%2BCompound%2BDesign%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D14%26spage%3D5757%26epage%3D5772%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jmcmar.2013.56.issue-14/production/jmcmar.2013.56.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/medium/jm-2013-004076_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4004076&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Mutations in the catalytic domain at the gatekeeper position represent the most prominent drug-resistant variants of kinases and significantly impair the efficacy of targeted cancer therapies. Understanding the mechanisms of drug resistance at the molecular and atomic levels will aid in the design and development of inhibitors that have the potential to overcome these resistance mutations. Herein, by introducing adaptive elements into the inhibitor core structure, we undertake the structure-based development of type II hybrid inhibitors to overcome gatekeeper drug-resistant mutations in cSrc-T338M, as well as clinically relevant tyrosine kinase KIT-T670I and Abl-T315I variants, as essential targets in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML). Using protein X-ray crystallography, we confirm the anticipated binding mode in cSrc, which proved to be essential for overcoming the respective resistances. More importantly, the novel compounds effectively inhibit clinically relevant gatekeeper mutants of KIT and Abl in biochemical and cellular studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72024" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72024" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Protein kinases represent a major enzyme family comprised of more than 500 members encoded in the human genome, which are involved in several signal transduction processes, including those responsible for cell proliferation, apoptosis, and cell survival.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> Since deregulation of signaling pathways, especially by constitutive activation of kinases, often leads to the onset of various diseases, including cancer, the inhibition of kinases has been at the leading edge of cancer research for decades.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Various kinase inhibitors bind to the ATP binding site (type I and II inhibitors)<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5-8)</a> and have proven to be powerful tools in the treatment of cancer. Imatinib targets tyrosine kinases such as KIT in gastrointestinal stromal tumors (GISTs)<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> and Bcr-Abl in chronic myelogenous leukemia (CML).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Similarly, gefitinib targets EGFR in non-small-cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Although these inhibitors are very successful in early disease stages in selected patient populations, the emergence of drug resistance during later stages of treatment is becoming an ever-increasing challenge.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> DNA sequencing efforts of primary tumors show a high incidence of mutations in the active site of targeted kinases, which are responsible for this resistance.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Thus, drug resistance is a major problem in the long-term treatment with targeted cancer therapies.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> Treatment of CML patients with imatinib (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a), for instance, leads on average to the incidence of drug resistance mutations in the kinase domain of Bcr-Abl or intolerance to imatinib in 30% of examined patient populations in the first five years.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Even more dramatically, in the case of patients suffering from solid GISTs, 14% of patients initially do not respond to imatinib treatment and 50% will develop resistance mutations in the kinase domain of the stem cell growth factor receptor KIT within the first two years.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Likewise, the efficacy of gefitinib in the treatment of NSCLC is significantly impaired by acquired resistance mutation T790M at the gatekeeper position of EGFR and renders even second-generation inhibitors that irreversibly modify a rare cysteine at the lip of the catalytic cleft with only limited clinical impact.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> This demonstrates that the development of new and selective inhibitors that can inhibit clinically relevant kinases is still of major importance for the treatment of diseases such as GIST, CML, and NSCLC.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/medium/jm-2013-004076_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) General scaffold of a 1,4-fused type II hybrid inhibitor, <b>1</b>, composed of type I and type III fragments, as well as hybrid compound <b>2</b>, as an initial rationally designed molecule to target cSrc wild-type and T338M. Imatinib and ponatinib represent approved type II inhibitors for the treatment of GISTs and CML. (B) Schematic overview on how to circumvent steric repulsion with bulky gatekeepers (e.g., methionine) in drug-resistant mutant kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4004076&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One of the most prominent and striking mutations is the replacement of the gatekeeper residue, a position that is known to control access to the ATP-binding site affecting inhibitor selectivity, with a bulkier and often more lipophilic residue, as is the case for T670I of the KIT oncogenic drug-resistant variant in GIST. The primary gain of function mutation V559D in the juxtamembrane region of KIT leads to constitutive activation, while the secondary mutation T670I at the gatekeeper position is accompanied by insensitivity toward imatinib as a first line therapy.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> Similarly the oncogenic fusion protein Bcr-Abl in CML results in stabilization of the active kinase conformation leading to a constitutively active protein. Additionally, the amino acid exchange of threonine for isoleucine at the gatekeeper position 315 (T315I) causes a steric repulsion that prohibits inhibitors from binding within the active site and causes resistance to imatinib.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Moreover, this substitution at position 315 represents the only variant out of more than 50 drug-resistant mutations occurring in the catalytic domain of Bcr-Abl that is presently unfeasible to address in cancer therapy with small molecule inhibitors<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> with one exception: the type II inhibitor ponatinib (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a) recently received accelerated approval by the FDA while still running in phase III clinical trials, but treatment potentially produces severe side effects such as hepatotoxicity and arterial thrombosis.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> Therefore, current efforts in kinase research focus on overcoming these mutant variants by developing allosteric inhibitors that exclusively bind outside the ATP binding site and lock the kinase in its inactive form.<a onclick="showRef(event, 'ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29">(26-29)</a></div><div class="NLM_p last">Recently, we presented the structure-guided development of type II inhibitors of cSrc. Fusion of a pyrazolo urea scaffold (type III, “allosteric”) with a quinazoline core (type I, ATP-competitive) resulted in potent type II cSrc inhibitors (<b>1</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a) that lock the kinase in the inactive DFG-out conformation; these inhibitors were also active on the drug-resistant T338M gatekeeper mutant of cSrc. Protein X-ray crystallography revealed the rotational flexibility of a central 1,4-substituted phenyl ring of the inhibitor, which allows the hybrids to circumvent sterically demanding gatekeepers.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Here, we present the structure-guided optimization of those inhibitors to target the clinically relevant kinases KIT and Abl and their respective gatekeeper mutant forms T670I and T315I in biochemical and cellular systems.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Structure-Based Design of Type II Hybrid Inhibitors against cSrc, KIT, and Abl</h3><div class="NLM_p">Since cSrc, KIT, and Abl belong to closely related families of tyrosine kinases, we used the gatekeeper mutant cSrc T338M as an initial model system to transfer to KIT T670I and Abl T315I. To evaluate this, we generated a superimposed model of both (Figure S1, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>), based on the X-ray structure of cSrc T338M in complex with <b>2a</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3F3W">3F3W</a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> From this model, we predicted that a binding mode highly similar to cSrc would occur, suggesting that the new hybrid compounds would also show an inhibitory activity for KIT and Abl, as well as their gatekeeper mutant forms. The quinazoline <i>N</i>1 addresses the hinge, and the urea moiety is sandwiched between helix C and the DFG-motif of the kinase, which adopts its “out” conformation. A phenyl ring allowing for rotational flexibility links these parts of the inhibitor and interacts with the DFG-phenylalanine through a favorable edge-to-face orientation.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The pyrazolo part points into the allosteric pocket, which is accessible only in the kinase’s inactive conformation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Taking into account the hybrid compound’s ability to overcome gatekeeper mutations as for cSrc T338M, we proposed that these small molecules would be promising binders to inhibit the gatekeeper mutated forms of KIT T670I and Abl T315I.</div><div class="NLM_p">Our optimization efforts were directed toward the extension of the hybrids at the quinazoline’s 6-position with H-bond acceptor moieties (e.g., <b>3g</b>,<b>h</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). We speculated that introduction of polar motifs would lead to the formation of an additional contact at the lip of the active site to Asp348 in cSrc (data not shown), as well as to the corresponding residues Asn680 in KIT and Asp325 in Abl as shown in the case of <b>3g</b> (Figure S1, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). In addition, the moderate solubility of the original compound would be increased. Furthermore, we exchanged the <i>meta</i>-positioned methyl group of the pyrazole connected phenyl ring with an amino moiety to improve the interaction within a polar subgroove adjacent to the allosteric binding site, which is formed by the polar side chain residues Glu310 (helix C), Asp404 (activation loop), and catalytic Lys295. We assumed that the ligand’s polar interplay with this region would give further benefit to the affinity of these hybrid compounds toward gatekeeper mutant forms of cSrc (T338M), KIT (T670I), and Abl (T315I). We also replaced the pyrazolo part by a 4-chloro-3-trifluormethylphenyl moiety (<b>6</b>), the hydrophobic motif of the known multikinase inhibitor sorafenib,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> to study structure–activity relationships (SARs) among different implemented type III scaffolds and to achieve further increases in potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Overview of Rationally Designed Small Molecule Library Consisting of Variably Fused 1,4- and 1,3-Fused Hybrid Derivatives as Well as Fragments and Compounds with Replaced Pyrazolo Part</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/medium/jm-2013-004076_0006.gif" alt="" id="fx22" /></img><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Synthesis of a Focused Library of Hybrid Compounds and Fragments</h3><div class="NLM_p">We synthesized a focused library of variably fused type II inhibitors (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) and paid particular attention to the derivatization of the quinazoline 6-position with various polar moieties frequently utilized in kinase inhibitor research (e.g., morpholine or methyl-piperazine).<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> Since they exhibited different structural compositions, we expected these inhibitors to show a distinct SAR regarding their potency toward the investigated kinases. We especially expected the 1,4-fused hybrids to perturb gatekeeper mutated forms of the kinases. The panel of inhibitors also included scaffolds with the pyrazolo part removed (<b>6a</b>,<b>b</b>) to (a) study the relevance of this structural motif concerning the binding affinity of the hybrid compounds and (b) further improve the inhibitory activity. Additionally, we incorporated type III pyrazolo-urea inhibitors (<b>5a</b>,<b>b</b>) into the set of tested compounds.</div><div class="NLM_p">Hybrid compounds with different variations on the quinazoline 6-position were synthesized using a generic route (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) starting with a <i>Pinner</i>-like cyclization of <i>m</i>-nitrophenyl hydrazine and pivaloyl acetonitrile to generate pyrazole <b>7</b>. The primary amine of <b>7</b> was then protected with 2,2,2-trichloroethyl chloroformate (Troc), yielding carbamate <b>8</b>, which subsequently was reacted with various primary amines to create the central urea moiety.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Fragments <b>5a</b> and <b>5b</b> were generated by treatment of <b>8</b> with methylamine hydrochloride to build up <b>5a</b>, and successive reduction with Pd/C provided the corresponding amine <b>5b</b>. Intermediates <b>9</b> and <b>10</b> were synthesized by reacting single Boc-protected 1,3- and 1,4-phenylenediamines with <b>8</b>. The 1,4-fused precursor <b>9</b> was then used to assemble quinazoline-pyrazoloureas <b>3e</b>–<b>i</b> by initial reduction to an intermediary amine and successive introduction of the orthogonal Fmoc-protecting group, providing <b>11</b>. An orthogonal protecting group strategy was essential to ensure selective derivatization of the quinazoline 6-position in <b>3e</b>. Next, 6-nitro-4-chloro-quinazoline was added via a two-step process, starting with Boc-deprotection and subsequent coupling of the quinazoline to form <b>12</b> by nucleophilic aromatic substitution (S<sub>N</sub>Ar). Reduction with Fe/AcOH provided <b>3e</b> which was further derivatized through direct amide formation with (<i>in situ</i> prepared) acid chlorides. Finally, Fmoc-cleavage provided compounds <b>3f</b>–<b>i</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/medium/jm-2013-004076_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of a Subset of Quinazoline Derivatives and Fragments<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4004076&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Pivaloyl acetonitrile, conc. HCl, EtOH, 90 °C; (ii) Troc-Cl, NaOH, EtOAc/H<sub>2</sub>O, 0 °C to rt; (iii) methylamine hydrochloride, DIPEA, DMSO, rt; (iv) <i>N</i>-Boc phenylenediamine, DIPEA, DMSO, rt; (v) ammonium formate, Pd/C, EtOH, 90 °C; (vi) Fmoc-Cl, NaHCO<sub>3</sub>, dioxane/H<sub>2</sub>O, rt; (vii) 4 M HCl in dioxane, rt; (viii) 4-chloro-6-aminoquinazoline, DIPEA, DCM, rt; (ix) iron chipping (activated with 1 N HCl), AcOH, EtOH, reflux; (x) corresponding acid chloride of <b>f–i</b>; THF, base (DIPEA or NMP), THF or DCM, rt; (xi) piperidine or morpholine in DMF, rt. The framed intermediate molecule was further used to generate other hybrid derivatives in a different synthetic route (See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Schemes S1 and S2).</p></p></figure><div class="NLM_p">Quinazoline derivatives <b>3a</b>, <b>3b</b>, and <b>4a</b> were prepared via Boc-deprotection of intermediates <b>9</b> and <b>10</b> (see above). The corresponding amines <b>13</b> and <b>14</b> (Scheme S1, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) were reacted with 6-nitro-4-chloroquinazoline or 4-chloroquinazoline, respectively, resulting in compounds <b>3a</b>, <b>3b</b>, and <b>4a</b>. Reduction with Pd/C (for <b>3a</b>) or SnCl<sub>2</sub> (for <b>3b</b>, <b>4a</b>) to the corresponding amines <b>3c</b>, <b>3d</b>, and <b>4b</b> was conducted to complete this subset of derivatives.</div><div class="NLM_p last">Compounds <b>6a</b> and <b>6b</b> (<a class="ref internalNav" href="#notes-1" aria-label="Scheme S2">Scheme S2</a>) were made by initial reaction of 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene with <i>tert</i>-butyl 4-aminophenylcarbamate. Boc-cleavage led to <b>15</b>, which then was treated with 4-chloro-6-nitroquinazoline to generate quinazoline urea <b>6a</b> in a S<sub>N</sub>Ar reaction. Finally, reduction with SnCl<sub>2</sub> was performed to prepare amine <b>6b</b>. Detailed synthetic procedures are described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Activity-Based <i>in Vitro</i> Characterization of Hybrid Compounds against cSrc</h3><div class="NLM_p">We characterized the focused compound collection against cSrc using an activity-based assay that quantifies phosphorylation of an artificial substrate by a particular kinase through homogeneous time-resolved FRET measurements (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). The observed IC<sub>50</sub> values (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) confirmed an improved activity of the 1,4-fused hybrid compounds <b>3f</b>–<b>h</b> (∼1 nM) with respect to both cSrc wild-type and its T338M mutant. In comparison to the most potent first generation hybrid compound (<b>2b</b>), this corresponded to a 14- and 23-fold increase in potency against wild-type and mutant cSrc, respectively. Converting the pyrazolo group into a 4-chloro-3-trifluormethylphenyl moiety significantly decreased the affinity (<b>6a</b>,<b>b</b>) and demonstrated that the pyrazolo part is an important structural feature for preserving the binding affinity of the hybrids within the allosteric site of cSrc (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). However, this element on its own (<b>5a</b>,<b>b</b>) did not show any inhibitory activity toward the protein due to the absence of the ability to lock the kinase in its inactive DFG-out conformation. Moreover, we illustrated a clear SAR among different derivatives concerning their efficacy against both cSrc variants. In general, the 1,4-fused hybrids <b>3f</b>–<b>h</b> were equally potent against both the wild-type and mutant kinase, while 1,3-fused analogs (<b>4a</b>,<b>b</b>) completely lost their potency against the mutant cSrc carrying the bulky methionine gatekeeper. This was to be expected from our previous study, in which we showed that the rigid 1,3-hybrid scaffold resulted in a steric repulsion between the gatekeeper residue and the inhibitor’s central phenyl ring leading to a lower affinity against the mutant form of cSrc.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Derivatizing the quinazoline 6-amine resulted in increased potency versus related nonmodified structures (<b>3f</b>–<b>i</b> vs <b>3a</b>–<b>e</b>). Except for <b>3c</b>, equipped with a primary amine, the whole set of 1,4-fused hybrid compounds follows this general observation. Notably, there was no difference in efficacy observed between <b>3f</b> and <b>3h</b> (both ∼1 nM), illustrating that an additional interaction to Asp348 is not obligatory for improved binding. Rather, the composition of quinazoline-6-amide and <i>meta</i>-amine is responsible for the observed effect.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. IC<sub>50</sub> Determinations of Hybrid Compounds and Fragments on Different Target Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char="±">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">cSrc<sup>WT</sup></th><th class="colsep0 rowsep0" align="center" char="±">cSrc<sup>T338M</sup></th><th class="colsep0 rowsep0" align="center" char="±">Abl<sup>WT</sup></th><th class="colsep0 rowsep0" align="center" char="±">Abl<sup>T315I</sup></th><th class="colsep0 rowsep0" align="center" char="±">cKIT<sup>WT</sup></th><th class="colsep0 rowsep0" align="center" char="±">cKIT<sup>V559D/T670I</sup></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3a</b></td><td class="colsep0 rowsep0" align="char" char="±">34.2 ± 22.6</td><td class="colsep0 rowsep0" align="char" char="±">126 ± 82.0</td><td class="colsep0 rowsep0" align="char" char="±">157 ± 76</td><td class="colsep0 rowsep0" align="char" char="±">561 ± 222</td><td class="colsep0 rowsep0" align="char" char="±">69.3 ± 19.3</td><td class="colsep0 rowsep0" align="char" char="±">637 ± 91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3b</b></td><td class="colsep0 rowsep0" align="char" char="±">19.9 ± 11.5</td><td class="colsep0 rowsep0" align="char" char="±">33.0 ± 5.1</td><td class="colsep0 rowsep0" align="char" char="±">42 ± 23</td><td class="colsep0 rowsep0" align="char" char="±">355 ± 116</td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 5.4</td><td class="colsep0 rowsep0" align="char" char="±">38.0 ± 16.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3c</b></td><td class="colsep0 rowsep0" align="char" char="±">12.0 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">5.9 ± 3.7</td><td class="colsep0 rowsep0" align="char" char="±">73 ± 36</td><td class="colsep0 rowsep0" align="char" char="±">81 ± 23</td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">7.6 ± 3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3d</b></td><td class="colsep0 rowsep0" align="char" char="±">37.9 ± 11.8</td><td class="colsep0 rowsep0" align="char" char="±">33.3 ± 10.2</td><td class="colsep0 rowsep0" align="char" char="±">40 ± 20</td><td class="colsep0 rowsep0" align="char" char="±">120 ± 43</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">24.0 ± 3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3e</b></td><td class="colsep0 rowsep0" align="char" char="±">145 ± 47</td><td class="colsep0 rowsep0" align="char" char="±">211 ± 120</td><td class="colsep0 rowsep0" align="char" char="±">1273 ± 301</td><td class="colsep0 rowsep0" align="char" char="±">3620 ± 1180</td><td class="colsep0 rowsep0" align="char" char="±">20.9 ± 6.5</td><td class="colsep0 rowsep0" align="char" char="±">305 ± 69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3f</b></td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">112 ± 45</td><td class="colsep0 rowsep0" align="char" char="±">441 ± 124</td><td class="colsep0 rowsep0" align="char" char="±">7.6 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">22.1 ± 13.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3g</b></td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">124 ± 54</td><td class="colsep0 rowsep0" align="char" char="±">1170 ± 450</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3h</b></td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">61 ± 53</td><td class="colsep0 rowsep0" align="char" char="±">176 ± 47</td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">6.9 ± 2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3i</b></td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">379 ± 70</td><td class="colsep0 rowsep0" align="char" char="±">820 ± 304</td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 3.4</td><td class="colsep0 rowsep0" align="char" char="±">9.2 ± 3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="char" char="±">39.3 ± 6.1</td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">9 ± 7</td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">29.2 ± 21.0</td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4b</b></td><td class="colsep0 rowsep0" align="char" char="±">304 ± 94</td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">23 ± 4</td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">30.1 ± 22.0</td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">4.5 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="char" char="±">3037 ± 200</td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">923 ± 305</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="char" char="±">14 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">388 ± 88</td><td class="colsep0 rowsep0" align="char" char="±">141 ± 50</td><td class="colsep0 rowsep0" align="char" char="±">21.9 ± 6.1</td><td class="colsep0 rowsep0" align="char" char="±">155 ± 84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">imatinib</td><td class="colsep0 rowsep0" align="char" char="±">2784 ± 481</td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">19.9 ± 2.7</td><td class="colsep0 rowsep0" align="char" char="±"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">21.6 ± 7.0</td><td class="colsep0 rowsep0" align="char" char="±">≥100000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sunitinib</td><td class="colsep0 rowsep0" align="char" char="±">555 ± 48</td><td class="colsep0 rowsep0" align="char" char="±">134 ± 41</td><td class="colsep0 rowsep0" align="char" char="±">1613 ± 938</td><td class="colsep0 rowsep0" align="char" char="±">504 ± 102</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">264 ± 92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ponatinib</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">156 ± 27</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dovitinib</td><td class="colsep0 rowsep0" align="char" char="±">80.8 ± 35.1</td><td class="colsep0 rowsep0" align="char" char="±">50.1 ± 15.4</td><td class="colsep0 rowsep0" align="char" char="±">450 ± 65</td><td class="colsep0 rowsep0" align="char" char="±">228 ± 67</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">48.3 ± 5.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">No inhibition at 100 μM compound concentration.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Complex Crystal Structures of Type II Hybrids in cSrc</h3><div class="NLM_p">To confirm the proposed general binding mode of our type II hybrids and to study the relevance of the newly introduced moieties we cocrystallized wild-type cSrc with <b>3g</b> and <b>3h</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). As anticipated by the modeling results, these hybrid inhibitors were bound in a type II manner, accessing both allosteric and ATP-binding pockets, thereby locking the kinase in its inactive DFG-out conformation. Similar to the crystal structure of the parent compound (<b>2a</b>), the quinazoline <i>N</i>1 generates a direct hydrogen bond to the peptide backbone of Met341, located within the cSrc hinge region. The 1,4-fused phenyl ring of the inhibitor is sandwiched between the gatekeeper and Phe405 of the DFG motif, whereas the urea part is embedded within the groove formed by helix C (stabilized by two hydrogen bonds to Glu310) and DFG motif (one hydrogen bond to Asp404). An additional interaction was created by the pyrazolo portion, which binds to the allosteric subpocket by forming a water-mediated hydrogen bond to Asp404 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). The newly introduced 6-quinazoline substituents (4-(dimethylamino)butanoic acid and 3-(4-methylpiperazin-1-yl)propanoic acid) contributed to the affinity by an additional hydrogen bond to Asp348. A novel protein ligand interaction was created by the inhibitor’s primary amino moiety via a polar contact to a small polar subpocket, which is located outward of the allosteric site and is comprised by a water molecule (W69) and polar amino acid side chains (Lys295, Glu310, and the backbone of the DFG-motif, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>C).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/medium/jm-2013-004076_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. 1,4-Substituted hybrid compounds in complex with wild-type cSrc. Diagrams of the experimental electron densities of cSrc–<b>3h</b> at 2.7 Å (A) and cSrc-<b>3g</b> at 3.3 Å (B) resolution are shown (2<i>F</i><sub>o</sub><i> – F</i><sub>c</sub> map contoured at 1σ). Hydrogen-bond interactions of the inhibitors with helix C (turquoise), the DFG-motif (pink), and the hinge region (orange) are shown by red dotted lines. The kinase domain is in the inactive DFG-out conformation, and the pyrazolourea moiety resides in the allosteric site flanked by helix C and the DFG-motif. <i>N</i>1 of the quinazoline makes a direct hydrogen bond to the main chain amide of Met341, which is an interaction commonly formed between anilinoquinazolines and the hinge region of several other protein kinase domains. In both complexes, the central phenyl moiety that links the quinazoline scaffold with the pyrazolourea fragment interacts with the side chain of Phe405 (DFG motif) in a favorable edge-to-face orientation. (C) The aromatic amine points into a polar subpocket that is formed by three polar amino acid side chains (Lys295, Glu310, and Asp404) and forms polar interactions with a water molecule (red sphere). A detailed illustration of this interaction, including electron density data, is provided in Figure S2, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4004076&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Hybrid Compounds Inhibit Drug-Resistant Mutants KIT V559D/T760I and Abl T315I</h3><div class="NLM_p">The results from activity-based studies on KIT and Abl were highly similar to those conducted with cSrc. Consistent with our previous studies, kinase selectivity profiling showed clear evidence for KIT as a possible target for our hybrid inhibitors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Within the kinase domain of KIT, the same principal features are potentially addressable by our newly designed binders because comparison to cSrc and biochemical investigations revealed strong inhibition against its constitutively active (V559D) and concomitant gatekeeper mutated (T670I) form. We observed IC<sub>50</sub> values in the low nanomolar range against KIT wild-type for <b>3b</b>–<b>d</b> and <b>3f</b>–<b>i</b> (2.6–7.6 nM) whereas the 1,3-fused inhibitors <b>4a</b> and <b>4b</b> were slightly less potent, eliciting values around 30 nM (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Consistent with the previous findings on cSrc, the more rigid compounds (<b>4a</b>,<b>b</b>) completely lost their inhibitory activity against the V559D/T670I mutant form. However, the activity of this double mutant was impeded by the bulk of the 1,4-fused compounds without significant loss of efficiency for most representatives (<b>3c</b> and <b>3g</b>–<b>i</b>, 2.7–9.2 nM) due to their adaptive phenyl ring, which most likely rotates by 90° and avoids a steric clash with the bulky gatekeeper (isoleucine). Strikingly, we observed a strong analog effect for <b>6a</b> and <b>6b</b> against KIT (1.0 and 4.5 nM), but the transfer of this effect to the gatekeeper mutant form was not achieved for <b>6b,</b> which exhibited a 1000-fold loss of potency, while <b>6a</b> revealed essentially no effect.</div><div class="NLM_p last">The 1,3-fused hybrid compounds <b>4a</b>,<b>b</b> showed a very high affinity for the Abl wild-type kinase (IC<sub>50</sub> = 9–23 nM) whereas they completely failed to inhibit the T315I gatekeeper mutant form (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). In contrast, the 1,4-fused hybrid compounds <b>3a</b>–<b>d</b> and <b>3f</b>–<b>h</b> exhibited a significant inhibition of wild-type Abl (IC<sub>50</sub> = 42–157 nM) and predominantly retained their potency toward Abl T315I (IC<sub>50</sub> = 81–176 nM). As seen in cSrc, fragments <b>5a</b>,<b>b</b> and scaffolds without the pyrazolo moiety <b>6a</b>,<b>b</b> showed no evidence of binding, suggesting that further interactions of this unique moiety were required for binding to Abl. Thus, our approach of using inhibitors with rotatable motifs to overcome gatekeeper mutations in kinases was successful for the <i>in vitro</i> inhibition of cSrc, KIT, and Abl (for biochemical selectivity profile of <b>3d</b> see Figure S3, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Type II Inhibitors are Active on GIST Cell Lines Expressing KIT T670I</h3><div class="NLM_p">We investigated inhibitory effects of selected derivatives on human, untreated, metastatic GIST cells harboring a 57 bp deletion of exon 11, which leads to expression of constitutively activated KIT (GIST-T1).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Additionally, we examined the corresponding T670I gatekeeper mutated variant (GIST-T1 T670I) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A,B,D). We treated each type of the cells for 72 h with <b>3b</b>, <b>3c</b>, <b>3d</b>, <b>3f</b>, <b>3h</b>, and <b>6b</b> (0–30 μM); imatinib and ponatinib served as control compounds. All tested compounds markedly reduced the number of viable GIST-T1 cells. In particular, <b>3b</b>, <b>3d</b>, and <b>6b</b>, without the quinazoline 6-position substitution, accounted for the most significant effects (GI<sub>50</sub> = 11–17 nM). Substituted representatives (<b>3f</b>,<b>h</b>) as well as <b>3c</b>, carrying a primary amine at the 6-position, were somewhat less effective (GI<sub>50</sub> = 105–402 nM). Treatment of imatinib-resistant GIST-T1 T670I cells generated a similar effect, showing the 1,4-fused quinazoline-pyrazolo urea hybrids to preserve their antiproliferative effects. The observed efficacies were comparable to those observed for GIST-T1 with <b>3b</b> and <b>3d</b>, which were the most potent derivatives (GI<sub>50</sub> = 24–28 nM), followed by <b>3c</b> (110 nM).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/medium/jm-2013-004076_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Dose–response curves of hybrid compounds on GIST cells expressing (A) constitutively active KIT (GIST-T1) as well as (B) the gatekeeper mutated KIT T670I (GIST-T1 T670I) and (C) the KIT negative cell line GIST-48B after 72 h incubation with the respective compounds; (D) GI<sub>50</sub> values on GIST-T1, GIST-T1 T670I, and GIST-48B; (E,F) Western blot analyses after 24 h of incubation with doses of <b>3d</b>, <b>3h</b>, and imatinib (IM) in GIST-T1 and GIST-T1 T670I.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4004076&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Notably, a strong inhibitory effect was also observed for <b>6b</b> with respect to GIST-T1 T670I (GI<sub>50</sub> = 121 nM). We observed an almost 8-fold discrepancy in the inhibition of the isolated protein KIT V559D/T670I (IC<sub>50</sub> = 923 nM) versus the inhibition in the corresponding cell line by <b>6b</b>. Compound <b>6b</b> may represent a slow binder, possessing a slow on- and off-rate and therefore its true activity within a biochemical system may not be fully evident. The difference in efficacy may be related to the marginal incubation times with the isolated protein (0.5 h) compared with cellular systems (72 h). A cellular system represents an open equilibrium binding situation and a slow off-rate could potentially lead to temporal target selectivity.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Treatment of KIT-negative GIST-48B cells did not result in decreased proliferation, indicating no incidence of generic toxicity for the whole set of tested compounds with GI<sub>50</sub> values ≥30 μM except <b>3c</b>, <b>3f</b>, and <b>3h</b>, which did not elicit any antiproliferative effect at concentrations up to 30 μM (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C). Therefore, the tested molecules without exception revealed an improved off-target profile in GISTs compared with imatinib (GI<sub>50</sub> = 20 μM) and ponatinib (2.1 μM), a phase III clinical candidate for treatment of CML.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">In order to study the immediate impact on cellular KIT autophosphorylation and disruption of downstream signaling, we monitored phosphorylation states of KIT Y703 (autophosphorylation site) and the related downstream targets Akt (pS473) and MAPK (pT202/Y204) by Western blot analysis (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>E,F). Treatment with <b>3d</b> and <b>3h</b> reduced cellular amounts of pKIT and simultaneously pAkt and pMAPK in GIST-T1 in a concentration-dependent manner. Applying 70 nM <b>3d</b> or 2000 nM <b>3h</b> led to 50% abrogation of the total amount of protein, confirming the direct effect of the hybrid compounds on KIT. The different substitution pattern of <b>3d</b> and <b>3h</b> led to different cellular performances (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A–D). Compound <b>3d</b> has no substituent on the quinazoline 6-position, whereas <b>3h</b> has an ethylenamide-linked methylpiperazine which apparently led to reduced efficacy by most likely increasing both polarity and molecular weight. This observation was accompanied by a simliar reduction of pKIT and downstream signaling levels through pAkt and pMAPK caused by <b>3d</b> and <b>3h</b> at distinct concentrations (50% reduction of pKIT at 35 nM and 400 nM, respectively) in the corresponding GIST-T1 T760I cells expressing gatekeeper mutated KIT. However, these results confirmed our initial hypothesis on clinically relevant gatekeeper mutations to be overcome in a cellular system by equipping small molecules with elements which incorporate rotational flexibility.</div><div class="NLM_p last">Additional experiments were performed in order to investigate the inhibitory effect on Bcr-Abl and the respective T315I gatekeeper mutated species in Ba/F3 cells (Figure S4, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). According to the biochemical investigations on isolated kinase domains, the 1,4-fused inhibitors were less potent. Nevertheless <b>3b</b> and <b>3d</b> were following the same trend reducing the viability of Ba/F3 Bcr-Abl cells (GI<sub>50</sub> = 4.1 μM and 4.3 μM) and furthermore retaining the antiproliferative effect on the gatekeeper resistant mutation in Ba/F3 Bcr-Abl T315I (GI<sub>50</sub> = 3.5 μM and 1.6 μM). Comparatively to the GIST studies, these results reflect the biochemical characterizations, which indicated that the inhibitory effect on KIT is more significant as compared with Abl.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Cytotoxicity and Inhibition of Metabolic Enzymes</h3><div class="NLM_p last">In order to explore the hybrid compounds’ general cytotoxicity additional studies using liposarcoma (LPS141), leiomyosarcoma (LMS676), and malignant peripheral nerve sheath tumor cells (MPNST) were conducted (Figure S5, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). There was no significant effect observed for the whole set of compounds. The most representative inhibitor, <b>3d</b>, showed GI<sub>50</sub>’s of around 15.1 μM (LPS141), 25.7 μM (LMS676), and 11.7 μM (MPNST), while its 6-position extended analogue <b>3h</b> did not significantly decrease the number of viable cells up to inhibitor concentrations of 30 μM. Interestingly, the marketed drug ponatinib reduced the viability of the respective cell lines to 50% at concentrations ranging from 0.1 to 0.8 μM. Next, we investigated the inhibitory impact of <b>3d</b> and <b>3h</b> on five CYPs (1A2, 2C9, 2C19, 2D6, and 3A4), as representative drug metabolizing enzymes and predictive markers for potential adverse effects (Table S2, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). None of the tested cytochromes except 3A4 (IC<sub>50</sub> = 14.8 μM and 1.95 μM for <b>3d</b> and <b>3h</b>) was remarkably inhibited.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11458" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11458" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The emergence of drug resistance in kinases due to acquired secondary mutations, with the most considerable mutations affecting the gatekeeper residue, is a central challenge for developing novel inhibitors for the long-term treatment of cancer. Here, we present the development and optimization of 1,4-fused quinazoline–pyrazolourea hybrids by structure-based design to compose and synthesize a focused library of inhibitors. SAR studies showed an improved activity of hybrid compounds <b>3f</b>–<b>h</b> toward cSrc (IC<sub>50</sub> ≈ 1 nM) compared with initially published inhibitors. An enhanced effect toward cSrc resulted from the newly introduced <i>meta</i>-oriented amino moiety at the pyrazolo-phenyl ring whereas the formation of an extra hydrogen bond to the kinase apparently was not crucial for increased potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, <b>3f</b> vs <b>3h</b>). Rather, the presence of a <i>meta</i>-amine and an obligatory amide at the quinazoline 6-position led to improved binding effects. These findings can be closely correlated to the enthalpy–entropy compensation caused by the entropically disfavored fixation of the ligand, for example in <b>3h</b>, which compensates the favorable enthalpic increase generated by the new hydrogen bond to Asp348 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). The binding between the protein and the polar moiety of the inhibitor contributes to the desolvation energy by stripping away the hydration shell. In the case of compounds <b>3g</b>–<b>i</b>, the surrounding tertiary amines represent an energetic barrier that must be overcome.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In addition, we achieved the transfer of the inhibitory activity onto stem cell factor receptor KIT (wild-type and V559D/T670I mutant, IC<sub>50</sub> = 3–8 nM and 3–38 nM, respectively, for <b>3b</b>–<b>d</b>, <b>3f</b>–<b>i</b>), as well as Abl kinase (wild-type and T315I mutant, IC<sub>50</sub> = 40–157 nM and 81–561 nM, respectively, for <b>3a</b>–<b>d</b>,<b>h</b>). The preserved inhibitory effects with respect to gatekeeper mutated kinases bearing bulky substituents on that position was likewise due to the spatial arrangement of the rotatable 1,4-fused phenyl ring connecting the inhibitor’s type I and type III parts. A 90° axial rotation of this element, as shown for addressing the T338M gatekeeper mutated form of cSrc,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> likewise accounted for the potent inhibition of the corresponding mutated kinases KIT T670I and Abl T315I.</div><div class="NLM_p">In cellular characterizations, we further extended the hybrids’ impact from significant <i>in vitro</i> inhibition of wild-type KIT as well as the gatekeeper and its simultaneously activating mutant form (V559D/T670I) to addressing the relevant stem cell factor receptor kinase species in human, untreated, metastatic GIST-T1 cells and, particularly, the KIT T670I positive cell line GIST-T1 T670I. We observed a significant impact in reduction of viable GIST-T1 (GI<sub>50</sub> = 11–17 nM for <b>3b/d</b>, <b>6b</b>) cells and moreover the inhibitory effect was maintained in GIST-T1 T670I (GI<sub>50</sub> = 24–121 nM for <b>3b/d</b>, <b>6b</b>) cells. The latter observation underlines our successful approach to generate hybrid compounds containing motifs with rotational flexibility that can override the mutations of gatekeeper residues in a cellular system. Notably, the inhibitory effect for compounds lacking further substitutions at the quinazoline 6-position (<b>3b</b>/<b>d</b>, <b>6b</b>) was superior to the effect of compounds bearing an extension (<b>3f</b>/<b>h</b>), suggesting that additional interactions with Asn680 (located at the lip of the hinge region) are not necessary at the cellular level, which agrees with the concept of enthalpy–entropy compensation. Furthermore, the introduction of polar moieties may affect the capability of the compounds to pass through the cell membrane, which may result in the generation of less significant cellular concentrations and thereby reduced potency of the quinazoline 6-position substituted compounds.</div><div class="NLM_p">The presented hybrid derivatives exhibit enormous potential in the therapeutic treatment of solid GISTs through addressing gain of function mutants of KIT, and due to their central and rotatable element they are similarly able to target the gatekeeper mutated T670I species. A recently released study by O’Hare et al. demonstrated that a linear triple bond as a connecting structural element between type I and type III like binders is likewise useful to overcome gatekeeper mutations in Abl due to its decreased spatial arrangement.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Derivatives harboring this structural motif were shown to conserve their inhibitory effect even against the T315I gatekeeper mutant form in xenograft models, and one representative (ponatinib) is now in phase III clinical trials as a pan-Bcr-Abl inhibitor for CML treatment.<a onclick="showRef(event, 'ref24 ref38'); return false;" href="javascript:void(0);" class="ref ref24 ref38">(24, 38)</a> Recently the FDA granted accelerated approval for ponatinib in the treatment of CML with resistance or intolerance to prior tyrosine kinase inhibitor therapy. However, severe side effects with hepatotoxicity leading to liver failure and death in some cases and 8–11% of treated patients revealing arterial thrombosis, were observed in clinical trials, indicating a rather complex pharmacology.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p last">In conclusion, our previously described quinazoline–pyrazolourea hybrids were optimized by using methods of medicinal chemistry. Using initial modeling studies and evaluating the improved effect by biochemical characterizations, we successfully obtained substantial transferability of the preliminarily determined binding mode to the clinically relevant kinases KIT and Abl. Furthermore, their constitutively active variants and gatekeeper mutants (T670I of KIT and T315I of Abl) were significantly inhibited as shown in biochemical characterizations using isolated kinase domains. Finally, compounds <b>3b</b>, <b>3c</b>, <b>3d</b>, <b>3f</b>, <b>3h</b>, and <b>6b</b> exhibit strong antiproliferative effects in cells derived from solid tumors harboring constitutively active KIT (GIST-T1) as well as gatekeeper mutated KIT T670I (GIST-T1 T670I) variants and thus represent valuable starting points for future medicinal chemistry endeavors.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30264" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30264" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">Unless otherwise noted, all reagents and solvents were purchased from Acros, Fluka, Sigma-Aldrich, or Merck and used without further purification. Dry solvents were purchased as anhydrous reagents from commercial suppliers. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance DRX 400 spectrometer at 400 and 101 MHz, respectively. <sup>1</sup>H chemical shifts are reported in δ (ppm) as s (singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet), m (multiplet), and bs (broad singlet) and are referenced to the residual solvent signal: CDCl<sub>3</sub> (7.26) or DMSO-<i>d</i><sub>6</sub> (2.50). <sup>13</sup>C spectra are referenced to the residual solvent signal: CDCl<sub>3</sub> (77.16) or DMSO-<i>d</i><sub>6</sub> (39.52). High-resolution electrospray ionization mass spectra (ESI-FTMS) were recorded on a Thermo LTQ Orbitrap (high-resolution mass spectrometer from Thermo Electron) coupled to an “Accela” HPLC system supplied with a “Hypersil GOLD” column (Thermo Electron). Analytical TLC was carried out on Merck 60 F245 aluminum-backed silica gel plates. Compounds were purified by column chromatography using Baker silica gel (40–70 μm particle size). Preparative HPLC was conducted on a Varian HPLC system (Pro Star 215) with a VP 250/21 nucleosil C18 PPN column from Macherey-Nagel and monitored by UV at λ = 254 nm. All final compounds were purified to ≥95% purity confirmed by LCMS analysis on LCQ Advantage MAX (1200 series, Agilent) with Eclipse XDB-C18-column (5 μM, 150 × 1.6 mm, Phenomenex).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 3-<i>tert</i>-Butyl-1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-amine Hydrochloride (<b>7</b>)</h4><div class="NLM_p last">A solution of <i>m</i>-nitrophenylhydrazine hydrochloride (2.00 g, 10.55 mmol) and pivaloylacetonitrile (1.53 g, 11.88 mmol) in dry EtOH (22 mL) was treated with concentrated HCl (3 mL) and refluxed for 12 h at 90 °C. The precipitate was filtered off and dried under reduced pressure before the crude was recrystallized from plain hexane yielding 2.94 g (9.91 mmol, 94%) of white crystals: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.45 (t, <i>J</i> = 2.1 Hz, 1H), 8.09 (m, 2H), 7.73 (t, <i>J</i> = 8.2 Hz, 1H), 5.48 (bs, 2H), 5.47 (s, 1H), 1.23 (s, 9H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.12, 148.09, 147.96, 140.59, 130.48, 127.70, 119.59, 115.99, 88.22, 31.93, 30.03. HRMS (ESI-MS) calcd: 261.13460 for C<sub>13</sub>H<sub>17</sub>N<sub>4</sub>O<sub>2</sub> [M + H<sup>+</sup>]. Found: 261.13456.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 2,2,2-Trichloroethyl 1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-ylcarbamate (<b>8</b>)</h4><div class="NLM_p last">NaOH (1.13 g, 28.3 mmol) was added to a suspension of <b>7</b> (2.94 g, 11.3 mmol) in EtOAc (20 mL) and H<sub>2</sub>O (6 mL) at 0 °C. The resulting reaction mixture was stirred for 30 min before 2,2,2-trichloroethyl chloroformate (2.28 mL, 17.0 mmol) was added dropwise. After an additional 30 min, the mixture was warmed to room temperature and stirred for 3 h. The organic layer was separated from the aqueous layer, which then was extracted with EtOAc (3 × 25 mL). The combined organic layers were once washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. Purification of the crude by silica gel column chromatography (20% EtOAc/petrol ether) lead to 4.79 g (11.0 mmol, 97%) of the desired product as a brown resin: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (s, 1H), 8.17 (dd, <i>J</i> = 8.1, 1.2 Hz, 1H), 7.88 (dd, <i>J</i> = 8.1 Hz, 1H), 7.60–7.65 (m, 1H), 6.35 (s, 1H), 4.76 (s, 2H), 3.08 (s, 1H), 1.33 (s, 9H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 163.56, 148.76, 139.44, 134.81, 130.48, 130.00, 122.31, 119.29, 99.55, 94.84, 76.32, 75.14, 32.72, 30.28. HRMS (ESI-MS) calcd: 435.03881 for C<sub>16</sub>H<sub>18</sub>Cl<sub>3</sub>N<sub>4</sub>O<sub>4</sub> [M + H<sup>+</sup>]. Found: 435.03874.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 1-(3-<i>tert</i>-Butyl-1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-yl)-3-methylurea (<b>4a</b>)</h4><div class="NLM_p last">A suspension of <b>8</b> (100 mg, 0.23 mmol), methylamine hydrochloride (155 mg, 230 mmol), and DIPEA (393 μL) in DMSO (2 mL) was stirred for 5 h at room temperature. Saturated sodium-bicarbonate solution was added, and the resulting mixture was extracted with EtOAc (5 × 15 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the volatiles were removed in vacuo. The crude was purified on silica gel using 0.5% MeOH/DCM which lead to 59 mg (0.19 mmol, 83%) of the desired product as a light yellow solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.39 (s, 1H), 8.32 (t, <i>J</i> = 2.1 Hz, 1H), 8.19 (ddd, <i>J</i> = 8.2, 2.2, 0.8 Hz, 1H), 8.00 (ddd, <i>J</i> = 8.0, 1.9, 0.8 Hz, 1H), 7.78 (t, <i>J</i> = 8.2 Hz, 1H), 6.40–6.33 (m, 1H), 6.29 (s, 1H), 2.58 (d, <i>J</i> = 4.6 Hz, 3H), 1.28 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.75, 155.33, 148.03, 139.84, 138.45, 130.65, 129.21, 121.06, 117.46, 98.23, 32.13, 30.03, 26.41. HRMS (ESI-MS) calcd: 318.15607 for C<sub>15</sub>H<sub>20</sub>N<sub>5</sub>O<sub>3</sub> [M + H<sup>+</sup>]. Found: 318.15611.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 1-(1-(3-Aminophenyl)-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-yl)-3-methylurea (<b>4b</b>)</h4><div class="NLM_p last">A solution of <b>4a</b> (104 mg, 0.33 mmol) and ammonium formate (124 mg, 1.97 mmol) in EtOH (7 mL) was treated with 5% Pd on charcoal (70 mg, 33 μmol). The resulting reaction mixture was refluxed for 1 h at 90 °C before the catalyst was filtered off and the volatiles were removed under reduced pressure. The crude was purified on silica gel (2% MeOH/DCM) yielding 67 mg (0.23 mmol, 70%) of a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (s, 1H), 7.10 (t, <i>J</i> = 7.9 Hz, 1H), 6.66 (t, <i>J</i> = 1.9 Hz, 1H), 6.60–6.52 (m, 2H), 6.43 (q, <i>J</i> = 4.1 Hz, 1H), 6.22 (s, 1H), 5.36 (s, 2H), 2.61 (d, <i>J</i> = 4.6 Hz, 3H), 1.25 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.99, 154.75, 149.62, 139.31, 137.83, 129.32, 112.63, 111.21, 109.77, 94.01, 31.94, 30.27, 26.21. HRMS (ESI-MS) calcd: 288.18189 for C<sub>15</sub>H<sub>22</sub>N<sub>5</sub>O [M + H<sup>+</sup>]. Found: 288.18188.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Procedure for the Preparation of <i>N</i>-Boc-Aminophenyl-3-(3-<i>tert</i>-butyl-1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-yl)ureas (<b>9</b>, <b>10</b>)</h4><div class="NLM_p">DIPEA was added to a solution of <i>N</i>-Boc-phenylenediamine in abs. DMSO and stirred under argon atmosphere at room temperature for 5 min. After addition of <b>8</b> in one portion, the resulting reaction mixture was stirred for 24 h at 60 °C. After cooling to room temperature, the mixture was poured into saturated bicarbonate solution followed by extraction with EtOAc (3 × 20 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the volatiles were removed under reduced pressure. The crude was purified by silica gel column chromatography.</div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> <i>tert</i>-Butyl 4-(3-(3-<i>tert</i>-Butyl-1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-yl)ureido)phenylcarbamate (<b>9</b>)</h5><div class="NLM_p last">Compound <b>9</b> was prepared as described in the general procedure using <i>tert-</i>butyl 4-aminophenylcarbamate (1.43 g, 6.88 mmol), DMSO (25 mL), DIPEA (2.36 mL, 13.8 mmol), and <b>8</b> (3 g, 6.88 mmol). The crude material was purified on silica gel (20–50% EtOAc/petrol ether) to yield 2.07 g (4.19 mmol, 61%) of a light yellow solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (s, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 1H), 7.80 (s, 2H), 7.72 (d, <i>J</i> = 7.7 Hz, 1H), 7.44–7.40 (m, 1H), 7.10 (d, <i>J</i> = 8.4 Hz, 2H), 6.99 (d, <i>J</i> = 8.6 Hz, 2H), 6.58 (s, 1H), 6.38 (s, 1H), 1.45 (s, 9H), 1.28 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.56, 151.93, 148.79, 139.40, 134.82, 130.51, 130.02, 122.36, 119.33, 99.55, 94.83, 76.35, 75.17, 60.73, 32.74, 30.29, 26.26, 21.24, 14.32. HRMS (ESI-MS) calcd: 495.23504 for C<sub>25</sub>H<sub>31</sub>N<sub>6</sub>O<sub>3</sub> [M + H<sup>+</sup>]. Found: 495.23445.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22"> <i>tert</i>-Butyl 3-(3-(3-<i>tert</i>-Butyl-1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-yl)ureido)phenylcarbamate (<b>10</b>)</h5><div class="NLM_p last">Compound <b>10</b> was prepared as described in the general procedure using <i>tert-</i>butyl 3-aminophenylcarbamate (300 mg, 0.69 mmol), DMSO (3 mL), DIPEA (236 μL, 1.38 mmol), and <b>8</b> (144 mg, 0.69 mmol). The crude material was purified on silica gel (0–0.5% MeOH/DCM) to yield 276 mg (0.56 mmol, 81%) of a light yellow solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.32 (s, 1H), 9.05 (s, 1H), 8.46 (s, 1H), 8.36 (t, <i>J</i> = 2.1 Hz, 1H), 8.22 (dd, <i>J</i> = 8.2, 1.5 Hz, 1H), 8.08–8.02 (m, 1H), 7.81 (t, <i>J</i> = 8.2 Hz, 1H), 7.57 (s, 1H), 7.11 (dd, <i>J</i> = 7.7, 4.5 Hz, 2H), 7.00–6.95 (m, 1H), 6.42 (s, 1H), 1.46 (s, 9H), 1.30 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.94, 152.70, 151.74, 148.14, 139.97, 139.61, 139.59, 137.80, 130.83, 129.57, 128.92, 121.42, 117.97, 112.28, 112.03, 108.07, 97.59, 79.01, 32.19, 30.07, 28.14. HRMS (ESI-MS) calcd: 495.23504 for C<sub>25</sub>H<sub>31</sub>N<sub>6</sub>O<sub>3</sub> [M + H<sup>+</sup>]. Found: 495.23443.</div></div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>tert</i>-Butyl 4-(3-(((9<i>H</i>-Fluoren-9-yl)methoxy)carbonylamino)phenyl)-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-yl)ureido)phenylcarbamate (<b>11</b>, 2 steps)</h4><div class="NLM_p">In a dry and argon-flushed flask, a solution of <b>9</b> (960 mg, 1.35 mmol) in EtOH (6 mL) was treated with ammoniumformate (510 mg, 8.1 mmol) and 5% Pd on charcoal (297 mg, 0.14 mmol) for 1 h at 70 °C. After filtration of the reaction mixture over Celite, the solvents were removed in vacuo. Recrystallization of the crude product from hexane resulted in 608 mg (1.31 mmol, 97%) of a pink solid, which was used without further purification: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.29 (s, 1H), 9.19 (s, 1H), 8.62 (s, 1H), 7.30 (q, <i>J</i> = 9.1 Hz, 4H), 7.13–7.09 (m, 1H), 6.69–6.68 (m, 1H), 6.62–6.53 (m, 2H), 6.30 (s, 1H), 5.37 (s, 2H), 1.46 (s, 9H), 1.26 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.94, 158.51, 153.68, 150.52, 148.16, 145.64, 140.02, 138.14, 134.99, 133.42, 130.27, 119.30, 113.64, 112.17, 110.73, 36.26, 32.83, 31.12, 29.02. HRMS (ESI-MS) calcd: 465.26087 for C<sub>25</sub>H<sub>33</sub>N<sub>6</sub>O<sub>3</sub> [M + H<sup>+</sup>]. Found: 465.26040.</div><div class="NLM_p last">NaHCO<sub>3</sub> (336 mg, 4.0 mmol) and Fmoc-Cl (297 mg, 0.14 mmol) were added to a suspension of the previously synthesized amine in water/dioxane (12 mL/17 mL), and the resulting reaction mixture was stirred overnight at room temperature. After addition of another 10 mL of water, the mixture was extracted with EtOAc (5 × 30 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the volatiles were removed under reduced pressure. The crude product was purified on silica gel (2% MeOH/DCM) resulting in 833 mg (1.21 mmol, 76%) of a pink resin: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.96 (s, 1H), 9.21 (s, 1H), 8.86 (s, 1H), 8.34 (s, 1H), 7.91 (d, <i>J</i> = 7.5 Hz, 2H), 7.75 (d, <i>J</i> = 7.5 Hz, 2H), 7.63 (s, 1H), 7.54 (bs, 1H), 7.44–7.40 (t, <i>J</i> = 7.3 Hz, 3H), 7.38–7.31 (m, 4H), 7.28 (d, <i>J</i> = 9.0 Hz, 2H), 7.13 (d, <i>J</i> = 7.5 Hz, 1H), 6.36 (s, 1H), 4.51 (d, <i>J</i> = 6.5 Hz, 2H), 4.31 (t, <i>J</i> = 6.5 Hz, 1H), 1.46 (s, 9H), 1.27 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.78, 153.38, 152.84, 151.33, 143.72, 140.82, 140.01, 138.80, 137.46, 134.80, 134.12, 133.80, 129.60, 127.71, 127.15, 125.13, 120.22, 118.64, 118.22, 114.38, 94.37, 91.87, 78.79, 65.68, 46.60, 32.04, 30.21, 28.17. HRMS (ESI-MS) calcd: 687.32894 for C<sub>40</sub>H<sub>43</sub>N<sub>6</sub>O<sub>5</sub> [M + H<sup>+</sup>]. Found: 687.32825.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (9<i>H</i>-Fluoren-9-yl)methyl 3-(3-<i>tert</i>-Butyl-5-(3-(4-(6-nitroquinazolin-4-ylamino)phenyl)ureido)-1<i>H</i>-pyrazol-1-yl)phenylcarbamate (<b>12</b>, 2 steps)</h4><div class="NLM_p">A solution of <b>11</b> (814 mg, 1.19 mmol) in dioxane (2 mL) was treated with HCl (8 mL, 4 M in dioxane) for 2 h at rt. After the reaction was completed, the volatiles were removed under reduced pressure and subsequently EtOAc (10 mL) and saturated sodium bicarbonate solution (10 mL) were added. The aqueous layer was extracted with EtOAc (3 × 20 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed in vacuo leading to 686 mg (1.17 mmol, 98%) of a light yellow solid, which was used without further purification: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.96 (s, 1H), 8.50 (s, 1H), 8.22 (s, 1H), 7.91 (d, <i>J</i> = 7.5 Hz, 2H), 7.76 (d, <i>J</i> = 7.4 Hz, 2H), 7.63 (s, 1H), 7.55 (s, 1H), 7.47–7.31 (m, 6H), 7.12 (d, <i>J</i> = 7.6 Hz, 1H), 7.03 (d, <i>J</i> = 8.7 Hz, 2H), 6.49 (d, <i>J</i> = 8.7 Hz, 2H), 6.33 (s, 1H), 4.84 (s, 2H), 4.51 (d, <i>J</i> = 6.5 Hz, 2H), 1.26 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.73, 153.38, 151.55, 144.12, 143.73, 140.82, 139.99, 138.87, 137.81, 129.57, 128.27, 127.72, 127.15, 125.14, 120.46, 120.22, 118.20, 114.36, 114.14, 94.09, 91.54, 65.69, 46.60, 32.03, 30.22. HRMS (ESI-MS) calcd: 587.27652 for C<sub>35</sub>H<sub>35</sub>N<sub>6</sub>O<sub>3</sub> [M + H<sup>+</sup>]. Found: 587.27588.</div><div class="NLM_p last">A solution of the previously synthesized amino hydrochloride (739 mg, 1.26 mmol) in DCM (33 mL) under argon atmosphere was treated with DIPEA (1 mL, 5.84 mmol) for 10 min at rt. Thereafter freshly prepared 4-chloro-6-nitroquinazolinol (317 mg, 1.51 mmol) was added, and the resulting reaction mixture was stirred for 22 h at rt. After addition of saturated sodium bicarbonate solution and separation of the phases, the aqueous layer was extracted with DCM (3 × 50 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the volatiles were removed under reduced pressure. The crude material was purified on silica gel (1–4% MeOH/DCM) yielding 743 mg (0.97 mmol, 77%) of the desired product as a yellow-orange solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H), 9.98 (s, 1H), 9.64 (s, 1H), 9.07 (s, 1H), 8.66 (s, 1H), 8.54 (dd, <i>J</i> = 9.2, 2.3 Hz, 1H), 8.44 (s, 1H), 7.95–7.84 (m, 3H), 7.74 (dd, <i>J</i> = 14.2, 8.2 Hz, 4H), 7.67 (s, 1H), 7.55 (s, 1H), 7.47 (d, <i>J</i> = 8.9 Hz, 2H), 7.43–7.40 (m, 3H), 7.34 (t, <i>J</i> = 7.1 Hz, 2H), 7.16 (d, <i>J</i> = 7.7 Hz, 1H), 6.40 (s, 1H), 4.51 (d, <i>J</i> = 6.5 Hz, 2H), 4.31 (t, <i>J</i> = 6.5 Hz, 1H), 1.28 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.80, 158.68, 157.85, 153.39, 153.13, 151.39, 144.42, 143.72, 140.81, 140.03, 138.82, 137.35, 136.13, 132.63, 129.62, 129.41, 127.71, 127.14, 126.56, 125.14, 123.65, 120.84, 120.21, 118.26, 118.23, 118.19, 114.39, 94.67, 65.70, 60.85, 46.60, 32.07, 30.22. HRMS (ESI-MS) calcd: 760.29904 for C<sub>43</sub>H<sub>38</sub>N<sub>9</sub>O<sub>5</sub> [M + H<sup>+</sup>]. Found: 760.30027.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (9<i>H</i>-Fluoren-9-yl)methyl 3-(5-(3-(4-(6-Aminoquinazolin-4-ylamino)phenyl)ureido)-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-1-yl)phenylcarbamate (<b>3e</b>)</h4><div class="NLM_p last">Iron turnings (269 mg, 4.56 mmol) were activated, by treating them two times with 1 N HCl for 20 min at room temperature, and added to a suspension of <b>12</b> (434 mg, 0.57 mmol) in EtOH (40 mL) and AcOH (0.13 mL, 2.28 mmol). The resulting reaction mixture was refluxed for 2.5 h. After removal of the iron turnings, the remaining solution was basified with aqueous NH<sub>3</sub>. The solvents were removed under reduced pressure, and the residue was dissolved with EtOAc and saturated sodium bicarbonate solution. Subsequently, the aqueous layer was extracted with EtOAc (10 × 40 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>. The crude was purified on silica gel (4–6% MeOH/DCM) leading to 316 mg (0.43 mmol, 75%) of an off yellow solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.98 (s, 1H), 9.29 (s, 1H), 8.99 (s, 1H), 8.42 (s, 1H), 8.28 (s, 1H), 7.90 (d, <i>J</i> = 7.5 Hz, 2H), 7.80–7.70 (m, 4H), 7.66 (s, 1H), 7.55 (s, 1H), 7.51 (d, <i>J</i> = 8.8 Hz, 1H), 7.47–7.38 (m, 5H), 7.37–7.33 (m, 3H), 7.22 (dd, <i>J</i> = 8.9, 2.0 Hz, 1H), 7.16 (d, <i>J</i> = 7.8 Hz, 1H), 6.39 (s, 1H), 5.56 (s, 2H), 4.51 (d, <i>J</i> = 6.5 Hz, 2H), 4.32 (t, <i>J</i> = 6.5 Hz, 1H),1.28 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.80, 156.04, 153.40, 151.40, 149.97, 147.16, 143.73, 142.36, 140.82, 140.03, 138.83, 137.47, 134.68, 134.37, 133.68, 129.62, 128.55, 127.72, 127.15, 125.14, 123.43, 122.57, 120.22, 118.26, 116.90, 116.59, 114.41, 101.14, 94.49, 65.69, 46.61, 32.06, 30.23. HRMS (ESI-MS) calcd: 730.32486 for C<sub>43</sub>H<sub>40</sub>N<sub>9</sub>O<sub>3</sub> [M + H<sup>+</sup>]. Found: 730.32501.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(4-(4-(3-(1-(3-Aminophenyl)-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-yl)ureido)phenylamino)quinazolin-6-yl)propionamide (<b>3f</b>)</h4><div class="NLM_p">A solution of <b>3e</b> (50 mg, 68.5 μmol) in abs. THF (4 mL) under argon atmosphere was cooled to 0 °C before DIPEA (23.4 μL, 137 μmol) was added. Subsequently a diluted solution of propionylchloride (7.45 μL, 82.2 μmol) in THF (7.45 mL) was added dropwise over 45 min. After addition was completed, the resulting reaction mixture was stirred for 10 min at 0 °C and for 1 h at room temperature. The volatiles were removed in vacuo, and the remaining solid was dissolved in EtOAc and saturated sodium bicarbonate solution. The aqueous layer was extracted with EtOAc (3 × 15 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>. After that, the volatiles were evaporated under reduced pressure leading to 73 mg of a yellow-green crude product, which was used without further purification.</div><div class="NLM_p last">The remaining solid (69 mg) was treated with morpholine (1 mL, 30% in DMF) for 15 min at room temperature. Afterward, the solvents were removed under reduced pressure, and the crude was purified on silica gel using 10% MeOH/DCM. The resulting yellow solid was dissolved in THF and filtered through a membrane filter. After removal of the solvent under reduced pressure, 32 mg (56.8 μmol, 83%) of the desired yellow solid was isolated: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.20 (s, 1H), 9.73 (s, 1H), 9.14 (s, 1H), 8.69 (s, 1H), 8.45 (s, 1H), 8.37 (s, 1H), 7.81 (dd, <i>J</i> = 9.0, 1.9 Hz, 1H), 7.72 (d, <i>J</i> = 8.9 Hz, 1H), 7.68 (d, <i>J</i> = 8.9 Hz, 2H), 7.43 (d, <i>J</i> = 8.9 Hz, 2H), 7.18–7.14 (m, 1H), 6.70 (d, <i>J</i> = 1.9 Hz, 1H), 6.61 (dd, <i>J</i> = 8.0, 1.7 Hz, 2H), 6.37 (s, 1H), 5.42 (s, 2H), 2.41 (q, <i>J</i> = 7.5 Hz, 2H), 1.27 (s, 9H), 1.14 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.12, 160.23, 157.91, 157.50, 153.29, 151.27, 149.81, 146.35, 139.08, 137.22, 136.76, 135.32, 133.73, 129.58, 128.21, 123.30, 118.12, 115.40, 112.97, 111.92, 111.50, 110.02, 93.54, 32.02, 30.30, 29.39, 9.66. HRMS (ESI-MS) calcd: 564.28300 for C<sub>31</sub>H<sub>34</sub>N<sub>9</sub>O<sub>2</sub> [M + H<sup>+</sup>]. Found: 564.28278.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Procedure for the Preparation of 1,4-Fused Hybrid Derivatives (<b>3g</b>–<b>i</b>)</h4><div class="NLM_p">(COCl)<sub>2</sub> and catalytic amounts of DMF were added to a suspension of the appropriate acid of choice in THF or DCM under an argon atmosphere. The resulting mixture was stirred for 2 h at 30–35 °C before <b>13</b>, dissolved in 1–2 mL of NMP, was added in one portion. After another hour of stirring at room temperature, the reaction was completed. Subsequently saturated sodium bicarbonate solution was added and the aqueous layer extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and the volatiles removed under reduced pressure. Treatment of the crude with a solution of 20–25% morpholine in THF or THF/DMF (4:1) for 30–60 min led to the removal of the Fmoc protecting group. After evaporation of the solvents in vacuo, the crude was purified by HPLC.</div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> <i>N</i>-(4-(4-(3-(1-(3-Aminophenyl)-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-yl)ureido)phenylamino)quinazolin-6-yl)-4-(dimethylamino)butanamide (<b>3g</b>)</h5><div class="NLM_p last">Compound <b>3g</b> was prepared as described in the general procedure using THF (3 mL), 4-(dimethylamino)butanoic acid (100 mg, 597 μmol), (COCl)<sub>2</sub> (52.3 μL, 597 μmol), DMF (two drops), and <b>3e</b> (50 mg, 68.5 μmol) in 1 mL of NMP. Deprotection was performed by treating the crude material with 20% morpholine in THF (2.4 mL) for 40 min. The volatiles were removed under reduced pressure, and the crude product was purified by preparative HPLC (H<sub>2</sub>O/MeCN + 0.1% TFA). The combined, product containing fractions were concentrated under reduced pressure and subsequently basified with saturated sodium bicarbonate solution. After extraction of the aqueous layer with EtOAc (3 × 15 mL), drying of the combined organic layers over Na<sub>2</sub>SO<sub>4</sub>, and evaporation of the residual solvent in vacuo, 27 mg (43.5 μmol, 64%) of the desired product was isolated as a light green solid: <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.22 (s, 1H), 9.70 (s, 1H), 9.12 (s, 1H), 8.67 (d, <i>J</i> = 1.6 Hz, 1H), 8.45 (s, 1H), 8.36 (s, 1H), 7.82 (d, <i>J</i> = 2.1 Hz, 1H), 7.72 (d, <i>J</i> = 8.9 Hz, 1H), 7.69 (d, <i>J</i> = 8.9 Hz, 2H), 7.45–7.40 (m, 2H), 7.16 (t, <i>J</i> = 7.9 Hz, 1H), 6.70 (t, <i>J</i> = 2.1 Hz, 1H), 6.62–6.61(t, <i>J</i> = 2.4 Hz, 1H), 6.61–6.60 (t, <i>J</i> = 2.2 Hz, 1H), 6.36 (s, 1H), 5.39 (s, 2H), 2.42 (t, <i>J</i> = 7.4 Hz, 2H), 2.37 (t, <i>J</i> = 7.4 Hz, 2H), 2.22 (s, 6H), 1.79 (p, <i>J</i> = 7.4 Hz, 2H), 1.27 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.14, 160.17, 157.46, 153.24, 151.25, 149.73, 146.34, 139.07, 137.17, 136.69, 135.29, 133.70, 129.49, 128.15, 124.87, 123.25, 118.10, 115.35, 112.92, 111.88, 111.45, 109.99, 93.55, 58.23, 44.79, 31.95, 30.40, 30.24, 22.59. HRMS (ESI-MS) calcd: 621.34085 for C<sub>34</sub>H<sub>41</sub>N<sub>10</sub>O<sub>2</sub> [M + H<sup>+</sup>]. Found: 621.34078.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> <i>N</i>-(4-(4-(3-(1-(3-Aminophenyl)-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-yl)ureido)phenylamino)quinazolin-6-yl)-3-(4-methylpiperazin-1-yl)propanamide·TFA (<b>3h</b>)</h5><div class="NLM_p last">Compound <b>3h</b> was prepared as described in the general procedure using DCM (3 mL), 3-(4-methylpiperazin-1-yl)propanoic acid (35 mg, 200 μmol), (COCl)<sub>2</sub> (17.5 μL, 200 μmol), DMF (three drops), and <b>3e</b> (50 mg, 68.5 μmol) in NMP (1.5 mL). Treatment of the crude with a solution of 20% morpholine in THF/DMF (5 mL, 4:1) for 1 h led to the removal of the Fmoc protecting group. After evaporation of the volatiles under reduced pressure, the crude product was purified by preparative HPLC (H<sub>2</sub>O/MeCN + 0.1% TFA) yielding 23 mg (29.6 μmol, 43%) of the desired product as a yellow solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.53 (s, 1H), 10.85 (s, 1H), 9.46 (s, 1H), 8.98 (s, 1H), 8.85 (s, 1H), 8.72 (s, 1H), 8.07 (d, <i>J</i> = 9.1 Hz, 1H), 7.89 (d, <i>J</i> = 9.0 Hz, 1H), 7.55 (q, <i>J</i> = 9.2 Hz, 4H), 7.35 (t, <i>J</i> = 8.0 Hz, 2H), 7.09 (s, 1H), 7.05 (d, <i>J</i> = 8.1 Hz, 1H), 6.92 (d, <i>J</i> = 7.9 Hz, 2H), 6.37 (s, 1H), 3.34 (s, 2H), 3.34 (bs, 8H), 2.94–2.87 (m, 2H), 2.86 (s, 3H), 1.28 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.87, 160.75, 159.31, 159.16, 158.80, 158.45, 158.10, 151.72, 149.70, 139.38, 138.75, 138.19, 137.17, 134.60, 130.68, 129.97, 125.51, 120.58, 118.12, 117.45, 116.54, 114.54, 113.97, 112.74, 95.77, 51.49, 50.19, 48.58, 41.99, 32.09, 31.44, 30.22. HRMS (ESI-MS) calcd: 662.36740 for C<sub>36</sub>H<sub>44</sub>N<sub>11</sub>O<sub>2</sub> [M + H<sup>+</sup>]. Found: 662.36721.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> <i>N</i>-(4-(4-(3-(1-(3-Aminophenyl)-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-yl)ureido)phenylamino)quinazolin-6-yl)-3-morpholinopropanamide·TFA (<b>3i</b>)</h5><div class="NLM_p last">Compound <b>3i</b> was prepared as described in the general procedure using DCM (3 mL), 3-morpholinopropanoic acid (50 mg, 256 μmol), (COCl)<sub>2</sub> (22.4 μL, 256 μmol), DMF (three drops), and <b>3e</b> (50 mg, 68.5 μmol) in 2 mL of NMP. Treatment of the crude with a solution of 25% morpholine in THF (2.5 mL) for 30 min led to Fmoc-deprotection. After evaporation of the volatiles under reduced pressure, the crude product was purified by preparative HPLC (H<sub>2</sub>O/MeCN + 0.1% TFA) yielding 37 mg (48.5 μmol, 71%) of the desired product as a yellow solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.56 (s, 1H), 10.92 (s, 1H), 9.52 (s, 1H), 8.98 (s, 1H), 8.85 (s, 2H), 8.08 (dd, <i>J</i> = 9.1, 1.5 Hz, 1H), 7.90 (d, <i>J</i> = 9.0 Hz, 1H), 7.55 (q, <i>J</i> = 9.3 Hz, 5H), 7.44 (t, <i>J</i> = 8.0 Hz, 2H), 7.27 (d, <i>J</i> = 4.7 Hz, 2H), 7.07 (d, <i>J</i> = 7.9 Hz, 1H), 6.38 (s, 1H), 4.01 (d, <i>J</i> = 11.2 Hz, 2H), 3.69 (t, <i>J</i> = 11.1 Hz, 2H), 3.49 (t, <i>J</i> = 7.2 Hz, 4H), 3.17 (d, <i>J</i> = 9.7 Hz, 2H), 2.99 (t, <i>J</i> = 7.2 Hz, 2H), 1.29 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.35, 161.03, 159.37, 159.19, 158.83, 158.47, 158.11, 151.93, 149.72, 139.55, 138.72, 138.28, 137.30, 134.56, 130.69, 130.20, 129.33, 125.57, 120.55, 118.19, 118.09, 117.32, 115.28, 114.41, 113.98, 112.90, 96.55, 63.43, 51.85, 51.45, 32.14, 30.21. HRMS (ESI-MS) calcd: 649.33576 for C<sub>35</sub>H<sub>41</sub>N<sub>10</sub>O<sub>3</sub> [M + H<sup>+</sup>]. Found: 649.33563.</div></div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedure for the Preparation of Aminophenyl-3-(3-<i>tert</i>-butyl-1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-yl)urea Hydrochlorides (<b>13</b>, <b>14</b>)</h4><div class="NLM_p">The corresponding <i>N</i>-Boc-protected molecules <b>9</b> and <b>10</b> were treated with 4 M HCl in dioxane for about 45 min at room temperature. The volatiles were removed in vacuo, giving the desired product, which was further used without further purification.</div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 1-(4-Aminophenyl)-3-(3-<i>tert</i>-butyl-1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-yl)urea Hydrochloride (<b>13</b>)</h5><div class="NLM_p last">Compound <b>13</b> was prepared as described in the general procedure using <b>9</b> (100 mg, 200 μmol) and 4 M HCl in dioxane (3 mL) to obtain 85 mg (197 μmol, 99%) of a fawn solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.21 (s, 2H), 9.86 (s, 1H), 9.16 (s, 1H), 8.36 (s, 1H), 8.20 (d, <i>J</i> = 8.1 Hz, 1H), 8.07 (d, <i>J</i> = 8.1 Hz, 1H), 7.80–7.76 (m, 1H), 7.50 (d, <i>J</i> = 8.8 Hz, 2H), 7.29 (d, <i>J</i> = 8.7 Hz, 2H), 6.41 (s, 1H), 1.30 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.93, 152.27, 148.12, 139.56, 139.38, 137.54, 130.81, 129.44, 125.21, 123.84, 121.38, 118.88, 117.86, 98.24, 32.20, 30.05. HRMS (ESI-MS) calcd: 395.18262 for C<sub>20</sub>H<sub>23</sub>N<sub>6</sub>O<sub>3</sub> [M + H<sup>+</sup>]. Found: 395.18221.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 1-(3-Aminophenyl)-3-(3-<i>tert</i>-butyl-1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-yl)urea Hydrochloride (<b>14</b>)</h5><div class="NLM_p last">Compound <b>14</b> was prepared as described in the general procedure using <b>10</b> (113 mg, 230 μmol) and 4 M HCl in dioxane (5 mL) to obtain 98 mg (228 μmol, 99%) of a fawn solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.27 (s, 2H), 10.00 (s, 1H), 9.19 (s, 1H), 8.36 (s, 1H), 8.20 (dd, <i>J</i> = 8.2, 1.3 Hz, 1H), 8.07 (dd, <i>J</i> = 8.1, 1.0 Hz, 1H), 7.78 (t, <i>J</i> = 8.2 Hz, 1H), 7.62 (s, 1H), 7.40–7.31 (m, 2H), 6.97 (dd, <i>J</i> = 6.5, 2.1 Hz, 1H), 6.41 (s, 1H), 1.30 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.97, 152.20, 148.15, 140.71, 139.58, 137.45, 132.05, 130.85, 130.17, 129.40, 121.41, 117.86, 117.43, 116.57, 112.52, 98.26, 32.22, 30.07. HRMS (ESI-MS) calcd: 395.18262 for C<sub>20</sub>H<sub>23</sub>N<sub>6</sub>O<sub>3</sub> [M + H<sup>+</sup>]. Found: 395.18182.</div></div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-Chloro-6-nitroquinazoline or 4-Chloroquinazoline</h4><div class="NLM_p last">A two-neck flask was flushed with argon and charged with 6-nitroquinazolin-4-ol or quinazolin-4-ol and thionyl chloride. A catalytic amount of DMF was added, and the reaction mixture was refluxed at 80 °C overnight. The thionyl chloride was evaporated under reduced pressure, and the remaining residue was dried under high vacuum and used without further purification.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-(3-<i>tert</i>-Butyl-1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-yl)-3-(4-(6-nitroquinazolin-4-ylamino)phenyl)urea (<b>3a</b>)</h4><div class="NLM_p last">A solution of the amino hydrochloride <b>13</b> (77 mg, 179 μmol) and DIPEA (153 μL, 894 μmol) in DCM (10 mL) was stirred for 5 min at room temperature. Then freshly prepared 4-chloro-6-nitroquinazoline (55 mg, 215 μmol) was added, and the resulting reaction mixture was stirred for 23 h at room temperature. After addition of saturated sodium bicarbonate solution the aqueous layer was extracted with EtOAc (3 × 10 mL) and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>. The volatiles were removed in vacuo, and the purification of the crude on silica gel (1–4% MeOH/DCM) lead to 45.1 mg (79.0 μmol, 44%) of an orange solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.41 (s, 1H), 9.63 (s, 1H), 9.11 (s, 1H), 8.65 (s, 1H), 8.60 (s, 1H), 8.54 (dd, <i>J</i> = 9.2, 2.4 Hz, 1H), 8.39 (s, 1H), 8.23 (d, <i>J</i> = 8.1 Hz, 1H), 8.07 (d, <i>J</i> = 8.1 Hz, 1H), 7.90 (d, <i>J</i> = 9.1 Hz, 1H), 7.82 (t, <i>J</i> = 8.1 Hz, 1H), 7.70 (d, <i>J</i> = 8.7 Hz, 2H), 7.45 (d, <i>J</i> = 8.8 Hz, 2H), 6.43 (s, 1H), 1.31 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.99, 158.79, 157.89, 153.15, 152.16, 148.17, 144.48, 139.73, 137.79, 136.06, 132.81, 130.88, 129.58, 129.44, 126.61, 123.74, 121.46, 120.87, 118.59, 117.89, 98.20, 35.46, 32.25, 30.11. HRMS (ESI-MS) calcd: 568.20514 for C<sub>28</sub>H<sub>26</sub>N<sub>9</sub>O<sub>5</sub> [M + H<sup>+</sup>]. Found: 568.20480.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> General Procedure for the Preparation of 1,3- And 1,4-Fused Nitro-Substituted Hybrid Compounds (<b>3b</b>, <b>4a</b>)</h4><div class="NLM_p">A suspension of <b>13</b> or <b>14</b> and freshly prepared 4-chloroquinazoline in 2-propanol was stirred for 3 h at 75 °C refluxing temperature. An excess of saturated sodium bicarbonate solution was added to the chilled reaction batch followed by extraction of the aqueous layer with EtOAc (4 × 20 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure before the crude material was purified on silica gel.</div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 1-(3-<i>tert</i>-Butyl-1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-yl)-3-(4-(quinazolin-4-ylamino)phenyl)urea (<b>3b</b>)</h5><div class="NLM_p last">Compound <b>3b</b> was prepared as described in the general procedure using <b>13</b> (137 mg, 0.32 mmol), 4-chloroquinazoline (116 mg, 0.70 mmol), and 2-propanol (6 mL). Silica gel column chromatography was performed using 2–4% MeOH/DCM and lead to 80 mg (0.15 mmol, 47%) of the desired product as white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.75 (s, 1H), 9.06 (s, 1H), 8.58 (s, 1H), 8.56–8.50 (m, 2H), 8.40 (t, <i>J</i> = 2.1 Hz, 1H), 8.23 (ddd, <i>J</i> = 8.3, 2.2, 0.7 Hz, 1H), 8.11–8.04 (m, 1H), 7.84 (dt, <i>J</i> = 14.9, 4.5 Hz, 2H), 7.77 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.9 Hz, 2H), 7.66–7.59 (m, 1H), 7.43 (d, <i>J</i> = 8.9 Hz, 2H), 6.44 (s, 1H), 1.31 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.89, 157.73, 154.59, 152.07, 149.57, 148.12, 139.68, 137.80, 135.32, 133.59, 132.90, 130.81, 129.53, 127.73, 126.12, 123.28, 122.91, 121.37, 118.56, 117.85, 115.10, 98.02, 32.18, 30.06. HRMS (ESI-MS) calcd: 523.22006 for C<sub>28</sub>H<sub>27</sub>N<sub>8</sub>O<sub>3</sub> [M + H<sup>+</sup>]. Found: 523.21936.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 1-(3-<i>tert</i>-Butyl-1-(3-nitrophenyl)-1<i>H</i>-pyrazol-5-yl)-3-(3-(quinazolin-4-ylamino)phenyl)urea (<b>4a</b>)</h5><div class="NLM_p last">Compound <b>4a</b> was prepared as described in the general procedure using <b>14</b> (135 mg, 0.31 mmol), 4-chloroquinazoline (130 mg, 0.79 mmol), and 2-propanol (6 mL). Silica gel column chromatography was performed using 1–2% MeOH/DCM yielding 106 mg (0.20 mmol, 65%) of the desired product as light yellow solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.79 (s, 1H), 9.15 (s, 1H), 8.59 (t, <i>J</i> = 8.7 Hz, 3H), 8.39 (t, <i>J</i> = 2.0 Hz, 1H), 8.23 (dd, <i>J</i> = 8.2, 1.5 Hz, 1H), 8.07 (dd, <i>J</i> = 8.1, 1.1 Hz, 1H), 7.99 (s, 1H), 7.89–7.76 (m, 3H), 7.67–7.60 (m, 1H), 7.49 (d, <i>J</i> = 7.9 Hz, 1H), 7.31–7.20 (m, 2H), 6.44 (s, 1H), 1.30 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.92, 157.78, 154.42, 151.91, 149.62, 148.14, 139.64, 139.55, 139.41, 137.77, 133.04, 130.83, 129.57, 128.72, 127.77, 126.27, 123.08, 121.41, 117.95, 116.55, 115.19, 113.88, 112.44, 97.75, 32.19, 30.06. HRMS (ESI-MS) calcd: 523.22006 for C<sub>28</sub>H<sub>27</sub>N<sub>8</sub>O<sub>3</sub> [M + H<sup>+</sup>]. Found: 523.21933.</div></div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 1-(1-(3-Aminophenyl)-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-yl)-3-(4-(6-aminoquinazolin-4-ylamino)phenyl)urea (<b>3c</b>)</h4><div class="NLM_p last">A solution of <b>3a</b> (79 mg, 0.14 mmol) in EtOH (5 mL) was treated with ammonium formate (52 mg, 0.82 mmol) and 5% Pd on charcoal (29 mg, 14 μmol) for 2 h at reflux. The catalyst/reaction mixture was filtered over Celite, and the filtrate was concentrated in vacuo. The crude material was purified on silica gel (4% MeOH/DCM) yielding 48.3 mg (0.1 mmol, 71%) of a yellow-orange solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.29 (s, 1H), 9.18 (s, 1H), 8.41 (s, 1H), 8.29 (s, 1H), 7.74 (d, <i>J</i> = 8.9 Hz, 2H), 7.51 (d, <i>J</i> = 8.8 Hz, 1H), 7.42 (d, <i>J</i> = 8.9 Hz, 2H), 7.36 (s, 1H), 7.23 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.18–7.14 (m, 1H), 6.72 (s, 1H), 6.62 (d, <i>J</i> = 8.1 Hz, 2H), 6.37 (s, 1H), 5.55 (s, 2H), 5.42 (s, 2H), 1.28 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.24, 156.07, 151.36, 150.04, 149.79, 147.15, 142.46, 139.11, 137.25, 134.82, 134.32, 129.57, 128.61, 123.44, 122.64, 118.18, 116.61, 112.97, 111.50, 110.02, 101.19, 93.67, 32.03, 30.31. HRMS (ESI-MS) calcd: 508.25678 for C<sub>28</sub>H<sub>30</sub>N<sub>9</sub>O [M + H<sup>+</sup>]. Found: 508.25641.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> General Procedure for the Preparation of 1,3- And 1,4-Fused Amino-Substituted Hybrid Compounds (<b>3d</b>, <b>4b</b>)</h4><div class="NLM_p">A suspension of <b>3b</b> or <b>4a</b> and SnCl<sub>2</sub> in EtOH was stirred for 1.5–3 h at 70 °C. The reaction mixture was concentrated in vacuo to a tenth of the starting volume. Subsequently water was added, and the resulting solution was extracted with EtOAc (7 × 30 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the volatiles were removed under reduced pressure before the crude material was purified on silica gel.</div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 1-(1-(3-Aminophenyl)-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-yl)-3-(4-(quinazolin-4-ylamino)phenyl)urea (<b>3d</b>)</h5><div class="NLM_p last">Compound <b>3d</b> was prepared as described in the general procedure using <b>3b</b> (84 mg, 0.16 mmol), SnCl<sub>2</sub> (61 mg, 0.32 mmol), and EtOH (7 mL). Silica gel column chromatography was performed (1–4% MeOH/DCM) resulting in 47 mg (0.10 mmol, 63%) of the desired product as a yellow solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.77 (s, 1H), 9.14 (s, 1H), 8.57–8.51 (m, 2H), 8.36 (s, 1H), 7.85 (t, <i>J</i> = 7.6 Hz, 1H), 7.77 (d, <i>J</i> = 8.2 Hz, 1H), 7.73 (d, <i>J</i> = 8.9 Hz, 2H), 7.65–7.59 (m, 1H), 7.45 (d, <i>J</i> = 8.9 Hz, 2H), 7.16 (t, <i>J</i> = 7.9 Hz, 1H), 6.69 (t, <i>J</i> = 1.9 Hz, 1H), 6.64–6.57 (m, 2H), 6.37 (s, 1H), 5.46 (s, 2H), 1.27 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.20, 157.74, 154.57, 151.21, 149.79, 149.44, 139.05, 137.18, 135.57, 133.34, 132.95, 129.55, 127.63, 126.17, 123.37, 122.94, 118.12, 115.09, 112.95, 111.47, 110.01, 93.47, 32.00, 30.28. HRMS (ESI-MS) calcd: 493.24588 for C<sub>28</sub>H<sub>29</sub>N<sub>8</sub>O [M + H<sup>+</sup>]. Found: 493.24541.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 1-(1-(3-Aminophenyl)-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-yl)-3-(3-(quinazolin-4-ylamino)phenyl)urea (<b>4b</b>)</h5><div class="NLM_p last">Compound <b>4b</b> was prepared as described in the general procedure using <b>4a</b> (145 mg, 0.28 mmol), SnCl<sub>2</sub> (156 mg, 0.82 mmol), and EtOH (10 mL). Silica gel column chromatography was performed (1–4% MeOH/DCM) resulting in 82 mg (0.17 mmol, 61%) of the desired product as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.80 (s, 1H), 9.21 (s, 1H), 8.61–8.57 (m, 2H), 8.39 (s, 1H), 8.03 (s, 1H), 7.87 (t, <i>J</i> = 7.6 Hz, 1H), 7.79 (d, <i>J</i> = 8.1 Hz, 1H), 7.64 (t, <i>J</i> = 7.6 Hz, 1H), 7.50 (d, <i>J</i> = 7.8 Hz, 1H), 7.29 (t, <i>J</i> = 8.0 Hz, 1H), 7.23 (d, <i>J</i> = 8.3 Hz, 1H), 7.16 (t, <i>J</i> = 7.9 Hz, 1H), 6.69 (t, <i>J</i> = 1.9 Hz, 1H), 6.63–6.58 (m, 2H), 6.37 (s, 1H), 5.45 (s, 2H), 1.26 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.21, 157.78, 154.42, 151.10, 149.80, 149.60, 139.59, 139.57, 139.02, 137.13, 133.05, 129.58, 128.75, 127.75, 126.27, 123.09, 116.29, 115.20, 113.52, 112.97, 112.05, 111.50, 110.02, 93.34, 31.99, 30.27. HRMS (ESI-MS) calcd: 493.24588 for C<sub>28</sub>H<sub>29</sub>N<sub>8</sub>O [M + H<sup>+</sup>]. Found: 493.24543.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Protein Preparations</h3><div class="NLM_p last">Protein preparations of cSrc and cSrc T338M were expressed and purified as described elsewhere.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> DNA encoding wild-type human Abl (residues S229–Q513; isoform 1a numbering) in a pET28a vector with an N-terminal His<sub>6</sub>-tag followed by a thrombin cleavage site was purchased from GeneArt, Regensburg, Germany. Abl protein was coexpressed with YopH (<i>Yersinia</i> outer protein H) in <i>Escherichia coli</i> BL21-DE3 as described elsewhere.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> After harvest and cell lysis, Abl protein was enriched by Ni-NTA chromatography, followed by gel filtration (High Load 16/60 Superdex 75, GE Healthcare) for buffer exchange (50 mM Tris, 150 mM NaCl, 2.5 mM CaCl<sub>2</sub>, 0.1% v/v 2-mercaptoethanol, pH 8.0). Eluate containing Abl protein was collected and the His-tag was removed by digestion with thrombin (GE Healthcare) at 4 °C overnight. Cleaved protein was isolated by ion exchange chromatography (MonoQ 5/50 GL; GE Healthcare) using buffers A (50 mM Tris, 1 mM DTT, 5% v/v glycerol, pH 8.5) and B (buffer A + 1 M NaCl) (0–30% B over 20 min; 1 mL/min). Finally, the buffer was adjusted to 25 mM Tris, 75 mM NaCl, 10% v/v glycerol, 5 mM DTT, pH 7.3, by gel filtration, and the protein was flash-frozen in small aliquots. All purification steps were carried out at 4 °C. Correct mass was confirmed by ESI-MS. Abl T315I was purchased from invitrogen (Lot no. 39639B, PV3866). KIT wild-type and KIT V559D/T670I were purchased from Proqinase (Lot no. 010, 0997-0000-1 and Lot no. 002, 1044-0000-1)</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Activity Based Assay for IC<sub>50</sub> Determination</h3><div class="NLM_p last">IC<sub>50</sub> determinations for cSrc, Abl, and KIT kinases were measured with the KinEASE-TK assay from Cisbio according to the manufacturer’s instructions. A biotinylated poly-Glu-Tyr substrate peptide was phosphorylated by the specific kinase of interest. After completion of the reaction, an anti-phosphotyrosine antibody labeled with europium cryptate and streptavidin labeled with the fluorophore XL665 were added. FRET between europium cryptate and XL665 was measured to quantify the phosphorylation of the substrate peptide. ATP concentrations were set at their respective <i>K</i><sub>M</sub> values (15 μM for wild-type cSrc, 1 μM for cSrc-T338M, 30 μM for wild-type Abl, 6 μM for Abl T315I, 90 μM for wild-type KIT and 20 μM for KIT V559D/T670I). A concentration of 100 nM substrate was used for wild-type and drug-resistant cSrc as well as Abl, while 250 nM was used for Abl T315I and 350 or 300 nM was used for KIT wild-type and KIT V559D/T670I respectively. Kinase and inhibitor were preincubated for 30–60 min before the reaction was started by addition of ATP and substrate peptide. A Tecan Safire<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> or Infinite M1000 plate reader was used to measure the fluorescence of the samples at 620 nm (Eu-labeled antibody) and 665 nm (XL665 labeled streptavidin) 60 μs after excitation at 317 nm. The quotient of both intensities for reactions made with eight different inhibitor concentrations was fit to a Hill four-parameter equation to determine IC<sub>50</sub> values. Each reaction was performed in duplicate, and at least three independent determinations of each IC<sub>50</sub> were made.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Crystallization and Structure Determination of cSrc-<b>3g</b> and cSrc-<b>3h</b></h3><div class="NLM_p last">For all complex structures, 2500 μM inhibitor (prepared in DMSO) was preincubated along with 250 μM wild-type cSrc (stored in 20 mM Tris pH 8.0, 100 mM NaCl, 1 mM DTT) for 1 h on ice to form the enzyme–inhibitor complex prior to crystallization. In the case of both <b>3g</b> and <b>3h</b>, crystals were grown using the hanging drop method at 20 °C after mixing 1–1.5 μL of protein–inhibitor solution with 1 μL of reservoir solution (125 mM MES (pH 6–7), 9–11.5% PEG 20000, 5% (v/v) glycerol). All crystals were directly frozen without the addition of glycerol. Diffraction data of the cSrc–<b>3g</b> complex crystal was measured in-house to a resolution of 3.30 Å (Bruker AXS microstar); the other data set was collected at the PX10SA beamline of the Swiss Light Source (PSI, Villingen, Switzerland) to a resolution of 2.7 Å for cSrc–<b>3h</b>, using wavelengths close to 1 Å. All data sets were processed with XDS<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and scaled using XSCALE.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Structure Determination and Refinement of cSrc–<b>3g</b> and cSrc–<b>3h</b></h3><div class="NLM_p last">All cSrc–inhibitor complex structures were solved by molecular replacement with PHASER<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> using the published cSrc structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ">2OIQ</a><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> as template. The two cSrc molecules in the asymmetric unit were manually modified using the program COOT.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The model was first refined with CNS<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> using simulated annealing to remove model bias. The final refinement was performed with REFMAC5.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Inhibitor topology files where generated using the Dundee PRODRG2 server.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Refined structures were validated with PROCHECK.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Data collection, structure refinement statistics, PDB-ID codes, and further details for the data collection, as well as Ramachandran plot results, are shown in Table S1, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. PyMOL<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> was used to generate the figures.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Reagents and Antibodies</h3><div class="NLM_p last">Imatinib, sunitinib, dovitinib, and ponatinib were purchased from LC Laboratories (Woburn, MA). Rabbit polyclonal antibodies to KIT and phospho-KIT Y703 were from DAKO (Carpinteria, CA) and Cell Signaling (Beverly Hills, CA), respectively. Polyclonal rabbit antibodies to total p42/44 mitogen-activated protein kinase (MAPK), phospho-p44/42 MAPK T202/Y204, phospho-AKT S473, total AKT, were from Cell Signaling (Beverly, MA). Beta Actin antibodies were purchased from Sigma (St. Louis, MO).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Cellular Studies</h3><div class="NLM_p last">GIST-T1, GIST-T1 T670I, and GIST-48B cell lines were cultured as previously described.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Viability studies were carried out using a sulforhodamin (SRB) assay.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> For these studies, the cell lines were plated at 15 000 to 30 000 cells per well in a 96-well flat-bottom plate (Falcon, Lincoln, NJ), cultured in serum-containing media for 1 day, and then incubated for 72 h with KIT inhibitors and DMSO-only solvent control. The SRB assay absorption was measured with a Genion luminometer (Tecan, Crailsheim, Germany), and the data were normalized to the DMSO-only control group. All experimental points were measured in triplicate wells for each plate and were replicated in at least two plates.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Western Blotting</h3><div class="NLM_p last">Protein lysates were prepared from cell line monolayers according to standard protocols.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Protein concentrations were determined with the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA). Electrophoresis and immunoblotting were carried out as previously described.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Changes in protein expression and phosphorylation as visualized by chemiluminescence were captured and quantified using a FUJI LAS3000 system with Science Lab 2001 ImageGauge 4.0 software (Fujifilm Medial Systems, Stamford CT, USA).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> GIST Cell Lines</h3><div class="NLM_p last">GIST-T1 was established from a human, untreated, metastatic GIST containing a 57 bp deletion in <i>KIT</i> exon 11, which is highly sensitive to imatinib at low nanomolar doses.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> GIST-T1 harbors a homozygous deletion and is p53 negative as measured by qRT-PCR and Western blot analysis. GIST-48 was established from a GIST that had progressed, after initial clinical response, during imatinib therapy. GIST-48 has a primary, homozygous <i>KIT</i> exon 11 missense mutation (V560D) and a heterozygous secondary <i>KIT</i> exon 17 (kinase activation loop) mutation (D820A).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> GIST-48 is imatinib-resistant, due to a secondary <i>KIT</i> exon 17 mutation. GIST-48B is a subline of GIST-48, which, despite retaining the activating <i>KIT</i> mutation in all cells, expresses KIT transcript (data not shown) and protein at essentially undetectable levels.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> GIST-48B is <i>TP53</i> wild-type and expresses p53 RNA and protein as measured by qRT-PCR and Western blot analysis. GIST-48 and GIST-48B cell lines have been established at the Brigham and Women’s Hospital in Boston, USA, by the Group of Professor Jonathan A. Fletcher. GIST-T1 has been established by Takahiro Taguchi at the Kochi University in Japan. GIST-T1 T670I was generated and kindly provided by Prof. Brian Rubin, Department of Molecular Genetics, Lerner Research Institute and Department of Anatomic Pathology and Taussing Cancer Center, Cleveland Clinic, Cleveland, OH 44195.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51"><a href="/doi/suppl/10.1021/jm4004076">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42716" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42716" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Detailed synthetic procedures for the preparation of <b>6a</b> and <b>6b</b> as well as synthetic schemes for <b>3c</b>,<b>d</b>, <b>4b</b>, and <b>6a</b>,<b>b</b>, crystal X-ray structure data of <b>3g</b> and <b>3h</b> in complex with cSrc, modeling studies of <b>3g</b> into the catalytic domains of Abl T315I and KIT T670I, selectivity profiling data of <b>3d</b>, CYP inhibition data, cytotoxicity data, Ba/F3 Bcr-Abl (and T315I) proliferation assay data, and a detailed overview of <b>3h</b>–cSrc interactions including electron density information. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm4004076/suppl_file/jm4004076_si_001.pdf">jm4004076_si_001.pdf (1.65 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID codes <a href="https://" class="ext-link">3TZ7</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TZ8">3TZ8</a>.</p><div class="testing" data-doi="10.1021/jm4004076" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30046" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30046" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sebastian Bauer</span> - <span class="hlFld-Affiliation affiliation">Department of Medical Oncology,
Sarcoma Center, West German Cancer Center, University
Duisburg-Essen Medical School, Hufelandstrasse 55, D-45122
Essen, Germany</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a0d3c5c2c1d3d4c9c1ce8ec2c1d5c5d2e0d5cb8dc5d3d3c5ce8ec4c5"><span class="__cf_email__" data-cfemail="6b180e090a181f020a0545090a1e0e192b1e00460e18180e05450f0e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Rauh</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Strasse 6, D-44227 Dortmund, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical Genomics Centre of the Max-Planck-Society,
Otto-Hahn-Strasse 15, D-44227 Dortmund, Germany</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4e2a2f20272b22603c2f3b260e3a3b632a213c3a233b202a602a2b"><span class="__cf_email__" data-cfemail="eb8f8a85828e87c5998a9e83ab9f9ec68f84999f869e858fc58f8e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">André Richters</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Strasse 6, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julia Ketzer</span> - <span class="hlFld-Affiliation affiliation">Department of Medical Oncology,
Sarcoma Center, West German Cancer Center, University
Duisburg-Essen Medical School, Hufelandstrasse 55, D-45122
Essen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthäus Getlik</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Strasse 6, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Grütter</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Strasse 6, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ralf Schneider</span> - <span class="hlFld-Affiliation affiliation">Chemical Genomics Centre of the Max-Planck-Society,
Otto-Hahn-Strasse 15, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johannes M. Heuckmann</span> - <span class="hlFld-Affiliation affiliation">Department of Translational Genomics, University of Cologne, Weyertal 115b, D-50931 Cologne,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefanie Heynck</span> - <span class="hlFld-Affiliation affiliation">Department of Translational Genomics, University of Cologne, Weyertal 115b, D-50931 Cologne,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin L. Sos</span> - <span class="hlFld-Affiliation affiliation">Department of Translational Genomics, University of Cologne, Weyertal 115b, D-50931 Cologne,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anu Gupta</span> - <span class="hlFld-Affiliation affiliation">Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anke Unger</span> - <span class="hlFld-Affiliation affiliation">Lead Discovery Center
GmbH, Otto-Hahn-Strasse 15, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carsten Schultz-Fademrecht</span> - <span class="hlFld-Affiliation affiliation">Lead Discovery Center
GmbH, Otto-Hahn-Strasse 15, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roman K. Thomas</span> - <span class="hlFld-Affiliation affiliation">Department of Translational Genomics, University of Cologne, Weyertal 115b, D-50931 Cologne,
Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pathology, University of Cologne, Joseph-Stelzmann Strasse 9,
D-50931 Cologne, Germany</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): RKT is a founder and shareholder of Blackfield AG, a company focused on cancer genome diagnostics and cancer genomics-based drug discovery. RKT received consulting and lecture fees (Sanofi-Aventis, Merck, Roche, Lilly, Boehringer Ingelheim, Astra-Zeneca, Atlas-Biolabs, Daiichi-Sankyo, Blackfield AG) as well as research support (Merck, EOS and AstraZeneca). DR received consultant and lecture fees from Astra-Zeneca, Merck-Serono, Takeda, Pfizer, Boehringer Ingelheim and Sanofi-Aventis.<br /></br></div></li></ul></div><div class="ack" id="ACK-d121e3824-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67028" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67028" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Brian Rubin for kindly providing GIST-T1 T670I and Idoya Lahortiga for providing Ba/F3 cells. We thank Jonathan A. Fletcher for providing the GIST48B and T. Taguchi for providing the GIST T1. This work was cofunded by the German federal state North Rhine Westphalia (NRW) and the European Union (European Regional Development Fund: Investing In Your Future), the German Federal Ministry for Education and Research (NGFNPlus) (Grant Nos. BMBF 01GS08104 and 01GS08100), the EU-Framework Programme CURELUNG (HEALTH-F2-2010-258677), the Deutsche Forschungsgemeinschaft through TH1386/3-1 and through SFB832, the Max Planck Society, the Behrens-Weise Foundation (M.I.F.A.NEUR8061), Stand Up To Cancer–American Association for Cancer Research Innovative Research Grant (No. SU2C-AACR-IR60109), and an anonymous foundation. This work was furthermore supported by funding from Max-Eder Fellowship from the Deutsche Krebshilfe (S. Bauer) and the Life Raft Group Research Initiative (S. Bauer). M.L.S. is a fellow of the International Association for the Study of Lung Cancer (IASLC).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i56" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i56"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i57" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i57"> Abbreviations</h2><tr><td class="NLM_term">Abl</td><td class="NLM_def"><p class="first last">Abelson kinase</p></td></tr><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">Bcr</td><td class="NLM_def"><p class="first last">breakpoint cluster region</p></td></tr><tr><td class="NLM_term">cSrc</td><td class="NLM_def"><p class="first last">cellular sarcoma kinase</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumors</p></td></tr><tr><td class="NLM_term">KIT</td><td class="NLM_def"><p class="first last">mast/stem cell growth factor receptor kinase</p></td></tr><tr><td class="NLM_term">LMS</td><td class="NLM_def"><p class="first last">leiomyosarcoma</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">liposarcoma</p></td></tr><tr><td class="NLM_term">MPNST</td><td class="NLM_def"><p class="first last">malignant peripheral nerve sheath tumor</p></td></tr><tr><td class="NLM_term">GI<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration for 50% of maximal inhibition of cell proliferation</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration causing 50% inhibition of enzyme activity</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methylpyrrolidinone</p></td></tr><tr><td class="NLM_term">MES</td><td class="NLM_def"><p class="first last">2-(<i>N</i>-morpholino)ethanesulfonic acid</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">poly(ethylene glycol)</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63844" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63844" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 55 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tückmantel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Proteus in the world of proteins: Conformational changes in protein kinases</span> <span class="citation_source-journal">Arch. Pharm. (Weinheim, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1002%2Fardp.201000028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=20336692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2010&pages=193-206&author=M.+Rabillerauthor=M.+Getlikauthor=S.+Kl%C3%BCterauthor=A.+Richtersauthor=S.+T%C3%BCckmantelauthor=J.+R.+Simardauthor=D.+Rauh&title=Proteus+in+the+world+of+proteins%3A+Conformational+changes+in+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Proteus in the world of proteins: Conformational changes in protein kinases</span></div><div class="casAuthors">Rabiller, Matthias; Getlik, Matthaeus; Klueter, Sabine; Richters, Andre; Tueckmantel, Sandra; Simard, Jeffrey R.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">193-206</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The 512 protein kinases encoded by the human genome are a prime example of Nature's ability to create diversity by introducing variations to a highly conserved theme.  The activity of each kinase domain is controlled by layers of regulatory mechanisms involving different combinations of post-translational modifications, intramol. contacts, and intermol. interactions.  Ultimately, they all achieve their effect by favoring particular conformations that promote or prevent the kinase domain from catalyzing protein phosphorylation.  The central role of kinases in various diseases has encouraged extensive investigations of their biol. function and 3-dimensional structures, yielding a more detailed understanding of the mechanisms that regulate protein kinase activity by conformational changes.  Here, the authors discuss these regulatory mechanisms and show how conformational changes can be exploited for the design of specific inhibitors that lock protein kinases in inactive conformations.  In addn., the authors highlight recent developments to monitor ligand-induced structural changes in protein kinases and for screening and identifying inhibitors that stabilize enzymically incompetent kinase conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRChkP9MKuIbVg90H21EOLACvtfcHk0ljG915wTgN11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D&md5=0833f19b8565afc03c39bf5fb5a87175</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fardp.201000028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201000028%26sid%3Dliteratum%253Aachs%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DT%25C3%25BCckmantel%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DProteus%2520in%2520the%2520world%2520of%2520proteins%253A%2520Conformational%2520changes%2520in%2520protein%2520kinases%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D2010%26volume%3D343%26spage%3D193%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0lhNO_poE0EOVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">–</span> <span class="NLM_lpage">1167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+anti-apoptotic+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520anti-apoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Weinstein, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, A. K.</span><span> </span><span class="NLM_article-title">Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy</span> <span class="citation_source-journal">Nat. Clin. Pract. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">448</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fncponc0558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=16894390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1OktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=448-457&author=I.+B.+Weinsteinauthor=A.+K.+Joe&title=Mechanisms+of+disease%3A+Oncogene+addiction%2D%2Da+rationale+for+molecular+targeting+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy</span></div><div class="casAuthors">Weinstein, I. Bernard; Joe, Andrew K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">448-457</span>CODEN:
                <span class="NLM_cas:coden">NCPOB5</span>;
        ISSN:<span class="NLM_cas:issn">1743-4254</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There has been considerable progress in the systemic treatment of cancer because of the rapid development and clin. application of mol. targeted agents.  Although patients with a particular type and stage of cancer are often treated as a single group, more-specific therapy is being considered, as subsets of these patients who are more likely to benefit from treatment with particular agents are being identified.  We previously introduced the concept of 'oncogene addiction' to explain how some cancers that contain multiple genetic, epigenetic, and chromosomal abnormalities are dependent on or 'addicted' to one or a few genes for both maintenance of the malignant phenotype and cell survival.  Thus, reversal of only one or a few of these abnormalities can inhibit cancer cell growth and in some cases translate to improved survival rates.  This review summarizes current exptl. and clin. evidence for the concept of oncogene addiction and describes mol. mechanisms that may explain this phenomenon.  In addn., we discuss how high-throughput screening methods, including gene-expression profiling and proteomics, and emerging methods for analyzing complex cellular networks can be used to identify the state of oncogene addiction, i.e. the 'Achilles' heel,' in specific cancers.  Finally, we discuss the use of mol. targeted agents in combination with other anticancer agents as a strategy to optimize therapy and prevent disease recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG33E0-PnEMrVg90H21EOLACvtfcHk0lhNO_poE0EOVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1OktL8%253D&md5=e630af1a5ccfe6e736cb48285bb0146e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fncponc0558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncponc0558%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DI.%2BB.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26atitle%3DMechanisms%2520of%2520disease%253A%2520Oncogene%2520addiction--a%2520rationale%2520for%2520molecular%2520targeting%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Oncol.%26date%3D2006%26volume%3D3%26spage%3D448%26epage%3D457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Overriding imatinib resistance with a novel ABL kinase inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1126%2Fscience.1099480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15256671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=399-401&author=N.+P.+Shahauthor=C.+Tranauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=C.+L.+Sawyers&title=Overriding+imatinib+resistance+with+a+novel+ABL+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor</span></div><div class="casAuthors">Shah, Neil P.; Tran, Chris; Lee, Francis Y.; Chen, Ping; Norris, Derek; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5682</span>),
    <span class="NLM_cas:pages">399-402</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding.  Crystallog. studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements.  BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants.  BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-pos. bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.  These data illustrate how mol. insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0O0Lhe8nKCrVg90H21EOLACvtfcHk0lhNO_poE0EOVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D&md5=b3827c3419b4c6b57893b11fd68f1f96</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099480%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DOverriding%2520imatinib%2520resistance%2520with%2520a%2520novel%2520ABL%2520kinase%2520inhibitor%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D399%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Steinberg, M.</span><span> </span><span class="NLM_article-title">Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2289</span><span class="NLM_x">–</span> <span class="NLM_lpage">2308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1016%2Fj.clinthera.2007.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=18158072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2007&pages=2289-2308&author=M.+Steinberg&title=Dasatinib%3A+A+tyrosine+kinase+inhibitor+for+the+treatment+of+chronic+myelogenous+leukemia+and+philadelphia+chromosome-positive+acute+lymphoblastic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia</span></div><div class="casAuthors">Steinberg, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2289-2308</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: The Philadelphia chromosome is formed from a translocation of genetic material involving human chromosomes 9 and 22.  The resulting gene product, BCR-ABL, encodes for an abnormal tyrosine kinase (TK) that is a factor in the pathol. of chronic myelogenous leukemia (CML).  Use of targeted therapy that inhibits BCR-ABL kinase activity may lead to hematol. and cytogenetic responses in affected individuals.  The oral TK inhibitor dasatinib was approved in 2006 for use in patients with CML or Philadelphia chromosome-pos. acute lymphoblastic leukemia (ALL) who are unable to tolerate or have not responded to other treatments.  Objective: This paper reviews the available data on dasatinib, including its pharmacokinetic and pharmacodynamic properties, findings of in vitro and in vivo studies, adverse effects, and potential place in therapy.  Methods: Pertinent information was identified through searches of MEDLINE (1966-May 2007), EMBASE (1980-first quarter 2007), and International Pharmaceutical Abstrs. (1970-May 2007) using the terms dasatinib, BMS-354825, chronic myelogenous leukemia, Sprycel, Philadelphia chromosome, and acute lymphoblastic leukemia.  All clin. studies and case reports published at the time of the search were included in this review.  Results: Obsd. mutations in the amino acid sequence of BCR-ABL cause the failure of treatment with existing TK inhibitors.  Dasatinib has shown in vitro and in vivo activity against BCR-ABL, including mutations that are resistant to other available TK inhibitors.  Preliminary results are available from several noncomparative studies of dasatinib in patients who were unable to tolerate or were resistant to previous therapies.  The 5 phases of START (SRC/ABL Tyrosine kinase inhibition Activity Research Trials of dasatinib) represent the largest and most comprehensive evaluation of dasatinib in the treatment of patients in all stages of CML or Philadelphia chromosome-pos. ALL who had undergone previous treatment for leukemia.  Dasatanib had the greatest benefit in patients in the chronic phase of CML, with complete hematol. responses in 90% of patients, 52% of whom achieved a major hematol. response.  Compared with those in the chronic phase, patients in the accelerated phase or blast crisis of CML, or with Philadelphia chromosome-pos. ALL had lower responses.  In the START-R trial, which compared the response to dasatinib and high-dose imatinib (800 mg/d), both regimens had comparable ability to induce a complete hematol. response (95% and 93%, resp.), although more patients achieved a major cytogenetic response with dasatinib (32% vs 7%).  Adverse effects include significant myelosuppression.  Dasatinib may have the potential for use in the management of nonleukemic malignancies.  Conclusions: Dasatinib has a wider spectrum of activity against a broader range of BCR-ABL forms than existing TK inhibitors.  It has shown clin. benefit and tolerability in patients in all phases of CML, as well as in those with Philadelphia chromosome-pos. ALL.  Dasatinib illustrates the potential for targeted drug development based on an understanding of the genetic alterations leading to CML and the development of resistance to treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn8AoiiPuTJrVg90H21EOLACvtfcHk0lgsNZYh7EZ2ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKjt7k%253D&md5=1219cbf8c0a882317a19db3a2c9a4605</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2007.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2007.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DM.%26atitle%3DDasatinib%253A%2520A%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520myelogenous%2520leukemia%2520and%2520philadelphia%2520chromosome-positive%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DClin.%2520Ther.%26date%3D2007%26volume%3D29%26spage%3D2289%26epage%3D2308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+Correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lgsNZYh7EZ2ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520Correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Balak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouerfelli, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6494</span><span class="NLM_x">–</span> <span class="NLM_lpage">6501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1158%2F1078-0432.CCR-06-1570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=17085664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6494-6501&author=M.+N.+Balakauthor=Y.+Gongauthor=G.+J.+Rielyauthor=R.+Somwarauthor=A.+R.+Liauthor=M.+F.+Zakowskiauthor=A.+Chiangauthor=G.+Yangauthor=O.+Ouerfelliauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=V.+A.+Millerauthor=W.+Pao&title=Novel+D761Y+and+common+secondary+T790M+mutations+in+epidermal+growth+factor+receptor-mutant+lung+adenocarcinomas+with+acquired+resistance+to+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors</span></div><div class="casAuthors">Balak, Marissa N.; Gong, Yixuan; Riely, Gregory J.; Somwar, Romel; Li, Allan R.; Zakowski, Maureen F.; Chiang, Anne; Yang, Guangli; Ouerfelli, Ouathek; Kris, Mark G.; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6494-6501</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In patients whose lung adenocarcinomas harbor epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations, acquired resistance to the tyrosine kinase inhibitors (TKI) gefitinib (Iressa) and erlotinib (Tarceva) has been assocd. with a second-site EGFR mutation, which leads to substitution of methionine for threonine at position 790 (T790M).  We aimed to elucidate the frequency and nature of secondary EGFR mutations in patients with acquired resistance to TKI monotherapy.  Exptl. Design: Tumor cells from patients with acquired resistance were examd. for secondary EGFR kinase domain mutations by mol. analyses.  RESULTS: Eight of 16 patients (50% obsd. rate; 95% confidence interval, 25-75%) had tumor cells with second-site EGFR mutations.  Seven mutations were T790M and one was a novel D761Y mutation found in a brain metastasis.  When combined with a drug-sensitive L858R mutation, the D761Y mutation modestly reduced the sensitivity of mutant EGFR to TKIs in both surrogate kinase and cell viability assays.  In an autopsy case, the T790M mutation was found in multiple visceral metastases but not in a brain lesion.  CONCLUSIONS: The T790M mutation is common in patients with acquired resistance.  The limited spectrum of TKI-resistant mutations in EGFR, which binds to erlotinib in the active conformation, contrasts with a wider range of second-site mutations seen with acquired resistance to imatinib, which binds to ABL and KIT, resp., in closed conformations.  Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anat. site and mode of binding to the kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmeHDQldYeDLVg90H21EOLACvtfcHk0lgsNZYh7EZ2ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI&md5=e817eb717673081d89ec3d58a04a7d4d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1570%26sid%3Dliteratum%253Aachs%26aulast%3DBalak%26aufirst%3DM.%2BN.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DChiang%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DOuerfelli%26aufirst%3DO.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNovel%2520D761Y%2520and%2520common%2520secondary%2520T790M%2520mutations%2520in%2520epidermal%2520growth%2520factor%2520receptor-mutant%2520lung%2520adenocarcinomas%2520with%2520acquired%2520resistance%2520to%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6494%26epage%3D6501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNitto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greig, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quenzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmett, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1542</span><span class="NLM_x">–</span> <span class="NLM_lpage">1547</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.+A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.+M.+Zhangauthor=G.+D.+Demetri&title=KIT+kinase+mutants+show+unique+mechanisms+of+drug+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0lgpMgiEWLV-qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKIT%2520kinase%2520mutants%2520show%2520unique%2520mechanisms%2520of%2520drug%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4342</span><span class="NLM_x">–</span> <span class="NLM_lpage">4349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1200%2FJCO.2003.04.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=14645423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=4342-4349&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=G.+D.+Demetriauthor=C.+D.+Blankeauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=L.+S.+McGreeveyauthor=C.+J.+Chenauthor=A.+D.+Van+den+Abbeeleauthor=B.+J.+Drukerauthor=B.+Kieseauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=S.+Singerauthor=C.+D.+Fletcherauthor=S.+Silbermanauthor=S.+Dimitrijevicauthor=J.+A.+Fletcher&title=Kinase+mutations+and+imatinib+response+in+patients+with+metastatic+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Demetri, George D.; Blanke, Charles D.; von Mehren, Margaret; Joensuu, Heikki; McGreevey, Laura S.; Chen, Chang-Jie; Van den Abbeele, Annick D.; Druker, Brian J.; Kiese, Beate; Eisenberg, Burton; Roberts, Peter J.; Singer, Samuel; Fletcher, Christopher D. M.; Silberman, Sandra; Dimitrijevic, Sasa; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4342-4349</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate.  The relationship between mutations in these kinases and clin. response to imatinib was examd. in a group of patients with advanced GIST.  Patients and Methods: GISTs from 127 patients enrolled onto a phase II clin. study of imatinib were examd. for mutations of KIT or PDGFRA.  Mutation types were correlated with clin. outcome.  Results: Activating mutations of KIT or PDGFRA were found in 112 (88.2%) and six (4.7%) GISTs, resp.  Most KIT mutations involved exon 9 (n = 23) or exon 11 (n = 85).  All KIT mutant isoforms, but only a subset of PDGFRA mutant isoforms, were sensitive to imatinib, in vitro.  In patients with GISTs harboring exon 11 KIT mutations, the partial response rate (PR) was 83.5%, whereas patients with tumors contg. an exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P = .0006) and 0.0% (P < .0001), resp.  Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation.  Conclusion: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clin. response to imatinib.  PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHal4hZZoc7Vg90H21EOLACvtfcHk0lgpMgiEWLV-qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D&md5=cbfd753460bdf0005c3bd93f12df98dc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.04.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.04.190%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DMcGreevey%26aufirst%3DL.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DKinase%2520mutations%2520and%2520imatinib%2520response%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D4342%26epage%3D4349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">906</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=897-906&author=E.+Jabbourauthor=J.+Cortesauthor=H.+Kantarjian&title=Long-term+outcomes+in+the+second-line+treatment+of+chronic+myeloid+leukemia%3A+a+review+of+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DLong-term%2520outcomes%2520in%2520the%2520second-line%2520treatment%2520of%2520chronic%2520myeloid%2520leukemia%253A%2520a%2520review%2520of%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DCancer%26date%3D2011%26volume%3D117%26spage%3D897%26epage%3D906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Mok, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunpaweravong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margono, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiwaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chewaskulyong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffield, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span> </span><span class="NLM_article-title">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">957</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1056%2FNEJMoa0810699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=19692680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=947-957&author=T.+S.+Mokauthor=Y.+L.+Wuauthor=S.+Thongprasertauthor=C.+H.+Yangauthor=D.+T.+Chuauthor=N.+Saijoauthor=P.+Sunpaweravongauthor=B.+Hanauthor=B.+Margonoauthor=Y.+Ichinoseauthor=Y.+Nishiwakiauthor=Y.+Oheauthor=J.+J.+Yangauthor=B.+Chewaskulyongauthor=H.+Jiangauthor=E.+L.+Duffieldauthor=C.+L.+Watkinsauthor=A.+A.+Armourauthor=M.+Fukuoka&title=Gefitinib+or+carboplatin-paclitaxel+in+pulmonary+adenocarcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span></div><div class="casAuthors">Mok, Tony S.; Wu, Yi-Long; Thongprasert, Sumitra; Yang, Chih-Hsin; Chu, Da-Tong; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.  METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calcd. to produce an area under the curve of 5 or 6 mg per mL per min) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients).  The primary end point was progression-free survival.  RESULTS: The 12-mo rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel.  The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin-paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P < 0.001).  In the subgroup of 261 patients who were pos. for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P < 0.001), whereas in the subgroup of 176 patients who were neg. for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P < 0.001).  The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group.  CONCLUSIONS: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia.  The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKhpFOiEQu7Vg90H21EOLACvtfcHk0lisQbANpzwvwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK&md5=31ce0983eedb9f248dcf0726adf18b88</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810699%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DChu%26aufirst%3DD.%2BT.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DSunpaweravong%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DMargono%26aufirst%3DB.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DArmour%26aufirst%3DA.%2BA.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520or%2520carboplatin-paclitaxel%2520in%2520pulmonary%2520adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D947%26epage%3D957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilhot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gathmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gattermann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabrilove, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousselot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiffers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelissen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoef, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gratwohl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letvak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R. A.</span><span> </span><span class="NLM_article-title">Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">2408</span><span class="NLM_x">–</span> <span class="NLM_lpage">2417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1056%2FNEJMoa062867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=17151364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12ntrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=2408-2417&author=B.+J.+Drukerauthor=F.+Guilhotauthor=S.+G.+O%E2%80%99Brienauthor=I.+Gathmannauthor=H.+Kantarjianauthor=N.+Gattermannauthor=M.+W.+Deiningerauthor=R.+T.+Silverauthor=J.+M.+Goldmanauthor=R.+M.+Stoneauthor=F.+Cervantesauthor=A.+Hochhausauthor=B.+L.+Powellauthor=J.+L.+Gabriloveauthor=P.+Rousselotauthor=J.+Reiffersauthor=J.+J.+Cornelissenauthor=T.+Hughesauthor=H.+Agisauthor=T.+Fischerauthor=G.+Verhoefauthor=J.+Shepherdauthor=G.+Saglioauthor=A.+Gratwohlauthor=J.+L.+Nielsenauthor=J.+P.+Radichauthor=B.+Simonssonauthor=K.+Taylorauthor=M.+Baccaraniauthor=C.+Soauthor=L.+Letvakauthor=R.+A.+Larson&title=Five-year+follow-up+of+patients+receiving+imatinib+for+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</span></div><div class="casAuthors">Druker, Brian J.; Guilhot, Francois; O'Brien, Stephen G.; Gathmann, Insa; Kantarjian, Hagop; Gattermann, Norbert; Deininger, Michael W. N.; Silver, Richard T.; Goldman, John M.; Stone, Richard M.; Cervantes, Francisco; Hochhaus, Andreas; Powell, Bayard L.; Gabrilove, Janice L.; Rousselot, Philippe; Reiffers, Josy; Cornelissen, Jan J.; Hughes, Timothy; Agis, Hermine; Fischer, Thomas; Verhoef, Gregor; Shepherd, John; Saglio, Giuseppe; Gratwohl, Alois; Nielsen, Johan L.; Radich, Jerald P.; Simonsson, Bengt; Taylor, Kerry; Baccarani, Michele; So, Charlene; Letvak, Laurie; Larson, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2408-2417</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase.  Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase.  For 5 years, we followed patients with CML who received imatinib as initial therapy.  METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematol., cytogenetic, and mol. responses; and adverse events.  RESULTS: The median follow-up was 60 mo.  Kaplan-Meier ests. of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 mo and 87% by 60 mo.  An estd. 7% of patients progressed to accelerated-phase CML or blast crisis, and the estd. overall survival of patients who received imatinib as initial therapy was 89% at 60 mo.  Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P < 0.001).  Grade 3 or 4 adverse events diminished over time, and there was no clin. significant change in the profile of adverse events.  CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUgIGWKzVtbrVg90H21EOLACvtfcHk0lisQbANpzwvwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12ntrzM&md5=7e57245d3a918c079722ce0dcd265f15</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa062867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa062867%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DGuilhot%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DGathmann%26aufirst%3DI.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DGattermann%26aufirst%3DN.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DSilver%26aufirst%3DR.%2BT.%26aulast%3DGoldman%26aufirst%3DJ.%2BM.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DB.%2BL.%26aulast%3DGabrilove%26aufirst%3DJ.%2BL.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DReiffers%26aufirst%3DJ.%26aulast%3DCornelissen%26aufirst%3DJ.%2BJ.%26aulast%3DHughes%26aufirst%3DT.%26aulast%3DAgis%26aufirst%3DH.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DVerhoef%26aufirst%3DG.%26aulast%3DShepherd%26aufirst%3DJ.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DGratwohl%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DJ.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26aulast%3DSimonsson%26aufirst%3DB.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DSo%26aufirst%3DC.%26aulast%3DLetvak%26aufirst%3DL.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26atitle%3DFive-year%2520follow-up%2520of%2520patients%2520receiving%2520imatinib%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D2408%26epage%3D2417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+kinase+domain+mutations+confer+polyclonal+resistance+to+the+tyrosine+kinase+inhibitor+imatinib+%28STI571%29+in+chronic+phase+and+blast+crisis+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0liSSsDsvGXgpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520confer%2520polyclonal%2520resistance%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520%2528STI571%2529%2520in%2520chronic%2520phase%2520and%2520blast%2520crisis%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26spage%3D117%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Griswold, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacPartlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumm, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moseson, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakiewicz, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">6082</span><span class="NLM_x">–</span> <span class="NLM_lpage">6093</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1128%2FMCB.02202-05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=16880519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1ylt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=6082-6093&author=I.+J.+Griswoldauthor=M.+MacPartlinauthor=T.+Bummauthor=V.+L.+Gossauthor=T.+O%E2%80%99Hareauthor=K.+A.+Leeauthor=A.+S.+Corbinauthor=E.+P.+Stoffregenauthor=C.+Smithauthor=K.+Johnsonauthor=E.+M.+Mosesonauthor=L.+J.+Woodauthor=R.+D.+Polakiewiczauthor=B.+J.+Drukerauthor=M.+W.+Deininger&title=Kinase+domain+mutants+of+Bcr-Abl+exhibit+altered+transformation+potency%2C+kinase+activity%2C+and+substrate+utilization%2C+irrespective+of+sensitivity+to+imatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib</span></div><div class="casAuthors">Griswold, Ian J.; MacPartlin, Mary; Bumm, Thomas; Goss, Valerie L.; O'Hare, Thomas; Lee, Kimberly A.; Corbin, Amie S.; Stoffregen, Eric P.; Smith, Caitlyn; Johnson, Kara; Moseson, Erika M.; Wood, Lisa J.; Polakiewicz, Roberto D.; Druker, Brian J.; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6082-6093</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Kinase domain (KD) mutations of Bcr-Abl interfering with imatinib binding are the major mechanism of acquired imatinib resistance in patients with Philadelphia chromosome-pos. leukemia.  Mutations of the ATP binding loop (p-loop) have been assocd. with a poor prognosis.  We compared the transformation potency of five common KD mutants in various biol. assays.  Relative to unmutated (native) Bcr-Abl, the ATP binding loop mutants Y253F and E255K exhibited increased transformation potency, M351T and H396P were less potent, and the performance of T315I was assay dependent.  The transformation potency of Y253F and M351T correlated with intrinsic Bcr-Abl kinase activity, whereas the kinase activity of E255K, H396P, and T315I did not correlate with transforming capabilities, suggesting that addnl. factors influence transformation potency.  Anal. of the phosphotyrosine proteome by mass spectroscopy showed differential phosphorylation among the mutants, a finding consistent with altered substrate specificity and pathway activation.  Mutations in the KD of Bcr-Abl influence kinase activity and signaling in a complex fashion, leading to gain- or loss-of-function variants.  The drug resistance and transformation potency of mutants may det. the outcome of patients on therapy with Abl kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQiqF9VlZX2rVg90H21EOLACvtfcHk0liSSsDsvGXgpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1ylt7w%253D&md5=562962addb97080148b210dcf7e12266</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FMCB.02202-05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.02202-05%26sid%3Dliteratum%253Aachs%26aulast%3DGriswold%26aufirst%3DI.%2BJ.%26aulast%3DMacPartlin%26aufirst%3DM.%26aulast%3DBumm%26aufirst%3DT.%26aulast%3DGoss%26aufirst%3DV.%2BL.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DK.%2BA.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DMoseson%26aufirst%3DE.%2BM.%26aulast%3DWood%26aufirst%3DL.%2BJ.%26aulast%3DPolakiewicz%26aufirst%3DR.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DKinase%2520domain%2520mutants%2520of%2520Bcr-Abl%2520exhibit%2520altered%2520transformation%2520potency%252C%2520kinase%2520activity%252C%2520and%2520substrate%2520utilization%252C%2520irrespective%2520of%2520sensitivity%2520to%2520imatinib%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2006%26volume%3D26%26spage%3D6082%26epage%3D6093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7389</span><span class="NLM_x">–</span> <span class="NLM_lpage">7395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=7389-7395&author=N.+P.+Shahauthor=C.+L.+Sawyers&title=Mechanisms+of+resistance+to+STI571+in+Philadelphia+chromosome-associated+leukemias"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520STI571%2520in%2520Philadelphia%2520chromosome-associated%2520leukemias%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D7389%26epage%3D7395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Willis, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demehri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crossman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederwieser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McWeeney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacs, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">2128</span><span class="NLM_x">–</span> <span class="NLM_lpage">2137</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=2128-2137&author=S.+G.+Willisauthor=T.+Langeauthor=S.+Demehriauthor=S.+Ottoauthor=L.+Crossmanauthor=D.+Niederwieserauthor=E.+P.+Stoffregenauthor=S.+McWeeneyauthor=I.+Kovacsauthor=B.+Parkauthor=B.+J.+Drukerauthor=M.+W.+Deininger&title=High-sensitivity+detection+of+BCR-ABL+kinase+domain+mutations+in+imatinib-naive+patients%3A+correlation+with+clonal+cytogenetic+evolution+but+not+response+to+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWillis%26aufirst%3DS.%2BG.%26aulast%3DLange%26aufirst%3DT.%26aulast%3DDemehri%26aufirst%3DS.%26aulast%3DOtto%26aufirst%3DS.%26aulast%3DCrossman%26aufirst%3DL.%26aulast%3DNiederwieser%26aufirst%3DD.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DMcWeeney%26aufirst%3DS.%26aulast%3DKovacs%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DB.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DHigh-sensitivity%2520detection%2520of%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520in%2520imatinib-naive%2520patients%253A%2520correlation%2520with%2520clonal%2520cytogenetic%2520evolution%2520but%2520not%2520response%2520to%2520therapy%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D2128%26epage%3D2137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kluterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.+H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+Inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0ljC4zSJzAXhvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520Inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3417</span><span class="NLM_x">–</span> <span class="NLM_lpage">3420</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1200%2FJCO.2012.43.1825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=22915655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3417-3420&author=J.+M.+Heuckmannauthor=D.+Rauhauthor=R.+K.+Thomas&title=Epidermal+growth+factor+receptor+%28EGFR%29+signaling+and+covalent+EGFR+inhibition+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor (EGFR) signaling and covalent EGF inhibition in lung cancer</span></div><div class="casAuthors">Heuckmann, Johannes M.; Rauh, Daniel; Thomas, Roman K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3417-3420</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The research of Ramalingam et al. (2012) entitled, 'Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, vs. erlotinib in patients with advanced non-small-cell lung cancer' is reviewed with commentary and refs.  In their paper, a novel irreversible ERBB family inhibitor, dacomitinib, improved progression-free survival compared with erlotinib in unselected patients with non-small-cell lung cancer without prior epidermal growth factor receptor-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8PW4hGdL2k7Vg90H21EOLACvtfcHk0ljC4zSJzAXhvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt73O&md5=45192d5ee846d2c25302286226cff733</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.1825%26sid%3Dliteratum%253Aachs%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520signaling%2520and%2520covalent%2520EGFR%2520inhibition%2520in%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3417%26epage%3D3420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wang, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynoso, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J. C.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S15</span><span class="NLM_x">–</span> <span class="NLM_lpage">S24</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2010&pages=S15-S24&issue=Suppl+1&author=W.+L.+Wangauthor=A.+Conleyauthor=D.+Reynosoauthor=L.+Noldenauthor=A.+J.+Lazarauthor=S.+Georgeauthor=J.+C.+Trent&title=Mechanisms+of+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DConley%26aufirst%3DA.%26aulast%3DReynoso%26aufirst%3DD.%26aulast%3DNolden%26aufirst%3DL.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DTrent%26aufirst%3DJ.%2BC.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2010%26volume%3D67%26issue%3DSuppl%25201%26spage%3DS15%26epage%3DS24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">The GIST paradigm: Lessons for other kinase-driven cancers</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1002%2Fpath.2798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=21125679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2011&pages=251-261&author=C.+R.+Antonescu&title=The+GIST+paradigm%3A+Lessons+for+other+kinase-driven+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The GIST paradigm: lessons for other kinase-driven cancers</span></div><div class="casAuthors">Antonescu, Cristina R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-261</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract, known to be notoriously refractory to conventional chemotherapy or radiation.  It is an ideal solid tumor model to apply our understanding from aberrant signal transduction to drug development, since nearly all tumors have a mutation in the KIT or, less often, the PDGFRA or BRAF genes.  The constitutively activated KIT and PDGFRA oncoproteins serve as crucial diagnostic and therapeutic targets.  The discovery of oncogenic KIT activation as a central mechanism of GIST pathogenesis suggested that inhibiting or blocking KIT signalling might be the milestone in the targeted therapy of GISTs.  Indeed, imatinib mesylate inhibits KIT kinase activity and represents the front-line drug for the treatment of unresectable and advanced GISTs, achieving a partial response or stable disease in about 80% of patients with metastatic GIST.  KIT mutation status has a significant impact on treatment response, emerging in recent years as a leading paradigm for genotype-driven targeted therapy.  In this review, parallels with other models in oncol. that share their addiction to a particular mutationally activated kinase are contrasted.  A better understanding of oncogene addiction as a common theme across tumors of diverse histologies underlies the clin. success of targeting such kinases with several selective kinase inhibitors.  Also remarkable is the similarity displayed in the mechanisms of drug failure after a successful but temporary clin. response to kinase inhibition.  Reactivation of the same oncogenic kinase, often by acquisition of second site mutations, is another emerging paradigm of secondary resistance in these tumor models.  The complexity of polyclonal resistance in imatinib-resistant patients argues that single next-generation kinase inhibitors will not be beneficial in all mutant clones.  Other broad therapeutic strategies could include combination of kinase inhibitors with targeting KIT downstream targets, such as PI3-K or MAPK/MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWlgzEuChm77Vg90H21EOLACvtfcHk0ljC4zSJzAXhvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlegsg%253D%253D&md5=e3da6e34c32b8905867ef97a9cac885b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fpath.2798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2798%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DThe%2520GIST%2520paradigm%253A%2520Lessons%2520for%2520other%2520kinase-driven%2520cancers%26jtitle%3DJ.%2520Pathol.%26date%3D2011%26volume%3D223%26spage%3D251%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Gibbons, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pricl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span> </span><span class="NLM_article-title">The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=293-299&author=D.+L.+Gibbonsauthor=S.+Priclauthor=H.+Kantarjianauthor=J.+Cortesauthor=A.+Quintas-Cardama&title=The+rise+and+fall+of+gatekeeper+mutations%3F+The+BCR-ABL1+T315I+paradigm"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26atitle%3DThe%2520rise%2520and%2520fall%2520of%2520gatekeeper%2520mutations%253F%2520The%2520BCR-ABL1%2520T315I%2520paradigm%26jtitle%3DCancer%26date%3D2011%26volume%3D118%26spage%3D293%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mac Partlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petillo, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">3189</span><span class="NLM_x">–</span> <span class="NLM_lpage">3195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3189-3195&author=C.+A.+Eideauthor=L.+T.+Adrianauthor=J.+W.+Tynerauthor=M.+Mac+Partlinauthor=D.+J.+Andersonauthor=S.+C.+Wiseauthor=B.+D.+Smithauthor=P.+A.+Petilloauthor=D.+L.+Flynnauthor=M.+W.+Deiningerauthor=T.+O%E2%80%99Hareauthor=B.+J.+Druker&title=The+ABL+switch+control+inhibitor+DCC-2036+is+active+against+the+chronic+myeloid+leukemia+mutant+BCR-ABLT315I+and+exhibits+a+narrow+resistance+profile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DMac%2BPartlin%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DPetillo%26aufirst%3DP.%2BA.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520ABL%2520switch%2520control%2520inhibitor%2520DCC-2036%2520is%2520active%2520against%2520the%2520chronic%2520myeloid%2520leukemia%2520mutant%2520BCR-ABLT315I%2520and%2520exhibits%2520a%2520narrow%2520resistance%2520profile%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3189%26epage%3D3195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">U.S. National Library of Medicine</span><span class="NLM_x">. </span><a href="http://www.clinicaltrials.gov/" class="extLink">http://www.clinicaltrials.gov/</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+National+Library+of+Medicine.+http%3A%2F%2Fwww.clinicaltrials.gov%2F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">U.S. Food and Drug Administration</span><span class="NLM_x">. </span><a href="http://www.fda.gov/" class="extLink">http://www.fda.gov/</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+Food+and+Drug+Administration.+http%3A%2F%2Fwww.fda.gov%2F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Fang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb300663j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCls7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=58-70&author=Z.+Fangauthor=C.+Gr%C3%BCtterauthor=D.+Rauh&title=Strategies+for+the+selective+regulation+of+kinases+with+allosteric+modulators%3A+exploiting+exclusive+structural+features"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features</span></div><div class="casAuthors">Fang, Zhizhou; Gruetter, Christian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-70</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The modulation of kinase function has become an important goal in modern drug discovery and chem. biol. research.  In cancer-targeted therapies, kinase inhibitors have been experiencing an upsurge, which can be measured by the increasing no. of kinase inhibitors approved by the FDA in recent years.  However, lack of efficacy, limited selectivity, and the emergence of acquired drug resistance still represent major bottlenecks in the clinic and challenge inhibitor development.  Most known kinase inhibitors target the active kinase and are ATP competitive.  A second class of small org. mols., which address remote sites of the kinase and stabilize enzymically inactive conformations, is rapidly moving to the forefront of kinase inhibitor research.  Such allosteric modulators bind to sites that are less conserved across the kinome and only accessible upon conformational changes.  These mols. are therefore thought to provide various advantages such as higher selectivity and extended drug target residence times.  This review highlights various strategies that have been developed to utilizing exclusive structural features of kinases and thereby modulating their activity allosterically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSjxxztmczXrVg90H21EOLACvtfcHk0lhnvfveVdnbvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCls7bN&md5=50864096bf66229ff74482a9b56847d6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcb300663j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300663j%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStrategies%2520for%2520the%2520selective%2520regulation%2520of%2520kinases%2520with%2520allosteric%2520modulators%253A%2520exploiting%2520exclusive%2520structural%2520features%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D58%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinase. Part II: The novel pharmacophore approach of type II and type III inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1427-1449&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinase.+Part+II%3A+The+novel+pharmacophore+approach+of+type+II+and+type+III+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinase.%2520Part%2520II%253A%2520The%2520novel%2520pharmacophore%2520approach%2520of%2520type%2520II%2520and%2520type%2520III%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1427%26epage%3D1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=709-723&author=P.+A.+Janneauthor=N.+Grayauthor=J.+Settleman&title=Factors+underlying+sensitivity+of+cancers+to+small-molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DFactors%2520underlying%2520sensitivity%2520of%2520cancers%2520to%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D709%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lhnvfveVdnbvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robubi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3915</span><span class="NLM_x">–</span> <span class="NLM_lpage">3926</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9002928" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3915-3926&author=M.+Getlikauthor=C.+Gr%C3%BCtterauthor=J.+R.+Simardauthor=S.+Kl%C3%BCterauthor=M.+Rabillerauthor=H.+B.+Rodeauthor=A.+Robubiauthor=D.+Rauh&title=Hybrid+compound+design+to+overcome+the+gatekeeper+T338M+mutation+in+cSrc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc</span></div><div class="casAuthors">Getlik, Matthaeus; Gruetter, Christian; Simard, Jeffrey R.; Kluter, Sabine; Rabiller, Matthias; Rode, Haridas B.; Robubi, Armin; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3915-3926</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistance remains a fundamental challenge in the development of kinase inhibitors that are effective over long-term treatments.  Allosteric inhibitors that bind to sites lying outside the highly conserved ATP pocket are thought to be more selective than ATP-competitive inhibitors and may circumvent some mechanisms of drug resistance.  Crystal structures of type I and allosteric type III inhibitors in complex with the tyrosine kinase cSrc allowed to develop these scaffolds into potent type II kinase inhibitors.  One of these compds., I (RL46), disrupts FAK-mediated focal adhesions in cancer cells via direct inhibition of cSrc.  Details gleaned from crystal structures revealed a key feature of a subset of these compds., a surprising flexibility in the vicinity of the gatekeeper residue that allows these compds. to overcome a dasatinib-resistant gatekeeper mutation emerging in cSrc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-72ZDo25pC7Vg90H21EOLACvtfcHk0lhnvfveVdnbvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D&md5=3ff187e49298ec4690c76a2bc2100274</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm9002928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9002928%26sid%3Dliteratum%253Aachs%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DRobubi%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHybrid%2520compound%2520design%2520to%2520overcome%2520the%2520gatekeeper%2520T338M%2520mutation%2520in%2520cSrc%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3915%26epage%3D3926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Hunter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, J. M.</span><span> </span><span class="NLM_article-title">Pi-pi interactions: The geometry and energetics of phenylalanine-phenylalanine interactions in proteins</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">218</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=1991&pages=837-846&author=C.+A.+Hunterauthor=J.+Singhauthor=J.+M.+Thornton&title=Pi-pi+interactions%3A+The+geometry+and+energetics+of+phenylalanine-phenylalanine+interactions+in+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DC.%2BA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DThornton%26aufirst%3DJ.%2BM.%26atitle%3DPi-pi%2520interactions%253A%2520The%2520geometry%2520and%2520energetics%2520of%2520phenylalanine-phenylalanine%2520interactions%2520in%2520proteins%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1991%26volume%3D218%26spage%3D837%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: A multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fnrd2130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=17016424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+A+multikinase+inhibitor+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span></div><div class="casAuthors">Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways.  The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process.  Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature.  The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compd. to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WjjfgNSCtbVg90H21EOLACvtfcHk0lgvfobolbhJ7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM&md5=490d4995170f3a7270ae9bbdd24b12e5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnrd2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2130%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520A%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D835%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28IRESSA%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0lgvfobolbhJ7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528IRESSA%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fnm0596-561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=8616716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&author=B.+J.+Drukerauthor=S.+Tamuraauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=S.+Fanningauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span></div><div class="casAuthors">Druker, Brian J.; Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Shane; Zimmermann, Jurg; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">The Bcr-Abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease.  A compd., designed to inhibit the Abl protein tyrosine kinase (CGP 57148), was evaluated for its effects on cells contg. the Bcr-Abl fusion protein.  Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compd.  In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the no. of Bcr-Abl colonies formed but no inhibition of normal colony formation.  This compd. may be useful in the treatment of Bcr-Abl-pos. leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzXj-25AHOrVg90H21EOLACvtfcHk0lgvfobolbhJ7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D&md5=1dc111cc883a1ed29964ae2c88c88cb9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnm0596-561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0596-561%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Nakatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, K.</span><span> </span><span class="NLM_article-title">STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1111%2Fj.1349-7006.2005.00018.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15723656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislOhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2005&pages=116-119&author=H.+Nakataniauthor=M.+Kobayashiauthor=T.+Jinauthor=T.+Taguchiauthor=T.+Sugimotoauthor=T.+Nakanoauthor=S.+Hamadaauthor=K.+Araki&title=STI571+%28Glivec%29+inhibits+the+interaction+between+c-KIT+and+heat+shock+protein+90+of+the+gastrointestinal+stromal+tumor+cell+line%2C+GIST-T1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1</span></div><div class="casAuthors">Nakatani, Hajime; Kobayashi, Michiya; Jin, Toufeng; Taguchi, Takahiro; Sugimoto, Takeki; Nakano, Takumi; Hamada, Shinichi; Araki, Keijiro</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-119</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">The gastrointestinal stromal tumor cell line, GIST-T1, has a heterogenic 57-base pair deletion in exon 11 of the c-kit mutation, and the c-KIT protein in the GIST-T1 cells constitutively activated.  The authors report that STI571 (Glivec; Novartis, Basel, Switzerland), a specific inhibitor of c-KIT, inhibits the clustering of c-KIT at the cell membrane of the GIST-T1 cells.  Furthermore, STI571 prevents the interaction between c-KIT and the mol. chaperone, heat shock protein 90 (Hsp90).  Geldanamycin, an inhibitor of Hsp90, also prevents interaction between c-KIT and Hsp90, and inhibits tyrosine phosphorylation of c-KIT.  The authors' results indicate that c-KIT mols. are assembled on the cell surface of the GIST-T1 cells, and that the interaction between c-KIT and Hsp90 plays an important role in c-KIT activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmR6opUwpxpLVg90H21EOLACvtfcHk0lg20nugBX3vhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislOhs7k%253D&md5=fb144a5c9de51a78e2a1d3d39940deff</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2005.00018.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2005.00018.x%26sid%3Dliteratum%253Aachs%26aulast%3DNakatani%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DT.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DT.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DHamada%26aufirst%3DS.%26aulast%3DAraki%26aufirst%3DK.%26atitle%3DSTI571%2520%2528Glivec%2529%2520inhibits%2520the%2520interaction%2520between%2520c-KIT%2520and%2520heat%2520shock%2520protein%252090%2520of%2520the%2520gastrointestinal%2520stromal%2520tumor%2520cell%2520line%252C%2520GIST-T1%26jtitle%3DCancer%2520Sci.%26date%3D2005%26volume%3D96%26spage%3D116%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span> </span><span class="NLM_article-title">Conformational adaptation in drug-target interactions and residence time</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1491</span><span class="NLM_x">–</span> <span class="NLM_lpage">1501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.4155%2Ffmc.11.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=21882942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSksLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1491-1501&author=R.+A.+Copeland&title=Conformational+adaptation+in+drug-target+interactions+and+residence+time"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational adaptation in drug-target interactions and residence time</span></div><div class="casAuthors">Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1491-1501</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Although drug-target interactions are commonly illustrated in terms of structurally static binding and dissocn. events, such descriptions are inadequate to explain the impact of conformational dynamics on these processes.  For high-affinity interactions, both the assocn. and dissocn. of drug mols. to and from their targets are often controlled by conformational changes of the target.  Conformational adaptation can greatly influence the residence time of a drug on its target (i.e., the lifetime of the binary drug-target complex); long residence time can lead to sustained pharmacol. and may also mitigate off-target toxicity.  In this perspective, the kinetics of drug-target assocn. and dissocn. reactions are explored, with particular emphasis on the impact of conformational adaptation on drug-target residence time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Bp8rlLqFa7Vg90H21EOLACvtfcHk0lg20nugBX3vhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSksLfO&md5=f995e1a9d854831af67a5d96eb14cac4</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.112%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DConformational%2520adaptation%2520in%2520drug-target%2520interactions%2520and%2520residence%2520time%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1491%26epage%3D1501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Klebe, G.</span> <span class="citation_source-book">Wirkstoffdesign: Entwurf und Wirkung von Arzneistoffen</span>. <span class="NLM_edition">2</span>nd ed.; <span class="NLM_publisher-name">Spektrum Akademischer Verlag</span>: <span class="NLM_publisher-loc">Heidelberg, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Klebe&title=Wirkstoffdesign%3A+Entwurf+und+Wirkung+von+Arzneistoffen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKlebe%26aufirst%3DG.%26btitle%3DWirkstoffdesign%253A%2520Entwurf%2520und%2520Wirkung%2520von%2520Arzneistoffen%26pub%3DSpektrum%2520Akademischer%2520Verlag%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+pan-BCR-ABL+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+T315I+mutant+and+overcomes+mutation-based+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520pan-BCR-ABL%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520T315I%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D401%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Lozzio, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozzio, B. B.</span><span> </span><span class="NLM_article-title">Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1182%2Fblood.V45.3.321.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=163658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A280%3ADyaE2M7gvFyjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1975&pages=321-334&author=C.+B.+Lozzioauthor=B.+B.+Lozzio&title=Human+chronic+myelogenous+leukemia+cell-line+with+positive+Philadelphia+chromosome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome</span></div><div class="casAuthors">Lozzio C B; Lozzio B B</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">321-34</span>
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    </div><div class="casAbstract">A cell-line derived from a patient with chronic myelogenous leukemia (CML) is described.  The new cell-line, which has over 175 serial passanges in a 3 1/2-yr period, has the following characteristics: (1) CML cells started to proliferate actively since they were first incubated in culture media.  A threefold increase in the total number of cells was observed during the first seven passages; the cell population increased by a factor of 10 to 20 every 7 days from passage 8 through 85; from 20 to 40 times from passage 86 through 150, and more than 40 times after 150 passages. (2) The majority of the nononucleated cells are undifferentiated blasts. (3) The karyotype of all the cells examined show the Philadelphia (Ph1) chromosome and a long acrocentric marker plus aneuploidy.  The Giemsa-banding studies identified the Ph1 chromosome as a terminal deletion of the long arm of chromosome 22:del(22)(q12) and the long acrocentric marker as an unbalanced reciprocal translocation of one chromosome 17 and the long arm of one chromosome 15. (4) The CML cells do not produce immunoglobulins, are free of mycoplasma, Epstein-Barr virus, and herpes-like virus particles. (5) CML cells have no alkaline phosphatase and myeloperoxidase activities and did not engulf inert particles. (6) Cultured CML cells provide a constant source of a specific antigen.  This CML cell-line represents a unique source of CML cells with meaningful indicators of malignancy for clinical and experimental studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSn4RF_5flkqEg6wdEZmT2rfW6udTcc2eYxZFXZimVK6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2M7gvFyjug%253D%253D&md5=d396e38802cebb103ab1c7b9adbe35af</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1182%2Fblood.V45.3.321.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V45.3.321.321%26sid%3Dliteratum%253Aachs%26aulast%3DLozzio%26aufirst%3DC.%2BB.%26aulast%3DLozzio%26aufirst%3DB.%2BB.%26atitle%3DHuman%2520chronic%2520myelogenous%2520leukemia%2520cell-line%2520with%2520positive%2520Philadelphia%2520chromosome%26jtitle%3DBlood%26date%3D1975%26volume%3D45%26spage%3D321%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Schneider, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janning, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">direct binding assay for the detection of type IV allosteric inhibitors of Abl</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">9138</span><span class="NLM_x">–</span> <span class="NLM_lpage">9141</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja303858w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1Wrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=9138-9141&author=R.+Schneiderauthor=C.+Beckerauthor=J.+R.+Simardauthor=M.+Getlikauthor=N.+Bohlkeauthor=P.+Janningauthor=D.+Rauh&title=direct+binding+assay+for+the+detection+of+type+IV+allosteric+inhibitors+of+Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Direct Binding Assay for the Detection of Type IV Allosteric Inhibitors of Abl</span></div><div class="casAuthors">Schneider, Ralf; Becker, Christian; Simard, Jeffrey R.; Getlik, Matthaeus; Bohlke, Nina; Janning, Petra; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9138-9141</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abelson (Abl) tyrosine kinase is an important cellular enzyme that is rendered constitutively active in the breakpoint cluster region (BCR)-Abl fusion protein, contributing to several forms of leukemia.  Although inhibiting BCR-Abl activity with imatinib shows great clin. success, many patients acquire secondary mutations that result in resistance to imatinib.  Second-generation inhibitors such as dasatinib and nilotinib can overcome the majority of these mutations but fail to treat patients with an esp. prevalent T315I mutation at the gatekeeper position of the kinase domain.  However, a combination of nilotinib with an allosteric type IV inhibitor was recently shown to overcome this clin. relevant point mutation.  In this study, we present the development of a direct binding assay that enables the straightforward detection of allosteric inhibitors which bind within the myristate pocket of Abl.  The assay is amenable to high-throughput screening and exclusively detects the binding of ligands to this unique allosteric site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHtVe0LFdqurVg90H21EOLACvtfcHk0lgtndWoQtk7KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1Wrt74%253D&md5=95aa204ff4d761f2a2155112abe35799</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fja303858w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja303858w%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DBohlke%26aufirst%3DN.%26aulast%3DJanning%26aufirst%3DP.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3Ddirect%2520binding%2520assay%2520for%2520the%2520detection%2520of%2520type%2520IV%2520allosteric%2520inhibitors%2520of%2520Abl%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D9138%26epage%3D9141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Kabsch, W.</span><span> </span><span class="NLM_article-title">Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1107%2FS0021889893005588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADyaK2cXptFeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=795-800&author=W.+Kabsch&title=Automatic+processing+of+rotation+diffraction+data+from+crystals+of+initially+unknown+symmetry+and+cell+constants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">795-800</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    </div><div class="casAbstract">An algorithm was developed for the automatic interpretation of a given set of obsd. reciprocal-lattice points.  It exts. a reduced cell and assigns indexes to each reflection by a graph-theor. implementation of the local indexing method.  All possible symmetries of the obsd. lattice compatible with the metric of the reduced cell are recognized and reported, together with the unit-cell consts. and the linear index transformation relating the conventional to the reduced cell.  This algorithm was incorporated into the program XDS (K., 1988), which is now able to process single-crystal area-detector data without prior knowledge of the symmetry and the unit-cell consts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD1lV8_7cDv7Vg90H21EOLACvtfcHk0lgtndWoQtk7KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXptFeltw%253D%253D&md5=2b703225206ce99af0d7e38acf6d75b3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0021889893005588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889893005588%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DAutomatic%2520processing%2520of%2520rotation%2520diffraction%2520data%2520from%2520crystals%2520of%2520initially%2520unknown%2520symmetry%2520and%2520cell%2520constants%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1993%26volume%3D26%26spage%3D795%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Pushing the boundaries of molecular replacement with maximum likelihood</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1373</span><span class="NLM_x">–</span> <span class="NLM_lpage">1382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1107%2FS0907444901012471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=11567148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmvFGltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2001&pages=1373-1382&author=R.+J.+Read&title=Pushing+the+boundaries+of+molecular+replacement+with+maximum+likelihood"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Pushing the boundaries of molecular replacement with maximum likelihood</span></div><div class="casAuthors">Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">D57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1373-1382</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">The mol.-replacement method works well with good models and simple unit cells, but often fails with more difficult problems.  Experience with likelihood in other areas of crystallog. suggests that it would improve performance significantly.  For mol. replacement, the form of the required likelihood function depends on whether there is ambiguity in the relative phases of the contributions from symmetry-related mols. (e.g. rotation vs. translation searches).  Likelihood functions used in structure refinement are appropriate only for translation (or six-dimensional) searches, where the correct translation will place all of the atoms in the model approx. correctly.  A new likelihood function that allows for unknown relative phases is suitable for rotation searches.  It is shown that correlations between sequence identity and coordinate error can be used to calibrate parameters for model quality in the likelihood functions.  Multiple models of a mol. can be combined in a statistically valid way by setting up the joint probability distribution of the true and model structure factors as a multivariate complex normal distribution, from which the conditional distribution of the true structure factor given the models can be derived.  Tests in a new mol.-replacement program, Beast, show that the likelihood-based targets are more sensitive and more accurate than previous targets.  The new multiple-model likelihood function has a dramatic impact on success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo23lasNP9RyLVg90H21EOLACvtfcHk0lgrY6fVQtfAMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmvFGltrc%253D&md5=b342c58edd40265324e0241ff75cec67</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444901012471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444901012471%26sid%3Dliteratum%253Aachs%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPushing%2520the%2520boundaries%2520of%2520molecular%2520replacement%2520with%2520maximum%2520likelihood%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2001%26volume%3D57%26spage%3D1373%26epage%3D1382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1016%2Fj.str.2007.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=17355866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=299-311&author=M.+A.+Seeligerauthor=B.+Nagarauthor=F.+Frankauthor=X.+Caoauthor=M.+N.+Hendersonauthor=J.+Kuriyan&title=c-Src+binds+to+the+cancer+drug+imatinib+with+an+inactive+Abl%2Fc-Kit+conformation+and+a+distributed+thermodynamic+penalty"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty</span></div><div class="casAuthors">Seeliger, Markus A.; Nagar, Bhushan; Frank, Filipp; Cao, Xiaoxian; Henderson, M. Nidanie; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-311</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor.  Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src.  The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Abl•imatinib and c-Kit•imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases.  Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodn. penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure.  Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2SQGjjXdg1LVg90H21EOLACvtfcHk0lgrY6fVQtfAMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D&md5=ddfbcf06d91b408ca5fb25af9774c334</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2007.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2007.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DFrank%26aufirst%3DF.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DHenderson%26aufirst%3DM.%2BN.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3Dc-Src%2520binds%2520to%2520the%2520cancer%2520drug%2520imatinib%2520with%2520an%2520inactive%2520Abl%252Fc-Kit%2520conformation%2520and%2520a%2520distributed%2520thermodynamic%2520penalty%26jtitle%3DStructure%26date%3D2007%26volume%3D15%26spage%3D299%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: Model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+Model-building+tools+for+molecular+graphics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lgrY6fVQtfAMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520Model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Brünger, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clore, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLano, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gros, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuszewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilges, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannu, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, G. L.</span><span> </span><span class="NLM_article-title">Crystallography & NMR system: A new software suite for macromolecular structure determination</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=905-921&author=A.+T.+Br%C3%BCngerauthor=P.+D.+Adamsauthor=G.+M.+Cloreauthor=W.+L.+DeLanoauthor=P.+Grosauthor=R.+W.+Grosse-Kunstleveauthor=J.+S.+Jiangauthor=J.+Kuszewskiauthor=M.+Nilgesauthor=N.+S.+Pannuauthor=R.+J.+Readauthor=L.+M.+Riceauthor=T.+Simonsonauthor=G.+L.+Warren&title=Crystallography+%26+NMR+system%3A+A+new+software+suite+for+macromolecular+structure+determination"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBr%25C3%25BCnger%26aufirst%3DA.%2BT.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DClore%26aufirst%3DG.%2BM.%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26aulast%3DGros%26aufirst%3DP.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DJiang%26aufirst%3DJ.%2BS.%26aulast%3DKuszewski%26aufirst%3DJ.%26aulast%3DNilges%26aufirst%3DM.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26aulast%3DSimonson%26aufirst%3DT.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26atitle%3DCrystallography%2520%2526%2520NMR%2520system%253A%2520A%2520new%2520software%2520suite%2520for%2520macromolecular%2520structure%2520determination%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1998%26volume%3D54%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lgHrr4GOg4M9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Schüttelkopf, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Aalten, D. M.</span><span> </span><span class="NLM_article-title">PRODRG: A tool for high-throughput crystallography of protein-ligand complexes</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1363</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=1355-1363&author=A.+W.+Sch%C3%BCttelkopfauthor=D.+M.+van+Aalten&title=PRODRG%3A+A+tool+for+high-throughput+crystallography+of+protein-ligand+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCttelkopf%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%26atitle%3DPRODRG%253A%2520A%2520tool%2520for%2520high-throughput%2520crystallography%2520of%2520protein-ligand%2520complexes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D1355%26epage%3D1363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Laskowski, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacArthur, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, J. M.</span><span> </span><span class="NLM_article-title">PROCHECK: A program to check the stereochemical quality of protein structures</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1107%2FS0021889892009944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADyaK3sXit12lurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=283-291&author=R.+A.+Laskowskiauthor=M.+W.+MacArthurauthor=D.+S.+Mossauthor=J.+M.+Thornton&title=PROCHECK%3A+A+program+to+check+the+stereochemical+quality+of+protein+structures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">PROCHECK: a program to check the stereochemical quality of protein structures</span></div><div class="casAuthors">Laskowski, Roman A.; MacArthur, Malcolm W.; Moss, David S.; Thornton, Janet M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-91</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    </div><div class="casAbstract">The PROCHECK suite of programs provides a detailed check on the stereochem. of a protein structure.  Its outputs comprise a no. of plots in PostScript format and a comprehensive residue-by-residue listing.  These give an assessment of the overall quality of the structure as compared with well-refined structures of the same resoln. and also highlight regions that may need further investigation.  The PROCHECK programs are useful for assessing the quality not only of protein structures in the process of being solved but also of existing structures and of those being modeled on known structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCe5FgJf4KH7Vg90H21EOLACvtfcHk0lgHrr4GOg4M9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXit12lurY%253D&md5=fb69fc4410cd716aaaa7cc0db06b3ed2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1107%2FS0021889892009944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889892009944%26sid%3Dliteratum%253Aachs%26aulast%3DLaskowski%26aufirst%3DR.%2BA.%26aulast%3DMacArthur%26aufirst%3DM.%2BW.%26aulast%3DMoss%26aufirst%3DD.%2BS.%26aulast%3DThornton%26aufirst%3DJ.%2BM.%26atitle%3DPROCHECK%253A%2520A%2520program%2520to%2520check%2520the%2520stereochemical%2520quality%2520of%2520protein%2520structures%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1993%26volume%3D26%26spage%3D283%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">DeLano, W. L.</span> The PyMOL Molecular Graphics System. <a href="http://www.pymol.org" class="extLink">http://www.pymol.org</a>,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DeLano%2C+W.+L.+The+PyMOL+Molecular+Graphics+System.+http%3A%2F%2Fwww.pymol.org%2C+2002."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Henze, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabellus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taeger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treckmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors</span> <span class="citation_source-journal">PloS ONE</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_elocation-id">e37776</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=J.+Henzeauthor=T.+M%C3%BChlenbergauthor=S.+Simonauthor=F.+Grabellusauthor=B.+Rubinauthor=G.+Taegerauthor=M.+Schulerauthor=J.+Treckmannauthor=M.+Debiec-Rychterauthor=T.+Taguchiauthor=J.+A.+Fletcherauthor=S.+Bauer&title=p53+modulation+as+a+therapeutic+strategy+in+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHenze%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DSimon%26aufirst%3DS.%26aulast%3DGrabellus%26aufirst%3DF.%26aulast%3DRubin%26aufirst%3DB.%26aulast%3DTaeger%26aufirst%3DG.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DTreckmann%26aufirst%3DJ.%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3Dp53%2520modulation%2520as%2520a%2520therapeutic%2520strategy%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DPloS%2520ONE%26date%3D2012%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Vichai, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirtikara, K.</span><span> </span><span class="NLM_article-title">Sulforhodamine B colorimetric assay for cytotoxicity screening</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1112</span><span class="NLM_x">–</span> <span class="NLM_lpage">1116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fnprot.2006.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=17406391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOitL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=1112-1116&author=V.+Vichaiauthor=K.+Kirtikara&title=Sulforhodamine+B+colorimetric+assay+for+cytotoxicity+screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Sulforhodamine B colorimetric assay for cytotoxicity screening</span></div><div class="casAuthors">Vichai, Vanicha; Kirtikara, Kanyawim</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1112-1116</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The sulforhodamine B (SRB) assay is used for cell d. detn., based on the measurement of cellular protein content.  The method described here was optimized for the toxicity screening of compds. to adherent cells in a 96-well format.  After an incubation period, cell monolayers are fixed with 10% (wt/vol) trichloroacetic acid and stained for 30 min, after which the excess dye is removed by washing repeatedly with 1% (vol/vol) acetic acid.  The protein-bound dye is dissolved in 10 mM Tris base soln. for OD detn. at 510 nm using a microplate reader.  The results are linear over a 20-fold range of cell nos. and the sensitivity is comparable to those of fluorometric methods.  The method not only allows a large no. of samples to be tested within a few days, but also requires only simple equipment and inexpensive reagents.  The SRB assay is therefore an efficient and highly cost-effective method for screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZ8pao808l7Vg90H21EOLACvtfcHk0lgwDAJCOdEb0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOitL3O&md5=7173035a1f9eb3f02dd7f1a947bca659</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2006.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2006.179%26sid%3Dliteratum%253Aachs%26aulast%3DVichai%26aufirst%3DV.%26aulast%3DKirtikara%26aufirst%3DK.%26atitle%3DSulforhodamine%2520B%2520colorimetric%2520assay%2520for%2520cytotoxicity%2520screening%26jtitle%3DNat.%2520Protoc.%26date%3D2006%26volume%3D1%26spage%3D1112%26epage%3D1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medeiros, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConarty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panigrahy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3999</span><span class="NLM_x">–</span> <span class="NLM_lpage">4006</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=3999-4006&author=A.+Duensingauthor=F.+Medeirosauthor=B.+McConartyauthor=N.+E.+Josephauthor=D.+Panigrahyauthor=S.+Singerauthor=C.+D.+Fletcherauthor=G.+D.+Demetriauthor=J.+A.+Fletcher&title=Mechanisms+of+oncogenic+KIT+signal+transduction+in+primary+gastrointestinal+stromal+tumors+%28GISTs%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMedeiros%26aufirst%3DF.%26aulast%3DMcConarty%26aufirst%3DB.%26aulast%3DJoseph%26aufirst%3DN.%2BE.%26aulast%3DPanigrahy%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520oncogenic%2520KIT%2520signal%2520transduction%2520in%2520primary%2520gastrointestinal%2520stromal%2520tumors%2520%2528GISTs%2529%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D3999%26epage%3D4006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Rubin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lux, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hibbard, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">KIT activation is a ubiquitous feature of gastrointestinal stromal tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">8118</span><span class="NLM_x">–</span> <span class="NLM_lpage">8121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=8118-8121&author=B.+P.+Rubinauthor=S.+Singerauthor=C.+Tsaoauthor=A.+Duensingauthor=M.+L.+Luxauthor=R.+Ruizauthor=M.+K.+Hibbardauthor=C.+J.+Chenauthor=S.+Xiaoauthor=D.+A.+Tuvesonauthor=G.+D.+Demetriauthor=C.+D.+Fletcherauthor=J.+A.+Fletcher&title=KIT+activation+is+a+ubiquitous+feature+of+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DTsao%26aufirst%3DC.%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DLux%26aufirst%3DM.%2BL.%26aulast%3DRuiz%26aufirst%3DR.%26aulast%3DHibbard%26aufirst%3DM.%2BK.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DXiao%26aufirst%3DS.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DKIT%2520activation%2520is%2520a%2520ubiquitous%2520feature%2520of%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D8118%26epage%3D8121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">9153</span><span class="NLM_x">–</span> <span class="NLM_lpage">9161</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9153-9161&author=S.+Bauerauthor=L.+K.+Yuauthor=G.+D.+Demetriauthor=J.+A.+Fletcher&title=Heat+shock+protein+90+inhibition+in+imatinib-resistant+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DL.%2BK.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DHeat%2520shock%2520protein%252090%2520inhibition%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9153%26epage%3D9161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabellus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taeger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6941</span><span class="NLM_x">–</span> <span class="NLM_lpage">6950</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6941-6950&author=T.+M%C3%BChlenbergauthor=Y.+Zhangauthor=A.+J.+Wagnerauthor=F.+Grabellusauthor=J.+Bradnerauthor=G.+Taegerauthor=H.+Langauthor=T.+Taguchiauthor=M.+Schulerauthor=J.+A.+Fletcherauthor=S.+Bauer&title=Inhibitors+of+deacetylases+suppress+oncogenic+KIT+signaling%2C+acetylate+HSP90%2C+and+induce+apoptosis+in+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DGrabellus%26aufirst%3DF.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DTaeger%26aufirst%3DG.%26aulast%3DLang%26aufirst%3DH.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DInhibitors%2520of%2520deacetylases%2520suppress%2520oncogenic%2520KIT%2520signaling%252C%2520acetylate%2520HSP90%252C%2520and%2520induce%2520apoptosis%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6941%26epage%3D6950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Helena  Kaitsiotou</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Julia  Hardick</span>, <span class="hlFld-ContribAuthor ">Thomas  Mühlenberg</span>, <span class="hlFld-ContribAuthor ">Julia  Ketzer</span>, <span class="hlFld-ContribAuthor ">Christiane  Ehrt</span>, <span class="hlFld-ContribAuthor ">Jasmin  Krüll</span>, <span class="hlFld-ContribAuthor ">Federico  Medda</span>, <span class="hlFld-ContribAuthor ">Oliver  Koch</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Giordanetto</span>, <span class="hlFld-ContribAuthor ">Sebastian  Bauer</span>, and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>  . </span><span class="cited-content_cbyCitation_article-title">Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (21)
                                     , 8801-8815. <a href="https://doi.org/10.1021/acs.jmedchem.7b00841" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00841</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00841%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInhibitors%252Bto%252BOvercome%252BSecondary%252BMutations%252Bin%252Bthe%252BStem%252BCell%252BFactor%252BReceptor%252BKIT%26aulast%3DKaitsiotou%26aufirst%3DHelena%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D08062017%26date%3D24102017%26date%3D09112017%26date%3D09102017%26volume%3D60%26issue%3D21%26spage%3D8801%26epage%3D8815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwangseo  Park</span>, <span class="hlFld-ContribAuthor ">Soyoung  Lee</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Dual Inhibitors for Wild Type and D816V Mutant of c-KIT Kinase through Virtual and Biochemical Screening of Natural Products. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2016,</strong> <em>79 </em>
                                    (2)
                                     , 293-299. <a href="https://doi.org/10.1021/acs.jnatprod.5b00851" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.5b00851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.5b00851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.5b00851%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DDiscovery%252Bof%252BDual%252BInhibitors%252Bfor%252BWild%252BType%252Band%252BD816V%252BMutant%252Bof%252Bc-KIT%252BKinase%252Bthrough%252BVirtual%252Band%252BBiochemical%252BScreening%252Bof%252BNatural%252BProducts%26aulast%3DPark%26aufirst%3DHwangseo%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D08102015%26date%3D25012016%26date%3D26022016%26volume%3D79%26issue%3D2%26spage%3D293%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sujin  Park</span>, <span class="hlFld-ContribAuthor ">Dah In  Kwon</span>, <span class="hlFld-ContribAuthor ">Jeeyeon  Lee</span>, and <span class="hlFld-ContribAuthor ">Ikyon  Kim</span>  . </span><span class="cited-content_cbyCitation_article-title">When Indolizine Meets Quinoline: Diversity-Oriented Synthesis of New Polyheterocycles and Their Optical Properties. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2015,</strong> <em>17 </em>
                                    (8)
                                     , 459-469. <a href="https://doi.org/10.1021/acscombsci.5b00031" title="DOI URL">https://doi.org/10.1021/acscombsci.5b00031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.5b00031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.5b00031%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DWhen%252BIndolizine%252BMeets%252BQuinoline%25253A%252BDiversity-Oriented%252BSynthesis%252Bof%252BNew%252BPolyheterocycles%252Band%252BTheir%252BOptical%252BProperties%26aulast%3DPark%26aufirst%3DSujin%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D17022015%26date%3D16062015%26date%3D23072015%26date%3D10082015%26volume%3D17%26issue%3D8%26spage%3D459%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">André  Richters</span>, <span class="hlFld-ContribAuthor ">Hoang D.  Nguyen</span>, <span class="hlFld-ContribAuthor ">Trang  Phan</span>, <span class="hlFld-ContribAuthor ">Jeffrey R.  Simard</span>, <span class="hlFld-ContribAuthor ">Christian  Grütter</span>, <span class="hlFld-ContribAuthor ">Julian  Engel</span>, and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of Type II and III DDR2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (10)
                                     , 4252-4262. <a href="https://doi.org/10.1021/jm500167q" title="DOI URL">https://doi.org/10.1021/jm500167q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500167q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500167q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BType%252BII%252Band%252BIII%252BDDR2%252BInhibitors%26aulast%3DRichters%26aufirst%3DAndr%25C3%25A9%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D29012014%26date%3D05052014%26date%3D22052014%26date%3D22042014%26volume%3D57%26issue%3D10%26spage%3D4252%26epage%3D4262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Honglin  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Lei</span>, <span class="hlFld-ContribAuthor ">Guotao  Tang</span>, <span class="hlFld-ContribAuthor ">Xuan  Cao</span>, <span class="hlFld-ContribAuthor ">Junmei  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>97 </em>
                                    (3)
                                     , 649-664. <a href="https://doi.org/10.1111/cbdd.13801" title="DOI URL">https://doi.org/10.1111/cbdd.13801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13801%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DRecent%252Badvances%252Bin%252BBcr%2525E2%252580%252590Abl%252Btyrosine%252Bkinase%252Binhibitors%252Bfor%252Boverriding%252BT315I%252Bmutation%26aulast%3DLiu%26aufirst%3DJuan%26date%3D2021%26date%3D2020%26volume%3D97%26issue%3D3%26spage%3D649%26epage%3D664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pranav  Gupta</span>, <span class="hlFld-ContribAuthor ">Yunali V.  Ashar</span>, <span class="hlFld-ContribAuthor ">Charles R.  Ashby</span>, <span class="hlFld-ContribAuthor ">Lusheng  Lin</span>, <span class="hlFld-ContribAuthor ">Zhe-Sheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00047-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00047-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00047-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00047-5%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BOncogenic%252BProtein%25252C%252BBreakpoint%252BCluster%252B%252528BCR%252529-Abelson%252BKinase%252B%252528ABL%252529%252Band%252BChronic%252BMyelocytic%252BLeukemia%252B%252528CML%252529%25253A%252BInsight%252BInto%252Bthe%252BDrug%252BResistance%252BMechanisms%252Band%252BApproaches%252Bfor%252BTargeting%252BBCR-ABL%252Bin%252BCML%26aulast%3DGupta%26aufirst%3DPranav%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oliver  Snow</span>, <span class="hlFld-ContribAuthor ">Nada  Lallous</span>, <span class="hlFld-ContribAuthor ">Kriti  Singh</span>, <span class="hlFld-ContribAuthor ">Nathan  Lack</span>, <span class="hlFld-ContribAuthor ">Paul  Rennie</span>, <span class="hlFld-ContribAuthor ">Artem  Cherkasov</span>. </span><span class="cited-content_cbyCitation_article-title">Androgen receptor plasticity and its implications for prostate cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Cancer Treatment Reviews</span><span> <strong>2019,</strong> <em>81 </em>, 101871. <a href="https://doi.org/10.1016/j.ctrv.2019.05.001" title="DOI URL">https://doi.org/10.1016/j.ctrv.2019.05.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ctrv.2019.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ctrv.2019.05.001%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Treatment%2520Reviews%26atitle%3DAndrogen%252Breceptor%252Bplasticity%252Band%252Bits%252Bimplications%252Bfor%252Bprostate%252Bcancer%252Btherapy%26aulast%3DSnow%26aufirst%3DOliver%26date%3D2019%26volume%3D81%26spage%3D101871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Cong  Wu</span>, <span class="hlFld-ContribAuthor ">Xin-Yue  Ren</span>, <span class="hlFld-ContribAuthor ">Guo-Wu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Research Progress of Diphenyl Urea Derivatives as Anticancer Agents and Synthetic Methodologies. </span><span class="cited-content_cbyCitation_journal-name">Mini-Reviews in Organic Chemistry</span><span> <strong>2019,</strong> <em>16 </em>
                                    (7)
                                     , 617-630. <a href="https://doi.org/10.2174/1570193X15666181029130418" title="DOI URL">https://doi.org/10.2174/1570193X15666181029130418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570193X15666181029130418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570193X15666181029130418%26sid%3Dliteratum%253Aachs%26jtitle%3DMini-Reviews%2520in%2520Organic%2520Chemistry%26atitle%3DResearch%252BProgress%252Bof%252BDiphenyl%252BUrea%252BDerivatives%252Bas%252BAnticancer%252BAgents%252Band%252BSynthetic%252BMethodologies%26aulast%3DWu%26aufirst%3DYi-Cong%26date%3D2019%26volume%3D16%26issue%3D7%26spage%3D617%26epage%3D630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Izzo</span>, <span class="hlFld-ContribAuthor ">Enrico Marco  Gottardi</span>, <span class="hlFld-ContribAuthor ">Santa  Errichiello</span>, <span class="hlFld-ContribAuthor ">Filomena  Daraio</span>, <span class="hlFld-ContribAuthor ">Claudia  Baratè</span>, <span class="hlFld-ContribAuthor ">Sara  Galimberti</span>. </span><span class="cited-content_cbyCitation_article-title">Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2019,</strong> <em>9 </em><a href="https://doi.org/10.3389/fonc.2019.00833" title="DOI URL">https://doi.org/10.3389/fonc.2019.00833</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2019.00833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2019.00833%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DMonitoring%252BChronic%252BMyeloid%252BLeukemia%25253A%252BHow%252BMolecular%252BTools%252BMay%252BDrive%252BTherapeutic%252BApproaches%26aulast%3DIzzo%26aufirst%3DBarbara%26date%3D2019%26date%3D2019%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feiyang  Liu</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Liu</span>, <span class="hlFld-ContribAuthor ">Shuang  Qi</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Wu</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Xuesong  Liu</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Juan  Ge</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Bai</span>, <span class="hlFld-ContribAuthor ">Yujiao  Cai</span>, <span class="hlFld-ContribAuthor ">Xudong  Xiao</span>, <span class="hlFld-ContribAuthor ">Feng  Qian</span>, <span class="hlFld-ContribAuthor ">Jun  Tang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Medical Oncology</span><span> <strong>2019,</strong> <em>11 </em>, 175883591984975. <a href="https://doi.org/10.1177/1758835919849757" title="DOI URL">https://doi.org/10.1177/1758835919849757</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1758835919849757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1758835919849757%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Medical%2520Oncology%26atitle%3DAxitinib%252Bovercomes%252Bmultiple%252Bimatinib%252Bresistant%252BcKIT%252Bmutations%252Bincluding%252Bthe%252Bgatekeeper%252Bmutation%252BT670I%252Bin%252Bgastrointestinal%252Bstromal%252Btumors%26aulast%3DLiu%26aufirst%3DFeiyang%26date%3D2019%26date%3D2019%26volume%3D11%26spage%3D175883591984975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Prause</span>, <span class="hlFld-ContribAuthor ">Sabrina  Niedermoser</span>, <span class="hlFld-ContribAuthor ">Carmen  Wängler</span>, <span class="hlFld-ContribAuthor ">Clemens  Decristoforo</span>, <span class="hlFld-ContribAuthor ">Uwe  Seibold</span>, <span class="hlFld-ContribAuthor ">Stephanie  Riester</span>, <span class="hlFld-ContribAuthor ">Takahiro  Taguchi</span>, <span class="hlFld-ContribAuthor ">Ralf  Schirrmacher</span>, <span class="hlFld-ContribAuthor ">Gert  Fricker</span>, <span class="hlFld-ContribAuthor ">Björn  Wängler</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, in vitro and in vivo evaluation of 18 F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors. </span><span class="cited-content_cbyCitation_journal-name">Nuclear Medicine and Biology</span><span> <strong>2018,</strong> <em>57 </em>, 1-11. <a href="https://doi.org/10.1016/j.nucmedbio.2017.11.004" title="DOI URL">https://doi.org/10.1016/j.nucmedbio.2017.11.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nucmedbio.2017.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nucmedbio.2017.11.004%26sid%3Dliteratum%253Aachs%26jtitle%3DNuclear%2520Medicine%2520and%2520Biology%26atitle%3DSynthesis%25252C%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Bevaluation%252Bof%252B18%252BF-fluoronorimatinib%252Bas%252Bradiotracer%252Bfor%252BImatinib-sensitive%252Bgastrointestinal%252Bstromal%252Btumors%26aulast%3DPrause%26aufirst%3DMartin%26date%3D2018%26volume%3D57%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Costantino</span>, <span class="hlFld-ContribAuthor ">Daniela  Barlocco</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Approaches to Multitarget Drugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 161-205. <a href="https://doi.org/10.1002/9783527674381.ch7" title="DOI URL">https://doi.org/10.1002/9783527674381.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527674381.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527674381.ch7%26sid%3Dliteratum%253Aachs%26atitle%3DDesigning%252BApproaches%252Bto%252BMultitarget%252BDrugs%26aulast%3DCostantino%26aufirst%3DLuca%26date%3D2017%26date%3D2017%26spage%3D161%26epage%3D205%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DDrug%252BSelectivity%26aulast%3DHandler%26aufirst%3DNorbert%26date%3D2017%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eugen  Bethke</span>, <span class="hlFld-ContribAuthor ">Boris  Pinchuk</span>, <span class="hlFld-ContribAuthor ">Christian  Renn</span>, <span class="hlFld-ContribAuthor ">Lydia  Witt</span>, <span class="hlFld-ContribAuthor ">Joachim  Schlosser</span>, <span class="hlFld-ContribAuthor ">Christian  Peifer</span>. </span><span class="cited-content_cbyCitation_article-title">From Type I to Type II: Design, Synthesis, and Characterization of Potent Pyrazin-2-ones as DFG-Out Inhibitors of PDGFRβ. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2016,</strong> <em>11 </em>
                                    (24)
                                     , 2664-2674. <a href="https://doi.org/10.1002/cmdc.201600494" title="DOI URL">https://doi.org/10.1002/cmdc.201600494</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201600494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201600494%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DFrom%252BType%2525E2%252580%252585I%252Bto%252BType%2525E2%252580%252585II%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BCharacterization%252Bof%252BPotent%252BPyrazin-2-ones%252Bas%252BDFG-Out%252BInhibitors%252Bof%252BPDGFR%2525CE%2525B2%26aulast%3DBethke%26aufirst%3DEugen%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D24%26spage%3D2664%26epage%3D2674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Shan</span>, <span class="hlFld-ContribAuthor ">Jinyun  Dong</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Pan</span>, <span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Yalin  Dong</span>, <span class="hlFld-ContribAuthor ">Maoyi  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>104 </em>, 139-147. <a href="https://doi.org/10.1016/j.ejmech.2015.09.034" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.09.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.09.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.09.034%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExpanding%252Bthe%252Bstructural%252Bdiversity%252Bof%252BBcr-Abl%252Binhibitors%25253A%252BDibenzoylpiperazin%252Bincorporated%252Bwith%252B1H-indazol-3-amine%26aulast%3DShan%26aufirst%3DYuanyuan%26date%3D2015%26volume%3D104%26spage%3D139%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Rauh</span>, <span class="hlFld-ContribAuthor ">Jeffrey R.  Simard</span>. </span><span class="cited-content_cbyCitation_article-title">FLiK and FLiP: Direct Binding Assays for the Identification of Stabilizers of Inactive Kinase and Phosphatase Conformations. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 17-36. <a href="https://doi.org/10.1002/9783527687503.ch2" title="DOI URL">https://doi.org/10.1002/9783527687503.ch2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527687503.ch2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527687503.ch2%26sid%3Dliteratum%253Aachs%26atitle%3DFLiK%252Band%252BFLiP%25253A%252BDirect%252BBinding%252BAssays%252Bfor%252Bthe%252BIdentification%252Bof%252BStabilizers%252Bof%252BInactive%252BKinase%252Band%252BPhosphatase%252BConformations%26aulast%3DRauh%26aufirst%3DDaniel%26date%3D2014%26date%3D2014%26spage%3D17%26epage%3D36%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DConcepts%252Band%252BCase%252BStudies%252Bin%252BChemical%252BBiology%26aulast%3DWaldmann%26aufirst%3DHerbert%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/medium/jm-2013-004076_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4004076&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/medium/jm-2013-004076_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) General scaffold of a 1,4-fused type II hybrid inhibitor, <b>1</b>, composed of type I and type III fragments, as well as hybrid compound <b>2</b>, as an initial rationally designed molecule to target cSrc wild-type and T338M. Imatinib and ponatinib represent approved type II inhibitors for the treatment of GISTs and CML. (B) Schematic overview on how to circumvent steric repulsion with bulky gatekeepers (e.g., methionine) in drug-resistant mutant kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4004076&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/medium/jm-2013-004076_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of a Subset of Quinazoline Derivatives and Fragments<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4004076&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Pivaloyl acetonitrile, conc. HCl, EtOH, 90 °C; (ii) Troc-Cl, NaOH, EtOAc/H<sub>2</sub>O, 0 °C to rt; (iii) methylamine hydrochloride, DIPEA, DMSO, rt; (iv) <i>N</i>-Boc phenylenediamine, DIPEA, DMSO, rt; (v) ammonium formate, Pd/C, EtOH, 90 °C; (vi) Fmoc-Cl, NaHCO<sub>3</sub>, dioxane/H<sub>2</sub>O, rt; (vii) 4 M HCl in dioxane, rt; (viii) 4-chloro-6-aminoquinazoline, DIPEA, DCM, rt; (ix) iron chipping (activated with 1 N HCl), AcOH, EtOH, reflux; (x) corresponding acid chloride of <b>f–i</b>; THF, base (DIPEA or NMP), THF or DCM, rt; (xi) piperidine or morpholine in DMF, rt. The framed intermediate molecule was further used to generate other hybrid derivatives in a different synthetic route (See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Schemes S1 and S2).</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/medium/jm-2013-004076_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. 1,4-Substituted hybrid compounds in complex with wild-type cSrc. Diagrams of the experimental electron densities of cSrc–<b>3h</b> at 2.7 Å (A) and cSrc-<b>3g</b> at 3.3 Å (B) resolution are shown (2<i>F</i><sub>o</sub><i> – F</i><sub>c</sub> map contoured at 1σ). Hydrogen-bond interactions of the inhibitors with helix C (turquoise), the DFG-motif (pink), and the hinge region (orange) are shown by red dotted lines. The kinase domain is in the inactive DFG-out conformation, and the pyrazolourea moiety resides in the allosteric site flanked by helix C and the DFG-motif. <i>N</i>1 of the quinazoline makes a direct hydrogen bond to the main chain amide of Met341, which is an interaction commonly formed between anilinoquinazolines and the hinge region of several other protein kinase domains. In both complexes, the central phenyl moiety that links the quinazoline scaffold with the pyrazolourea fragment interacts with the side chain of Phe405 (DFG motif) in a favorable edge-to-face orientation. (C) The aromatic amine points into a polar subpocket that is formed by three polar amino acid side chains (Lys295, Glu310, and Asp404) and forms polar interactions with a water molecule (red sphere). A detailed illustration of this interaction, including electron density data, is provided in Figure S2, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4004076&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/medium/jm-2013-004076_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Dose–response curves of hybrid compounds on GIST cells expressing (A) constitutively active KIT (GIST-T1) as well as (B) the gatekeeper mutated KIT T670I (GIST-T1 T670I) and (C) the KIT negative cell line GIST-48B after 72 h incubation with the respective compounds; (D) GI<sub>50</sub> values on GIST-T1, GIST-T1 T670I, and GIST-48B; (E,F) Western blot analyses after 24 h of incubation with doses of <b>3d</b>, <b>3h</b>, and imatinib (IM) in GIST-T1 and GIST-T1 T670I.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm4004076/production/images/large/jm-2013-004076_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4004076&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46533" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46533" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 55 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tückmantel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Proteus in the world of proteins: Conformational changes in protein kinases</span> <span class="citation_source-journal">Arch. Pharm. (Weinheim, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1002%2Fardp.201000028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=20336692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2010&pages=193-206&author=M.+Rabillerauthor=M.+Getlikauthor=S.+Kl%C3%BCterauthor=A.+Richtersauthor=S.+T%C3%BCckmantelauthor=J.+R.+Simardauthor=D.+Rauh&title=Proteus+in+the+world+of+proteins%3A+Conformational+changes+in+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Proteus in the world of proteins: Conformational changes in protein kinases</span></div><div class="casAuthors">Rabiller, Matthias; Getlik, Matthaeus; Klueter, Sabine; Richters, Andre; Tueckmantel, Sandra; Simard, Jeffrey R.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">193-206</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The 512 protein kinases encoded by the human genome are a prime example of Nature's ability to create diversity by introducing variations to a highly conserved theme.  The activity of each kinase domain is controlled by layers of regulatory mechanisms involving different combinations of post-translational modifications, intramol. contacts, and intermol. interactions.  Ultimately, they all achieve their effect by favoring particular conformations that promote or prevent the kinase domain from catalyzing protein phosphorylation.  The central role of kinases in various diseases has encouraged extensive investigations of their biol. function and 3-dimensional structures, yielding a more detailed understanding of the mechanisms that regulate protein kinase activity by conformational changes.  Here, the authors discuss these regulatory mechanisms and show how conformational changes can be exploited for the design of specific inhibitors that lock protein kinases in inactive conformations.  In addn., the authors highlight recent developments to monitor ligand-induced structural changes in protein kinases and for screening and identifying inhibitors that stabilize enzymically incompetent kinase conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRChkP9MKuIbVg90H21EOLACvtfcHk0lic-oJPqLHygw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D&md5=0833f19b8565afc03c39bf5fb5a87175</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fardp.201000028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201000028%26sid%3Dliteratum%253Aachs%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DT%25C3%25BCckmantel%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DProteus%2520in%2520the%2520world%2520of%2520proteins%253A%2520Conformational%2520changes%2520in%2520protein%2520kinases%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D2010%26volume%3D343%26spage%3D193%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0lic-oJPqLHygw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">–</span> <span class="NLM_lpage">1167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+anti-apoptotic+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520anti-apoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Weinstein, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, A. K.</span><span> </span><span class="NLM_article-title">Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy</span> <span class="citation_source-journal">Nat. Clin. Pract. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">448</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fncponc0558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=16894390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1OktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=448-457&author=I.+B.+Weinsteinauthor=A.+K.+Joe&title=Mechanisms+of+disease%3A+Oncogene+addiction%2D%2Da+rationale+for+molecular+targeting+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy</span></div><div class="casAuthors">Weinstein, I. Bernard; Joe, Andrew K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">448-457</span>CODEN:
                <span class="NLM_cas:coden">NCPOB5</span>;
        ISSN:<span class="NLM_cas:issn">1743-4254</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There has been considerable progress in the systemic treatment of cancer because of the rapid development and clin. application of mol. targeted agents.  Although patients with a particular type and stage of cancer are often treated as a single group, more-specific therapy is being considered, as subsets of these patients who are more likely to benefit from treatment with particular agents are being identified.  We previously introduced the concept of 'oncogene addiction' to explain how some cancers that contain multiple genetic, epigenetic, and chromosomal abnormalities are dependent on or 'addicted' to one or a few genes for both maintenance of the malignant phenotype and cell survival.  Thus, reversal of only one or a few of these abnormalities can inhibit cancer cell growth and in some cases translate to improved survival rates.  This review summarizes current exptl. and clin. evidence for the concept of oncogene addiction and describes mol. mechanisms that may explain this phenomenon.  In addn., we discuss how high-throughput screening methods, including gene-expression profiling and proteomics, and emerging methods for analyzing complex cellular networks can be used to identify the state of oncogene addiction, i.e. the 'Achilles' heel,' in specific cancers.  Finally, we discuss the use of mol. targeted agents in combination with other anticancer agents as a strategy to optimize therapy and prevent disease recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG33E0-PnEMrVg90H21EOLACvtfcHk0lj0ISqwb5BmKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1OktL8%253D&md5=e630af1a5ccfe6e736cb48285bb0146e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fncponc0558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncponc0558%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DI.%2BB.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26atitle%3DMechanisms%2520of%2520disease%253A%2520Oncogene%2520addiction--a%2520rationale%2520for%2520molecular%2520targeting%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Oncol.%26date%3D2006%26volume%3D3%26spage%3D448%26epage%3D457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Overriding imatinib resistance with a novel ABL kinase inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1126%2Fscience.1099480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15256671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=399-401&author=N.+P.+Shahauthor=C.+Tranauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=C.+L.+Sawyers&title=Overriding+imatinib+resistance+with+a+novel+ABL+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor</span></div><div class="casAuthors">Shah, Neil P.; Tran, Chris; Lee, Francis Y.; Chen, Ping; Norris, Derek; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5682</span>),
    <span class="NLM_cas:pages">399-402</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding.  Crystallog. studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements.  BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants.  BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-pos. bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.  These data illustrate how mol. insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0O0Lhe8nKCrVg90H21EOLACvtfcHk0lj0ISqwb5BmKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D&md5=b3827c3419b4c6b57893b11fd68f1f96</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099480%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DOverriding%2520imatinib%2520resistance%2520with%2520a%2520novel%2520ABL%2520kinase%2520inhibitor%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D399%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Steinberg, M.</span><span> </span><span class="NLM_article-title">Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2289</span><span class="NLM_x">–</span> <span class="NLM_lpage">2308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1016%2Fj.clinthera.2007.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=18158072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2007&pages=2289-2308&author=M.+Steinberg&title=Dasatinib%3A+A+tyrosine+kinase+inhibitor+for+the+treatment+of+chronic+myelogenous+leukemia+and+philadelphia+chromosome-positive+acute+lymphoblastic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia</span></div><div class="casAuthors">Steinberg, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2289-2308</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: The Philadelphia chromosome is formed from a translocation of genetic material involving human chromosomes 9 and 22.  The resulting gene product, BCR-ABL, encodes for an abnormal tyrosine kinase (TK) that is a factor in the pathol. of chronic myelogenous leukemia (CML).  Use of targeted therapy that inhibits BCR-ABL kinase activity may lead to hematol. and cytogenetic responses in affected individuals.  The oral TK inhibitor dasatinib was approved in 2006 for use in patients with CML or Philadelphia chromosome-pos. acute lymphoblastic leukemia (ALL) who are unable to tolerate or have not responded to other treatments.  Objective: This paper reviews the available data on dasatinib, including its pharmacokinetic and pharmacodynamic properties, findings of in vitro and in vivo studies, adverse effects, and potential place in therapy.  Methods: Pertinent information was identified through searches of MEDLINE (1966-May 2007), EMBASE (1980-first quarter 2007), and International Pharmaceutical Abstrs. (1970-May 2007) using the terms dasatinib, BMS-354825, chronic myelogenous leukemia, Sprycel, Philadelphia chromosome, and acute lymphoblastic leukemia.  All clin. studies and case reports published at the time of the search were included in this review.  Results: Obsd. mutations in the amino acid sequence of BCR-ABL cause the failure of treatment with existing TK inhibitors.  Dasatinib has shown in vitro and in vivo activity against BCR-ABL, including mutations that are resistant to other available TK inhibitors.  Preliminary results are available from several noncomparative studies of dasatinib in patients who were unable to tolerate or were resistant to previous therapies.  The 5 phases of START (SRC/ABL Tyrosine kinase inhibition Activity Research Trials of dasatinib) represent the largest and most comprehensive evaluation of dasatinib in the treatment of patients in all stages of CML or Philadelphia chromosome-pos. ALL who had undergone previous treatment for leukemia.  Dasatanib had the greatest benefit in patients in the chronic phase of CML, with complete hematol. responses in 90% of patients, 52% of whom achieved a major hematol. response.  Compared with those in the chronic phase, patients in the accelerated phase or blast crisis of CML, or with Philadelphia chromosome-pos. ALL had lower responses.  In the START-R trial, which compared the response to dasatinib and high-dose imatinib (800 mg/d), both regimens had comparable ability to induce a complete hematol. response (95% and 93%, resp.), although more patients achieved a major cytogenetic response with dasatinib (32% vs 7%).  Adverse effects include significant myelosuppression.  Dasatinib may have the potential for use in the management of nonleukemic malignancies.  Conclusions: Dasatinib has a wider spectrum of activity against a broader range of BCR-ABL forms than existing TK inhibitors.  It has shown clin. benefit and tolerability in patients in all phases of CML, as well as in those with Philadelphia chromosome-pos. ALL.  Dasatinib illustrates the potential for targeted drug development based on an understanding of the genetic alterations leading to CML and the development of resistance to treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn8AoiiPuTJrVg90H21EOLACvtfcHk0lj0ISqwb5BmKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKjt7k%253D&md5=1219cbf8c0a882317a19db3a2c9a4605</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2007.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2007.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DM.%26atitle%3DDasatinib%253A%2520A%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520myelogenous%2520leukemia%2520and%2520philadelphia%2520chromosome-positive%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DClin.%2520Ther.%26date%3D2007%26volume%3D29%26spage%3D2289%26epage%3D2308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+Correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0ljj3q4Bccc6jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520Correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Balak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouerfelli, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6494</span><span class="NLM_x">–</span> <span class="NLM_lpage">6501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1158%2F1078-0432.CCR-06-1570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=17085664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6494-6501&author=M.+N.+Balakauthor=Y.+Gongauthor=G.+J.+Rielyauthor=R.+Somwarauthor=A.+R.+Liauthor=M.+F.+Zakowskiauthor=A.+Chiangauthor=G.+Yangauthor=O.+Ouerfelliauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=V.+A.+Millerauthor=W.+Pao&title=Novel+D761Y+and+common+secondary+T790M+mutations+in+epidermal+growth+factor+receptor-mutant+lung+adenocarcinomas+with+acquired+resistance+to+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors</span></div><div class="casAuthors">Balak, Marissa N.; Gong, Yixuan; Riely, Gregory J.; Somwar, Romel; Li, Allan R.; Zakowski, Maureen F.; Chiang, Anne; Yang, Guangli; Ouerfelli, Ouathek; Kris, Mark G.; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6494-6501</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In patients whose lung adenocarcinomas harbor epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations, acquired resistance to the tyrosine kinase inhibitors (TKI) gefitinib (Iressa) and erlotinib (Tarceva) has been assocd. with a second-site EGFR mutation, which leads to substitution of methionine for threonine at position 790 (T790M).  We aimed to elucidate the frequency and nature of secondary EGFR mutations in patients with acquired resistance to TKI monotherapy.  Exptl. Design: Tumor cells from patients with acquired resistance were examd. for secondary EGFR kinase domain mutations by mol. analyses.  RESULTS: Eight of 16 patients (50% obsd. rate; 95% confidence interval, 25-75%) had tumor cells with second-site EGFR mutations.  Seven mutations were T790M and one was a novel D761Y mutation found in a brain metastasis.  When combined with a drug-sensitive L858R mutation, the D761Y mutation modestly reduced the sensitivity of mutant EGFR to TKIs in both surrogate kinase and cell viability assays.  In an autopsy case, the T790M mutation was found in multiple visceral metastases but not in a brain lesion.  CONCLUSIONS: The T790M mutation is common in patients with acquired resistance.  The limited spectrum of TKI-resistant mutations in EGFR, which binds to erlotinib in the active conformation, contrasts with a wider range of second-site mutations seen with acquired resistance to imatinib, which binds to ABL and KIT, resp., in closed conformations.  Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anat. site and mode of binding to the kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmeHDQldYeDLVg90H21EOLACvtfcHk0ljj3q4Bccc6jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI&md5=e817eb717673081d89ec3d58a04a7d4d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1570%26sid%3Dliteratum%253Aachs%26aulast%3DBalak%26aufirst%3DM.%2BN.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DChiang%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DOuerfelli%26aufirst%3DO.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNovel%2520D761Y%2520and%2520common%2520secondary%2520T790M%2520mutations%2520in%2520epidermal%2520growth%2520factor%2520receptor-mutant%2520lung%2520adenocarcinomas%2520with%2520acquired%2520resistance%2520to%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6494%26epage%3D6501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNitto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greig, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quenzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmett, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1542</span><span class="NLM_x">–</span> <span class="NLM_lpage">1547</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.+A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.+M.+Zhangauthor=G.+D.+Demetri&title=KIT+kinase+mutants+show+unique+mechanisms+of+drug+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0lhw1-T2hwtTWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKIT%2520kinase%2520mutants%2520show%2520unique%2520mechanisms%2520of%2520drug%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4342</span><span class="NLM_x">–</span> <span class="NLM_lpage">4349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1200%2FJCO.2003.04.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=14645423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=4342-4349&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=G.+D.+Demetriauthor=C.+D.+Blankeauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=L.+S.+McGreeveyauthor=C.+J.+Chenauthor=A.+D.+Van+den+Abbeeleauthor=B.+J.+Drukerauthor=B.+Kieseauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=S.+Singerauthor=C.+D.+Fletcherauthor=S.+Silbermanauthor=S.+Dimitrijevicauthor=J.+A.+Fletcher&title=Kinase+mutations+and+imatinib+response+in+patients+with+metastatic+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Demetri, George D.; Blanke, Charles D.; von Mehren, Margaret; Joensuu, Heikki; McGreevey, Laura S.; Chen, Chang-Jie; Van den Abbeele, Annick D.; Druker, Brian J.; Kiese, Beate; Eisenberg, Burton; Roberts, Peter J.; Singer, Samuel; Fletcher, Christopher D. M.; Silberman, Sandra; Dimitrijevic, Sasa; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4342-4349</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate.  The relationship between mutations in these kinases and clin. response to imatinib was examd. in a group of patients with advanced GIST.  Patients and Methods: GISTs from 127 patients enrolled onto a phase II clin. study of imatinib were examd. for mutations of KIT or PDGFRA.  Mutation types were correlated with clin. outcome.  Results: Activating mutations of KIT or PDGFRA were found in 112 (88.2%) and six (4.7%) GISTs, resp.  Most KIT mutations involved exon 9 (n = 23) or exon 11 (n = 85).  All KIT mutant isoforms, but only a subset of PDGFRA mutant isoforms, were sensitive to imatinib, in vitro.  In patients with GISTs harboring exon 11 KIT mutations, the partial response rate (PR) was 83.5%, whereas patients with tumors contg. an exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P = .0006) and 0.0% (P < .0001), resp.  Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation.  Conclusion: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clin. response to imatinib.  PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHal4hZZoc7Vg90H21EOLACvtfcHk0lhw1-T2hwtTWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D&md5=cbfd753460bdf0005c3bd93f12df98dc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.04.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.04.190%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DMcGreevey%26aufirst%3DL.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DKinase%2520mutations%2520and%2520imatinib%2520response%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D4342%26epage%3D4349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">906</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=897-906&author=E.+Jabbourauthor=J.+Cortesauthor=H.+Kantarjian&title=Long-term+outcomes+in+the+second-line+treatment+of+chronic+myeloid+leukemia%3A+a+review+of+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DLong-term%2520outcomes%2520in%2520the%2520second-line%2520treatment%2520of%2520chronic%2520myeloid%2520leukemia%253A%2520a%2520review%2520of%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DCancer%26date%3D2011%26volume%3D117%26spage%3D897%26epage%3D906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Mok, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunpaweravong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margono, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiwaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chewaskulyong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffield, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span> </span><span class="NLM_article-title">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">957</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1056%2FNEJMoa0810699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=19692680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=947-957&author=T.+S.+Mokauthor=Y.+L.+Wuauthor=S.+Thongprasertauthor=C.+H.+Yangauthor=D.+T.+Chuauthor=N.+Saijoauthor=P.+Sunpaweravongauthor=B.+Hanauthor=B.+Margonoauthor=Y.+Ichinoseauthor=Y.+Nishiwakiauthor=Y.+Oheauthor=J.+J.+Yangauthor=B.+Chewaskulyongauthor=H.+Jiangauthor=E.+L.+Duffieldauthor=C.+L.+Watkinsauthor=A.+A.+Armourauthor=M.+Fukuoka&title=Gefitinib+or+carboplatin-paclitaxel+in+pulmonary+adenocarcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span></div><div class="casAuthors">Mok, Tony S.; Wu, Yi-Long; Thongprasert, Sumitra; Yang, Chih-Hsin; Chu, Da-Tong; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.  METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calcd. to produce an area under the curve of 5 or 6 mg per mL per min) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients).  The primary end point was progression-free survival.  RESULTS: The 12-mo rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel.  The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin-paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P < 0.001).  In the subgroup of 261 patients who were pos. for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P < 0.001), whereas in the subgroup of 176 patients who were neg. for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P < 0.001).  The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group.  CONCLUSIONS: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia.  The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKhpFOiEQu7Vg90H21EOLACvtfcHk0lhw1-T2hwtTWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK&md5=31ce0983eedb9f248dcf0726adf18b88</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810699%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DChu%26aufirst%3DD.%2BT.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DSunpaweravong%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DMargono%26aufirst%3DB.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DArmour%26aufirst%3DA.%2BA.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520or%2520carboplatin-paclitaxel%2520in%2520pulmonary%2520adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D947%26epage%3D957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilhot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gathmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gattermann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabrilove, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousselot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiffers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelissen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoef, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gratwohl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letvak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R. A.</span><span> </span><span class="NLM_article-title">Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">2408</span><span class="NLM_x">–</span> <span class="NLM_lpage">2417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1056%2FNEJMoa062867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=17151364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12ntrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=2408-2417&author=B.+J.+Drukerauthor=F.+Guilhotauthor=S.+G.+O%E2%80%99Brienauthor=I.+Gathmannauthor=H.+Kantarjianauthor=N.+Gattermannauthor=M.+W.+Deiningerauthor=R.+T.+Silverauthor=J.+M.+Goldmanauthor=R.+M.+Stoneauthor=F.+Cervantesauthor=A.+Hochhausauthor=B.+L.+Powellauthor=J.+L.+Gabriloveauthor=P.+Rousselotauthor=J.+Reiffersauthor=J.+J.+Cornelissenauthor=T.+Hughesauthor=H.+Agisauthor=T.+Fischerauthor=G.+Verhoefauthor=J.+Shepherdauthor=G.+Saglioauthor=A.+Gratwohlauthor=J.+L.+Nielsenauthor=J.+P.+Radichauthor=B.+Simonssonauthor=K.+Taylorauthor=M.+Baccaraniauthor=C.+Soauthor=L.+Letvakauthor=R.+A.+Larson&title=Five-year+follow-up+of+patients+receiving+imatinib+for+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</span></div><div class="casAuthors">Druker, Brian J.; Guilhot, Francois; O'Brien, Stephen G.; Gathmann, Insa; Kantarjian, Hagop; Gattermann, Norbert; Deininger, Michael W. N.; Silver, Richard T.; Goldman, John M.; Stone, Richard M.; Cervantes, Francisco; Hochhaus, Andreas; Powell, Bayard L.; Gabrilove, Janice L.; Rousselot, Philippe; Reiffers, Josy; Cornelissen, Jan J.; Hughes, Timothy; Agis, Hermine; Fischer, Thomas; Verhoef, Gregor; Shepherd, John; Saglio, Giuseppe; Gratwohl, Alois; Nielsen, Johan L.; Radich, Jerald P.; Simonsson, Bengt; Taylor, Kerry; Baccarani, Michele; So, Charlene; Letvak, Laurie; Larson, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2408-2417</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase.  Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase.  For 5 years, we followed patients with CML who received imatinib as initial therapy.  METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematol., cytogenetic, and mol. responses; and adverse events.  RESULTS: The median follow-up was 60 mo.  Kaplan-Meier ests. of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 mo and 87% by 60 mo.  An estd. 7% of patients progressed to accelerated-phase CML or blast crisis, and the estd. overall survival of patients who received imatinib as initial therapy was 89% at 60 mo.  Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P < 0.001).  Grade 3 or 4 adverse events diminished over time, and there was no clin. significant change in the profile of adverse events.  CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUgIGWKzVtbrVg90H21EOLACvtfcHk0liGvXd2CB4HBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12ntrzM&md5=7e57245d3a918c079722ce0dcd265f15</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa062867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa062867%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DGuilhot%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DGathmann%26aufirst%3DI.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DGattermann%26aufirst%3DN.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DSilver%26aufirst%3DR.%2BT.%26aulast%3DGoldman%26aufirst%3DJ.%2BM.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DB.%2BL.%26aulast%3DGabrilove%26aufirst%3DJ.%2BL.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DReiffers%26aufirst%3DJ.%26aulast%3DCornelissen%26aufirst%3DJ.%2BJ.%26aulast%3DHughes%26aufirst%3DT.%26aulast%3DAgis%26aufirst%3DH.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DVerhoef%26aufirst%3DG.%26aulast%3DShepherd%26aufirst%3DJ.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DGratwohl%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DJ.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26aulast%3DSimonsson%26aufirst%3DB.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DSo%26aufirst%3DC.%26aulast%3DLetvak%26aufirst%3DL.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26atitle%3DFive-year%2520follow-up%2520of%2520patients%2520receiving%2520imatinib%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D2408%26epage%3D2417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+kinase+domain+mutations+confer+polyclonal+resistance+to+the+tyrosine+kinase+inhibitor+imatinib+%28STI571%29+in+chronic+phase+and+blast+crisis+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0liGvXd2CB4HBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520confer%2520polyclonal%2520resistance%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520%2528STI571%2529%2520in%2520chronic%2520phase%2520and%2520blast%2520crisis%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26spage%3D117%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Griswold, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacPartlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumm, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moseson, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakiewicz, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">6082</span><span class="NLM_x">–</span> <span class="NLM_lpage">6093</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1128%2FMCB.02202-05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=16880519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1ylt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=6082-6093&author=I.+J.+Griswoldauthor=M.+MacPartlinauthor=T.+Bummauthor=V.+L.+Gossauthor=T.+O%E2%80%99Hareauthor=K.+A.+Leeauthor=A.+S.+Corbinauthor=E.+P.+Stoffregenauthor=C.+Smithauthor=K.+Johnsonauthor=E.+M.+Mosesonauthor=L.+J.+Woodauthor=R.+D.+Polakiewiczauthor=B.+J.+Drukerauthor=M.+W.+Deininger&title=Kinase+domain+mutants+of+Bcr-Abl+exhibit+altered+transformation+potency%2C+kinase+activity%2C+and+substrate+utilization%2C+irrespective+of+sensitivity+to+imatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib</span></div><div class="casAuthors">Griswold, Ian J.; MacPartlin, Mary; Bumm, Thomas; Goss, Valerie L.; O'Hare, Thomas; Lee, Kimberly A.; Corbin, Amie S.; Stoffregen, Eric P.; Smith, Caitlyn; Johnson, Kara; Moseson, Erika M.; Wood, Lisa J.; Polakiewicz, Roberto D.; Druker, Brian J.; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6082-6093</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Kinase domain (KD) mutations of Bcr-Abl interfering with imatinib binding are the major mechanism of acquired imatinib resistance in patients with Philadelphia chromosome-pos. leukemia.  Mutations of the ATP binding loop (p-loop) have been assocd. with a poor prognosis.  We compared the transformation potency of five common KD mutants in various biol. assays.  Relative to unmutated (native) Bcr-Abl, the ATP binding loop mutants Y253F and E255K exhibited increased transformation potency, M351T and H396P were less potent, and the performance of T315I was assay dependent.  The transformation potency of Y253F and M351T correlated with intrinsic Bcr-Abl kinase activity, whereas the kinase activity of E255K, H396P, and T315I did not correlate with transforming capabilities, suggesting that addnl. factors influence transformation potency.  Anal. of the phosphotyrosine proteome by mass spectroscopy showed differential phosphorylation among the mutants, a finding consistent with altered substrate specificity and pathway activation.  Mutations in the KD of Bcr-Abl influence kinase activity and signaling in a complex fashion, leading to gain- or loss-of-function variants.  The drug resistance and transformation potency of mutants may det. the outcome of patients on therapy with Abl kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQiqF9VlZX2rVg90H21EOLACvtfcHk0lg50qXItuPJYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1ylt7w%253D&md5=562962addb97080148b210dcf7e12266</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FMCB.02202-05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.02202-05%26sid%3Dliteratum%253Aachs%26aulast%3DGriswold%26aufirst%3DI.%2BJ.%26aulast%3DMacPartlin%26aufirst%3DM.%26aulast%3DBumm%26aufirst%3DT.%26aulast%3DGoss%26aufirst%3DV.%2BL.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DK.%2BA.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DMoseson%26aufirst%3DE.%2BM.%26aulast%3DWood%26aufirst%3DL.%2BJ.%26aulast%3DPolakiewicz%26aufirst%3DR.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DKinase%2520domain%2520mutants%2520of%2520Bcr-Abl%2520exhibit%2520altered%2520transformation%2520potency%252C%2520kinase%2520activity%252C%2520and%2520substrate%2520utilization%252C%2520irrespective%2520of%2520sensitivity%2520to%2520imatinib%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2006%26volume%3D26%26spage%3D6082%26epage%3D6093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7389</span><span class="NLM_x">–</span> <span class="NLM_lpage">7395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=7389-7395&author=N.+P.+Shahauthor=C.+L.+Sawyers&title=Mechanisms+of+resistance+to+STI571+in+Philadelphia+chromosome-associated+leukemias"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520STI571%2520in%2520Philadelphia%2520chromosome-associated%2520leukemias%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D7389%26epage%3D7395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Willis, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demehri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crossman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederwieser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McWeeney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacs, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">2128</span><span class="NLM_x">–</span> <span class="NLM_lpage">2137</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=2128-2137&author=S.+G.+Willisauthor=T.+Langeauthor=S.+Demehriauthor=S.+Ottoauthor=L.+Crossmanauthor=D.+Niederwieserauthor=E.+P.+Stoffregenauthor=S.+McWeeneyauthor=I.+Kovacsauthor=B.+Parkauthor=B.+J.+Drukerauthor=M.+W.+Deininger&title=High-sensitivity+detection+of+BCR-ABL+kinase+domain+mutations+in+imatinib-naive+patients%3A+correlation+with+clonal+cytogenetic+evolution+but+not+response+to+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWillis%26aufirst%3DS.%2BG.%26aulast%3DLange%26aufirst%3DT.%26aulast%3DDemehri%26aufirst%3DS.%26aulast%3DOtto%26aufirst%3DS.%26aulast%3DCrossman%26aufirst%3DL.%26aulast%3DNiederwieser%26aufirst%3DD.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DMcWeeney%26aufirst%3DS.%26aulast%3DKovacs%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DB.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DHigh-sensitivity%2520detection%2520of%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520in%2520imatinib-naive%2520patients%253A%2520correlation%2520with%2520clonal%2520cytogenetic%2520evolution%2520but%2520not%2520response%2520to%2520therapy%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D2128%26epage%3D2137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kluterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.+H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+Inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0liKofPr-oKn2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520Inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3417</span><span class="NLM_x">–</span> <span class="NLM_lpage">3420</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1200%2FJCO.2012.43.1825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=22915655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3417-3420&author=J.+M.+Heuckmannauthor=D.+Rauhauthor=R.+K.+Thomas&title=Epidermal+growth+factor+receptor+%28EGFR%29+signaling+and+covalent+EGFR+inhibition+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor (EGFR) signaling and covalent EGF inhibition in lung cancer</span></div><div class="casAuthors">Heuckmann, Johannes M.; Rauh, Daniel; Thomas, Roman K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3417-3420</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The research of Ramalingam et al. (2012) entitled, 'Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, vs. erlotinib in patients with advanced non-small-cell lung cancer' is reviewed with commentary and refs.  In their paper, a novel irreversible ERBB family inhibitor, dacomitinib, improved progression-free survival compared with erlotinib in unselected patients with non-small-cell lung cancer without prior epidermal growth factor receptor-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8PW4hGdL2k7Vg90H21EOLACvtfcHk0liajGoUdTK24A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt73O&md5=45192d5ee846d2c25302286226cff733</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.1825%26sid%3Dliteratum%253Aachs%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520signaling%2520and%2520covalent%2520EGFR%2520inhibition%2520in%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3417%26epage%3D3420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wang, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynoso, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J. C.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S15</span><span class="NLM_x">–</span> <span class="NLM_lpage">S24</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2010&pages=S15-S24&issue=Suppl+1&author=W.+L.+Wangauthor=A.+Conleyauthor=D.+Reynosoauthor=L.+Noldenauthor=A.+J.+Lazarauthor=S.+Georgeauthor=J.+C.+Trent&title=Mechanisms+of+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DConley%26aufirst%3DA.%26aulast%3DReynoso%26aufirst%3DD.%26aulast%3DNolden%26aufirst%3DL.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DTrent%26aufirst%3DJ.%2BC.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2010%26volume%3D67%26issue%3DSuppl%25201%26spage%3DS15%26epage%3DS24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">The GIST paradigm: Lessons for other kinase-driven cancers</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1002%2Fpath.2798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=21125679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2011&pages=251-261&author=C.+R.+Antonescu&title=The+GIST+paradigm%3A+Lessons+for+other+kinase-driven+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The GIST paradigm: lessons for other kinase-driven cancers</span></div><div class="casAuthors">Antonescu, Cristina R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-261</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract, known to be notoriously refractory to conventional chemotherapy or radiation.  It is an ideal solid tumor model to apply our understanding from aberrant signal transduction to drug development, since nearly all tumors have a mutation in the KIT or, less often, the PDGFRA or BRAF genes.  The constitutively activated KIT and PDGFRA oncoproteins serve as crucial diagnostic and therapeutic targets.  The discovery of oncogenic KIT activation as a central mechanism of GIST pathogenesis suggested that inhibiting or blocking KIT signalling might be the milestone in the targeted therapy of GISTs.  Indeed, imatinib mesylate inhibits KIT kinase activity and represents the front-line drug for the treatment of unresectable and advanced GISTs, achieving a partial response or stable disease in about 80% of patients with metastatic GIST.  KIT mutation status has a significant impact on treatment response, emerging in recent years as a leading paradigm for genotype-driven targeted therapy.  In this review, parallels with other models in oncol. that share their addiction to a particular mutationally activated kinase are contrasted.  A better understanding of oncogene addiction as a common theme across tumors of diverse histologies underlies the clin. success of targeting such kinases with several selective kinase inhibitors.  Also remarkable is the similarity displayed in the mechanisms of drug failure after a successful but temporary clin. response to kinase inhibition.  Reactivation of the same oncogenic kinase, often by acquisition of second site mutations, is another emerging paradigm of secondary resistance in these tumor models.  The complexity of polyclonal resistance in imatinib-resistant patients argues that single next-generation kinase inhibitors will not be beneficial in all mutant clones.  Other broad therapeutic strategies could include combination of kinase inhibitors with targeting KIT downstream targets, such as PI3-K or MAPK/MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWlgzEuChm77Vg90H21EOLACvtfcHk0liajGoUdTK24A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlegsg%253D%253D&md5=e3da6e34c32b8905867ef97a9cac885b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fpath.2798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2798%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DThe%2520GIST%2520paradigm%253A%2520Lessons%2520for%2520other%2520kinase-driven%2520cancers%26jtitle%3DJ.%2520Pathol.%26date%3D2011%26volume%3D223%26spage%3D251%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Gibbons, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pricl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span> </span><span class="NLM_article-title">The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=293-299&author=D.+L.+Gibbonsauthor=S.+Priclauthor=H.+Kantarjianauthor=J.+Cortesauthor=A.+Quintas-Cardama&title=The+rise+and+fall+of+gatekeeper+mutations%3F+The+BCR-ABL1+T315I+paradigm"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26atitle%3DThe%2520rise%2520and%2520fall%2520of%2520gatekeeper%2520mutations%253F%2520The%2520BCR-ABL1%2520T315I%2520paradigm%26jtitle%3DCancer%26date%3D2011%26volume%3D118%26spage%3D293%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mac Partlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petillo, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">3189</span><span class="NLM_x">–</span> <span class="NLM_lpage">3195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3189-3195&author=C.+A.+Eideauthor=L.+T.+Adrianauthor=J.+W.+Tynerauthor=M.+Mac+Partlinauthor=D.+J.+Andersonauthor=S.+C.+Wiseauthor=B.+D.+Smithauthor=P.+A.+Petilloauthor=D.+L.+Flynnauthor=M.+W.+Deiningerauthor=T.+O%E2%80%99Hareauthor=B.+J.+Druker&title=The+ABL+switch+control+inhibitor+DCC-2036+is+active+against+the+chronic+myeloid+leukemia+mutant+BCR-ABLT315I+and+exhibits+a+narrow+resistance+profile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DMac%2BPartlin%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DPetillo%26aufirst%3DP.%2BA.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520ABL%2520switch%2520control%2520inhibitor%2520DCC-2036%2520is%2520active%2520against%2520the%2520chronic%2520myeloid%2520leukemia%2520mutant%2520BCR-ABLT315I%2520and%2520exhibits%2520a%2520narrow%2520resistance%2520profile%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3189%26epage%3D3195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">U.S. National Library of Medicine</span><span class="NLM_x">. </span><a href="http://www.clinicaltrials.gov/" class="extLink">http://www.clinicaltrials.gov/</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+National+Library+of+Medicine.+http%3A%2F%2Fwww.clinicaltrials.gov%2F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">U.S. Food and Drug Administration</span><span class="NLM_x">. </span><a href="http://www.fda.gov/" class="extLink">http://www.fda.gov/</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+Food+and+Drug+Administration.+http%3A%2F%2Fwww.fda.gov%2F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Fang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb300663j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCls7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=58-70&author=Z.+Fangauthor=C.+Gr%C3%BCtterauthor=D.+Rauh&title=Strategies+for+the+selective+regulation+of+kinases+with+allosteric+modulators%3A+exploiting+exclusive+structural+features"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features</span></div><div class="casAuthors">Fang, Zhizhou; Gruetter, Christian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-70</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The modulation of kinase function has become an important goal in modern drug discovery and chem. biol. research.  In cancer-targeted therapies, kinase inhibitors have been experiencing an upsurge, which can be measured by the increasing no. of kinase inhibitors approved by the FDA in recent years.  However, lack of efficacy, limited selectivity, and the emergence of acquired drug resistance still represent major bottlenecks in the clinic and challenge inhibitor development.  Most known kinase inhibitors target the active kinase and are ATP competitive.  A second class of small org. mols., which address remote sites of the kinase and stabilize enzymically inactive conformations, is rapidly moving to the forefront of kinase inhibitor research.  Such allosteric modulators bind to sites that are less conserved across the kinome and only accessible upon conformational changes.  These mols. are therefore thought to provide various advantages such as higher selectivity and extended drug target residence times.  This review highlights various strategies that have been developed to utilizing exclusive structural features of kinases and thereby modulating their activity allosterically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSjxxztmczXrVg90H21EOLACvtfcHk0litMxX0dq2QeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCls7bN&md5=50864096bf66229ff74482a9b56847d6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcb300663j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300663j%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStrategies%2520for%2520the%2520selective%2520regulation%2520of%2520kinases%2520with%2520allosteric%2520modulators%253A%2520exploiting%2520exclusive%2520structural%2520features%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D58%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinase. Part II: The novel pharmacophore approach of type II and type III inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1427-1449&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinase.+Part+II%3A+The+novel+pharmacophore+approach+of+type+II+and+type+III+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinase.%2520Part%2520II%253A%2520The%2520novel%2520pharmacophore%2520approach%2520of%2520type%2520II%2520and%2520type%2520III%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1427%26epage%3D1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=709-723&author=P.+A.+Janneauthor=N.+Grayauthor=J.+Settleman&title=Factors+underlying+sensitivity+of+cancers+to+small-molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DFactors%2520underlying%2520sensitivity%2520of%2520cancers%2520to%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D709%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0litMxX0dq2QeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robubi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3915</span><span class="NLM_x">–</span> <span class="NLM_lpage">3926</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9002928" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3915-3926&author=M.+Getlikauthor=C.+Gr%C3%BCtterauthor=J.+R.+Simardauthor=S.+Kl%C3%BCterauthor=M.+Rabillerauthor=H.+B.+Rodeauthor=A.+Robubiauthor=D.+Rauh&title=Hybrid+compound+design+to+overcome+the+gatekeeper+T338M+mutation+in+cSrc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc</span></div><div class="casAuthors">Getlik, Matthaeus; Gruetter, Christian; Simard, Jeffrey R.; Kluter, Sabine; Rabiller, Matthias; Rode, Haridas B.; Robubi, Armin; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3915-3926</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistance remains a fundamental challenge in the development of kinase inhibitors that are effective over long-term treatments.  Allosteric inhibitors that bind to sites lying outside the highly conserved ATP pocket are thought to be more selective than ATP-competitive inhibitors and may circumvent some mechanisms of drug resistance.  Crystal structures of type I and allosteric type III inhibitors in complex with the tyrosine kinase cSrc allowed to develop these scaffolds into potent type II kinase inhibitors.  One of these compds., I (RL46), disrupts FAK-mediated focal adhesions in cancer cells via direct inhibition of cSrc.  Details gleaned from crystal structures revealed a key feature of a subset of these compds., a surprising flexibility in the vicinity of the gatekeeper residue that allows these compds. to overcome a dasatinib-resistant gatekeeper mutation emerging in cSrc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-72ZDo25pC7Vg90H21EOLACvtfcHk0ljqrMGDU0tlGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D&md5=3ff187e49298ec4690c76a2bc2100274</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm9002928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9002928%26sid%3Dliteratum%253Aachs%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DRobubi%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHybrid%2520compound%2520design%2520to%2520overcome%2520the%2520gatekeeper%2520T338M%2520mutation%2520in%2520cSrc%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3915%26epage%3D3926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Hunter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, J. M.</span><span> </span><span class="NLM_article-title">Pi-pi interactions: The geometry and energetics of phenylalanine-phenylalanine interactions in proteins</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">218</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=1991&pages=837-846&author=C.+A.+Hunterauthor=J.+Singhauthor=J.+M.+Thornton&title=Pi-pi+interactions%3A+The+geometry+and+energetics+of+phenylalanine-phenylalanine+interactions+in+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DC.%2BA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DThornton%26aufirst%3DJ.%2BM.%26atitle%3DPi-pi%2520interactions%253A%2520The%2520geometry%2520and%2520energetics%2520of%2520phenylalanine-phenylalanine%2520interactions%2520in%2520proteins%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1991%26volume%3D218%26spage%3D837%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: A multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fnrd2130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=17016424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+A+multikinase+inhibitor+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span></div><div class="casAuthors">Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways.  The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process.  Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature.  The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compd. to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WjjfgNSCtbVg90H21EOLACvtfcHk0ljqrMGDU0tlGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM&md5=490d4995170f3a7270ae9bbdd24b12e5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnrd2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2130%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520A%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D835%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28IRESSA%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0ljqrMGDU0tlGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528IRESSA%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fnm0596-561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=8616716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&author=B.+J.+Drukerauthor=S.+Tamuraauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=S.+Fanningauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span></div><div class="casAuthors">Druker, Brian J.; Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Shane; Zimmermann, Jurg; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">The Bcr-Abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease.  A compd., designed to inhibit the Abl protein tyrosine kinase (CGP 57148), was evaluated for its effects on cells contg. the Bcr-Abl fusion protein.  Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compd.  In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the no. of Bcr-Abl colonies formed but no inhibition of normal colony formation.  This compd. may be useful in the treatment of Bcr-Abl-pos. leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzXj-25AHOrVg90H21EOLACvtfcHk0liTHyr5sICqWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D&md5=1dc111cc883a1ed29964ae2c88c88cb9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnm0596-561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0596-561%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Nakatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, K.</span><span> </span><span class="NLM_article-title">STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1111%2Fj.1349-7006.2005.00018.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15723656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislOhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2005&pages=116-119&author=H.+Nakataniauthor=M.+Kobayashiauthor=T.+Jinauthor=T.+Taguchiauthor=T.+Sugimotoauthor=T.+Nakanoauthor=S.+Hamadaauthor=K.+Araki&title=STI571+%28Glivec%29+inhibits+the+interaction+between+c-KIT+and+heat+shock+protein+90+of+the+gastrointestinal+stromal+tumor+cell+line%2C+GIST-T1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1</span></div><div class="casAuthors">Nakatani, Hajime; Kobayashi, Michiya; Jin, Toufeng; Taguchi, Takahiro; Sugimoto, Takeki; Nakano, Takumi; Hamada, Shinichi; Araki, Keijiro</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-119</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">The gastrointestinal stromal tumor cell line, GIST-T1, has a heterogenic 57-base pair deletion in exon 11 of the c-kit mutation, and the c-KIT protein in the GIST-T1 cells constitutively activated.  The authors report that STI571 (Glivec; Novartis, Basel, Switzerland), a specific inhibitor of c-KIT, inhibits the clustering of c-KIT at the cell membrane of the GIST-T1 cells.  Furthermore, STI571 prevents the interaction between c-KIT and the mol. chaperone, heat shock protein 90 (Hsp90).  Geldanamycin, an inhibitor of Hsp90, also prevents interaction between c-KIT and Hsp90, and inhibits tyrosine phosphorylation of c-KIT.  The authors' results indicate that c-KIT mols. are assembled on the cell surface of the GIST-T1 cells, and that the interaction between c-KIT and Hsp90 plays an important role in c-KIT activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmR6opUwpxpLVg90H21EOLACvtfcHk0liTHyr5sICqWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislOhs7k%253D&md5=fb144a5c9de51a78e2a1d3d39940deff</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2005.00018.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2005.00018.x%26sid%3Dliteratum%253Aachs%26aulast%3DNakatani%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DT.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DT.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DHamada%26aufirst%3DS.%26aulast%3DAraki%26aufirst%3DK.%26atitle%3DSTI571%2520%2528Glivec%2529%2520inhibits%2520the%2520interaction%2520between%2520c-KIT%2520and%2520heat%2520shock%2520protein%252090%2520of%2520the%2520gastrointestinal%2520stromal%2520tumor%2520cell%2520line%252C%2520GIST-T1%26jtitle%3DCancer%2520Sci.%26date%3D2005%26volume%3D96%26spage%3D116%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span> </span><span class="NLM_article-title">Conformational adaptation in drug-target interactions and residence time</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1491</span><span class="NLM_x">–</span> <span class="NLM_lpage">1501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.4155%2Ffmc.11.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=21882942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSksLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1491-1501&author=R.+A.+Copeland&title=Conformational+adaptation+in+drug-target+interactions+and+residence+time"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational adaptation in drug-target interactions and residence time</span></div><div class="casAuthors">Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1491-1501</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Although drug-target interactions are commonly illustrated in terms of structurally static binding and dissocn. events, such descriptions are inadequate to explain the impact of conformational dynamics on these processes.  For high-affinity interactions, both the assocn. and dissocn. of drug mols. to and from their targets are often controlled by conformational changes of the target.  Conformational adaptation can greatly influence the residence time of a drug on its target (i.e., the lifetime of the binary drug-target complex); long residence time can lead to sustained pharmacol. and may also mitigate off-target toxicity.  In this perspective, the kinetics of drug-target assocn. and dissocn. reactions are explored, with particular emphasis on the impact of conformational adaptation on drug-target residence time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Bp8rlLqFa7Vg90H21EOLACvtfcHk0ljLSLlgHH5h5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSksLfO&md5=f995e1a9d854831af67a5d96eb14cac4</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.112%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DConformational%2520adaptation%2520in%2520drug-target%2520interactions%2520and%2520residence%2520time%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1491%26epage%3D1501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Klebe, G.</span> <span class="citation_source-book">Wirkstoffdesign: Entwurf und Wirkung von Arzneistoffen</span>. <span class="NLM_edition">2</span>nd ed.; <span class="NLM_publisher-name">Spektrum Akademischer Verlag</span>: <span class="NLM_publisher-loc">Heidelberg, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Klebe&title=Wirkstoffdesign%3A+Entwurf+und+Wirkung+von+Arzneistoffen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKlebe%26aufirst%3DG.%26btitle%3DWirkstoffdesign%253A%2520Entwurf%2520und%2520Wirkung%2520von%2520Arzneistoffen%26pub%3DSpektrum%2520Akademischer%2520Verlag%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+pan-BCR-ABL+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+T315I+mutant+and+overcomes+mutation-based+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520pan-BCR-ABL%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520T315I%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D401%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Lozzio, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozzio, B. B.</span><span> </span><span class="NLM_article-title">Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1182%2Fblood.V45.3.321.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=163658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A280%3ADyaE2M7gvFyjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1975&pages=321-334&author=C.+B.+Lozzioauthor=B.+B.+Lozzio&title=Human+chronic+myelogenous+leukemia+cell-line+with+positive+Philadelphia+chromosome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome</span></div><div class="casAuthors">Lozzio C B; Lozzio B B</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">321-34</span>
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    </div><div class="casAbstract">A cell-line derived from a patient with chronic myelogenous leukemia (CML) is described.  The new cell-line, which has over 175 serial passanges in a 3 1/2-yr period, has the following characteristics: (1) CML cells started to proliferate actively since they were first incubated in culture media.  A threefold increase in the total number of cells was observed during the first seven passages; the cell population increased by a factor of 10 to 20 every 7 days from passage 8 through 85; from 20 to 40 times from passage 86 through 150, and more than 40 times after 150 passages. (2) The majority of the nononucleated cells are undifferentiated blasts. (3) The karyotype of all the cells examined show the Philadelphia (Ph1) chromosome and a long acrocentric marker plus aneuploidy.  The Giemsa-banding studies identified the Ph1 chromosome as a terminal deletion of the long arm of chromosome 22:del(22)(q12) and the long acrocentric marker as an unbalanced reciprocal translocation of one chromosome 17 and the long arm of one chromosome 15. (4) The CML cells do not produce immunoglobulins, are free of mycoplasma, Epstein-Barr virus, and herpes-like virus particles. (5) CML cells have no alkaline phosphatase and myeloperoxidase activities and did not engulf inert particles. (6) Cultured CML cells provide a constant source of a specific antigen.  This CML cell-line represents a unique source of CML cells with meaningful indicators of malignancy for clinical and experimental studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSn4RF_5flkqEg6wdEZmT2rfW6udTcc2eYfA1gdjaXnzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2M7gvFyjug%253D%253D&md5=d396e38802cebb103ab1c7b9adbe35af</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1182%2Fblood.V45.3.321.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V45.3.321.321%26sid%3Dliteratum%253Aachs%26aulast%3DLozzio%26aufirst%3DC.%2BB.%26aulast%3DLozzio%26aufirst%3DB.%2BB.%26atitle%3DHuman%2520chronic%2520myelogenous%2520leukemia%2520cell-line%2520with%2520positive%2520Philadelphia%2520chromosome%26jtitle%3DBlood%26date%3D1975%26volume%3D45%26spage%3D321%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Schneider, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janning, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">direct binding assay for the detection of type IV allosteric inhibitors of Abl</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">9138</span><span class="NLM_x">–</span> <span class="NLM_lpage">9141</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja303858w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1Wrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=9138-9141&author=R.+Schneiderauthor=C.+Beckerauthor=J.+R.+Simardauthor=M.+Getlikauthor=N.+Bohlkeauthor=P.+Janningauthor=D.+Rauh&title=direct+binding+assay+for+the+detection+of+type+IV+allosteric+inhibitors+of+Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Direct Binding Assay for the Detection of Type IV Allosteric Inhibitors of Abl</span></div><div class="casAuthors">Schneider, Ralf; Becker, Christian; Simard, Jeffrey R.; Getlik, Matthaeus; Bohlke, Nina; Janning, Petra; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9138-9141</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abelson (Abl) tyrosine kinase is an important cellular enzyme that is rendered constitutively active in the breakpoint cluster region (BCR)-Abl fusion protein, contributing to several forms of leukemia.  Although inhibiting BCR-Abl activity with imatinib shows great clin. success, many patients acquire secondary mutations that result in resistance to imatinib.  Second-generation inhibitors such as dasatinib and nilotinib can overcome the majority of these mutations but fail to treat patients with an esp. prevalent T315I mutation at the gatekeeper position of the kinase domain.  However, a combination of nilotinib with an allosteric type IV inhibitor was recently shown to overcome this clin. relevant point mutation.  In this study, we present the development of a direct binding assay that enables the straightforward detection of allosteric inhibitors which bind within the myristate pocket of Abl.  The assay is amenable to high-throughput screening and exclusively detects the binding of ligands to this unique allosteric site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHtVe0LFdqurVg90H21EOLACvtfcHk0lidWA_ckLmiPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1Wrt74%253D&md5=95aa204ff4d761f2a2155112abe35799</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fja303858w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja303858w%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DBohlke%26aufirst%3DN.%26aulast%3DJanning%26aufirst%3DP.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3Ddirect%2520binding%2520assay%2520for%2520the%2520detection%2520of%2520type%2520IV%2520allosteric%2520inhibitors%2520of%2520Abl%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D9138%26epage%3D9141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Kabsch, W.</span><span> </span><span class="NLM_article-title">Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1107%2FS0021889893005588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADyaK2cXptFeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=795-800&author=W.+Kabsch&title=Automatic+processing+of+rotation+diffraction+data+from+crystals+of+initially+unknown+symmetry+and+cell+constants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">795-800</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    </div><div class="casAbstract">An algorithm was developed for the automatic interpretation of a given set of obsd. reciprocal-lattice points.  It exts. a reduced cell and assigns indexes to each reflection by a graph-theor. implementation of the local indexing method.  All possible symmetries of the obsd. lattice compatible with the metric of the reduced cell are recognized and reported, together with the unit-cell consts. and the linear index transformation relating the conventional to the reduced cell.  This algorithm was incorporated into the program XDS (K., 1988), which is now able to process single-crystal area-detector data without prior knowledge of the symmetry and the unit-cell consts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD1lV8_7cDv7Vg90H21EOLACvtfcHk0lidWA_ckLmiPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXptFeltw%253D%253D&md5=2b703225206ce99af0d7e38acf6d75b3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0021889893005588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889893005588%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DAutomatic%2520processing%2520of%2520rotation%2520diffraction%2520data%2520from%2520crystals%2520of%2520initially%2520unknown%2520symmetry%2520and%2520cell%2520constants%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1993%26volume%3D26%26spage%3D795%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Pushing the boundaries of molecular replacement with maximum likelihood</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1373</span><span class="NLM_x">–</span> <span class="NLM_lpage">1382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1107%2FS0907444901012471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=11567148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmvFGltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2001&pages=1373-1382&author=R.+J.+Read&title=Pushing+the+boundaries+of+molecular+replacement+with+maximum+likelihood"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Pushing the boundaries of molecular replacement with maximum likelihood</span></div><div class="casAuthors">Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">D57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1373-1382</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">The mol.-replacement method works well with good models and simple unit cells, but often fails with more difficult problems.  Experience with likelihood in other areas of crystallog. suggests that it would improve performance significantly.  For mol. replacement, the form of the required likelihood function depends on whether there is ambiguity in the relative phases of the contributions from symmetry-related mols. (e.g. rotation vs. translation searches).  Likelihood functions used in structure refinement are appropriate only for translation (or six-dimensional) searches, where the correct translation will place all of the atoms in the model approx. correctly.  A new likelihood function that allows for unknown relative phases is suitable for rotation searches.  It is shown that correlations between sequence identity and coordinate error can be used to calibrate parameters for model quality in the likelihood functions.  Multiple models of a mol. can be combined in a statistically valid way by setting up the joint probability distribution of the true and model structure factors as a multivariate complex normal distribution, from which the conditional distribution of the true structure factor given the models can be derived.  Tests in a new mol.-replacement program, Beast, show that the likelihood-based targets are more sensitive and more accurate than previous targets.  The new multiple-model likelihood function has a dramatic impact on success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo23lasNP9RyLVg90H21EOLACvtfcHk0lidWA_ckLmiPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmvFGltrc%253D&md5=b342c58edd40265324e0241ff75cec67</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444901012471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444901012471%26sid%3Dliteratum%253Aachs%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPushing%2520the%2520boundaries%2520of%2520molecular%2520replacement%2520with%2520maximum%2520likelihood%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2001%26volume%3D57%26spage%3D1373%26epage%3D1382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1016%2Fj.str.2007.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=17355866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=299-311&author=M.+A.+Seeligerauthor=B.+Nagarauthor=F.+Frankauthor=X.+Caoauthor=M.+N.+Hendersonauthor=J.+Kuriyan&title=c-Src+binds+to+the+cancer+drug+imatinib+with+an+inactive+Abl%2Fc-Kit+conformation+and+a+distributed+thermodynamic+penalty"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty</span></div><div class="casAuthors">Seeliger, Markus A.; Nagar, Bhushan; Frank, Filipp; Cao, Xiaoxian; Henderson, M. Nidanie; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-311</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor.  Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src.  The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Abl•imatinib and c-Kit•imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases.  Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodn. penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure.  Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2SQGjjXdg1LVg90H21EOLACvtfcHk0lidWA_ckLmiPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D&md5=ddfbcf06d91b408ca5fb25af9774c334</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2007.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2007.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DFrank%26aufirst%3DF.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DHenderson%26aufirst%3DM.%2BN.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3Dc-Src%2520binds%2520to%2520the%2520cancer%2520drug%2520imatinib%2520with%2520an%2520inactive%2520Abl%252Fc-Kit%2520conformation%2520and%2520a%2520distributed%2520thermodynamic%2520penalty%26jtitle%3DStructure%26date%3D2007%26volume%3D15%26spage%3D299%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: Model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+Model-building+tools+for+molecular+graphics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lg4FXF3pNkApQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520Model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Brünger, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clore, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLano, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gros, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuszewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilges, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannu, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, G. L.</span><span> </span><span class="NLM_article-title">Crystallography & NMR system: A new software suite for macromolecular structure determination</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=905-921&author=A.+T.+Br%C3%BCngerauthor=P.+D.+Adamsauthor=G.+M.+Cloreauthor=W.+L.+DeLanoauthor=P.+Grosauthor=R.+W.+Grosse-Kunstleveauthor=J.+S.+Jiangauthor=J.+Kuszewskiauthor=M.+Nilgesauthor=N.+S.+Pannuauthor=R.+J.+Readauthor=L.+M.+Riceauthor=T.+Simonsonauthor=G.+L.+Warren&title=Crystallography+%26+NMR+system%3A+A+new+software+suite+for+macromolecular+structure+determination"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBr%25C3%25BCnger%26aufirst%3DA.%2BT.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DClore%26aufirst%3DG.%2BM.%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26aulast%3DGros%26aufirst%3DP.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DJiang%26aufirst%3DJ.%2BS.%26aulast%3DKuszewski%26aufirst%3DJ.%26aulast%3DNilges%26aufirst%3DM.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26aulast%3DSimonson%26aufirst%3DT.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26atitle%3DCrystallography%2520%2526%2520NMR%2520system%253A%2520A%2520new%2520software%2520suite%2520for%2520macromolecular%2520structure%2520determination%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1998%26volume%3D54%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lg4FXF3pNkApQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Schüttelkopf, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Aalten, D. M.</span><span> </span><span class="NLM_article-title">PRODRG: A tool for high-throughput crystallography of protein-ligand complexes</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1363</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=1355-1363&author=A.+W.+Sch%C3%BCttelkopfauthor=D.+M.+van+Aalten&title=PRODRG%3A+A+tool+for+high-throughput+crystallography+of+protein-ligand+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCttelkopf%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%26atitle%3DPRODRG%253A%2520A%2520tool%2520for%2520high-throughput%2520crystallography%2520of%2520protein-ligand%2520complexes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D1355%26epage%3D1363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Laskowski, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacArthur, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, J. M.</span><span> </span><span class="NLM_article-title">PROCHECK: A program to check the stereochemical quality of protein structures</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1107%2FS0021889892009944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADyaK3sXit12lurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=283-291&author=R.+A.+Laskowskiauthor=M.+W.+MacArthurauthor=D.+S.+Mossauthor=J.+M.+Thornton&title=PROCHECK%3A+A+program+to+check+the+stereochemical+quality+of+protein+structures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">PROCHECK: a program to check the stereochemical quality of protein structures</span></div><div class="casAuthors">Laskowski, Roman A.; MacArthur, Malcolm W.; Moss, David S.; Thornton, Janet M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-91</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    </div><div class="casAbstract">The PROCHECK suite of programs provides a detailed check on the stereochem. of a protein structure.  Its outputs comprise a no. of plots in PostScript format and a comprehensive residue-by-residue listing.  These give an assessment of the overall quality of the structure as compared with well-refined structures of the same resoln. and also highlight regions that may need further investigation.  The PROCHECK programs are useful for assessing the quality not only of protein structures in the process of being solved but also of existing structures and of those being modeled on known structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCe5FgJf4KH7Vg90H21EOLACvtfcHk0lg4FXF3pNkApQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXit12lurY%253D&md5=fb69fc4410cd716aaaa7cc0db06b3ed2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1107%2FS0021889892009944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889892009944%26sid%3Dliteratum%253Aachs%26aulast%3DLaskowski%26aufirst%3DR.%2BA.%26aulast%3DMacArthur%26aufirst%3DM.%2BW.%26aulast%3DMoss%26aufirst%3DD.%2BS.%26aulast%3DThornton%26aufirst%3DJ.%2BM.%26atitle%3DPROCHECK%253A%2520A%2520program%2520to%2520check%2520the%2520stereochemical%2520quality%2520of%2520protein%2520structures%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1993%26volume%3D26%26spage%3D283%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">DeLano, W. L.</span> The PyMOL Molecular Graphics System. <a href="http://www.pymol.org" class="extLink">http://www.pymol.org</a>,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DeLano%2C+W.+L.+The+PyMOL+Molecular+Graphics+System.+http%3A%2F%2Fwww.pymol.org%2C+2002."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Henze, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabellus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taeger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treckmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors</span> <span class="citation_source-journal">PloS ONE</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_elocation-id">e37776</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=J.+Henzeauthor=T.+M%C3%BChlenbergauthor=S.+Simonauthor=F.+Grabellusauthor=B.+Rubinauthor=G.+Taegerauthor=M.+Schulerauthor=J.+Treckmannauthor=M.+Debiec-Rychterauthor=T.+Taguchiauthor=J.+A.+Fletcherauthor=S.+Bauer&title=p53+modulation+as+a+therapeutic+strategy+in+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHenze%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DSimon%26aufirst%3DS.%26aulast%3DGrabellus%26aufirst%3DF.%26aulast%3DRubin%26aufirst%3DB.%26aulast%3DTaeger%26aufirst%3DG.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DTreckmann%26aufirst%3DJ.%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3Dp53%2520modulation%2520as%2520a%2520therapeutic%2520strategy%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DPloS%2520ONE%26date%3D2012%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Vichai, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirtikara, K.</span><span> </span><span class="NLM_article-title">Sulforhodamine B colorimetric assay for cytotoxicity screening</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1112</span><span class="NLM_x">–</span> <span class="NLM_lpage">1116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm4004076&amp;key=10.1038%2Fnprot.2006.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm4004076&amp;key=17406391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm4004076&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOitL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=1112-1116&author=V.+Vichaiauthor=K.+Kirtikara&title=Sulforhodamine+B+colorimetric+assay+for+cytotoxicity+screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Sulforhodamine B colorimetric assay for cytotoxicity screening</span></div><div class="casAuthors">Vichai, Vanicha; Kirtikara, Kanyawim</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1112-1116</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The sulforhodamine B (SRB) assay is used for cell d. detn., based on the measurement of cellular protein content.  The method described here was optimized for the toxicity screening of compds. to adherent cells in a 96-well format.  After an incubation period, cell monolayers are fixed with 10% (wt/vol) trichloroacetic acid and stained for 30 min, after which the excess dye is removed by washing repeatedly with 1% (vol/vol) acetic acid.  The protein-bound dye is dissolved in 10 mM Tris base soln. for OD detn. at 510 nm using a microplate reader.  The results are linear over a 20-fold range of cell nos. and the sensitivity is comparable to those of fluorometric methods.  The method not only allows a large no. of samples to be tested within a few days, but also requires only simple equipment and inexpensive reagents.  The SRB assay is therefore an efficient and highly cost-effective method for screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZ8pao808l7Vg90H21EOLACvtfcHk0lgVTm5MTKyKUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOitL3O&md5=7173035a1f9eb3f02dd7f1a947bca659</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2006.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2006.179%26sid%3Dliteratum%253Aachs%26aulast%3DVichai%26aufirst%3DV.%26aulast%3DKirtikara%26aufirst%3DK.%26atitle%3DSulforhodamine%2520B%2520colorimetric%2520assay%2520for%2520cytotoxicity%2520screening%26jtitle%3DNat.%2520Protoc.%26date%3D2006%26volume%3D1%26spage%3D1112%26epage%3D1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medeiros, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConarty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panigrahy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3999</span><span class="NLM_x">–</span> <span class="NLM_lpage">4006</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=3999-4006&author=A.+Duensingauthor=F.+Medeirosauthor=B.+McConartyauthor=N.+E.+Josephauthor=D.+Panigrahyauthor=S.+Singerauthor=C.+D.+Fletcherauthor=G.+D.+Demetriauthor=J.+A.+Fletcher&title=Mechanisms+of+oncogenic+KIT+signal+transduction+in+primary+gastrointestinal+stromal+tumors+%28GISTs%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMedeiros%26aufirst%3DF.%26aulast%3DMcConarty%26aufirst%3DB.%26aulast%3DJoseph%26aufirst%3DN.%2BE.%26aulast%3DPanigrahy%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520oncogenic%2520KIT%2520signal%2520transduction%2520in%2520primary%2520gastrointestinal%2520stromal%2520tumors%2520%2528GISTs%2529%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D3999%26epage%3D4006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Rubin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lux, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hibbard, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">KIT activation is a ubiquitous feature of gastrointestinal stromal tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">8118</span><span class="NLM_x">–</span> <span class="NLM_lpage">8121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=8118-8121&author=B.+P.+Rubinauthor=S.+Singerauthor=C.+Tsaoauthor=A.+Duensingauthor=M.+L.+Luxauthor=R.+Ruizauthor=M.+K.+Hibbardauthor=C.+J.+Chenauthor=S.+Xiaoauthor=D.+A.+Tuvesonauthor=G.+D.+Demetriauthor=C.+D.+Fletcherauthor=J.+A.+Fletcher&title=KIT+activation+is+a+ubiquitous+feature+of+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DTsao%26aufirst%3DC.%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DLux%26aufirst%3DM.%2BL.%26aulast%3DRuiz%26aufirst%3DR.%26aulast%3DHibbard%26aufirst%3DM.%2BK.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DXiao%26aufirst%3DS.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DKIT%2520activation%2520is%2520a%2520ubiquitous%2520feature%2520of%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D8118%26epage%3D8121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">9153</span><span class="NLM_x">–</span> <span class="NLM_lpage">9161</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9153-9161&author=S.+Bauerauthor=L.+K.+Yuauthor=G.+D.+Demetriauthor=J.+A.+Fletcher&title=Heat+shock+protein+90+inhibition+in+imatinib-resistant+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DL.%2BK.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DHeat%2520shock%2520protein%252090%2520inhibition%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9153%26epage%3D9161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabellus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taeger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6941</span><span class="NLM_x">–</span> <span class="NLM_lpage">6950</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6941-6950&author=T.+M%C3%BChlenbergauthor=Y.+Zhangauthor=A.+J.+Wagnerauthor=F.+Grabellusauthor=J.+Bradnerauthor=G.+Taegerauthor=H.+Langauthor=T.+Taguchiauthor=M.+Schulerauthor=J.+A.+Fletcherauthor=S.+Bauer&title=Inhibitors+of+deacetylases+suppress+oncogenic+KIT+signaling%2C+acetylate+HSP90%2C+and+induce+apoptosis+in+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DGrabellus%26aufirst%3DF.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DTaeger%26aufirst%3DG.%26aulast%3DLang%26aufirst%3DH.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DInhibitors%2520of%2520deacetylases%2520suppress%2520oncogenic%2520KIT%2520signaling%252C%2520acetylate%2520HSP90%252C%2520and%2520induce%2520apoptosis%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6941%26epage%3D6950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3F3W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3F3W','PDB','3F3W'); return false;">PDB: 3F3W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ','PDB','2OIQ'); return false;">PDB: 2OIQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TZ8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TZ8','PDB','3TZ8'); return false;">PDB: 3TZ8</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i51"><a href="/doi/suppl/10.1021/jm4004076">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_43323"></div></div></div></div></div><hr /></hr><p class="last">Detailed synthetic procedures for the preparation of <b>6a</b> and <b>6b</b> as well as synthetic schemes for <b>3c</b>,<b>d</b>, <b>4b</b>, and <b>6a</b>,<b>b</b>, crystal X-ray structure data of <b>3g</b> and <b>3h</b> in complex with cSrc, modeling studies of <b>3g</b> into the catalytic domains of Abl T315I and KIT T670I, selectivity profiling data of <b>3d</b>, CYP inhibition data, cytotoxicity data, Ba/F3 Bcr-Abl (and T315I) proliferation assay data, and a detailed overview of <b>3h</b>–cSrc interactions including electron density information. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm4004076/suppl_file/jm4004076_si_001.pdf">jm4004076_si_001.pdf (1.65 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID codes <a href="https://" class="ext-link">3TZ7</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TZ8">3TZ8</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm4004076&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-14%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm4004076" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm4004076" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677afd09b89ad18f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
